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Protocol Title: Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy 
and Nivolumab Combination Therapy in Subjects with Virus-Positive and Virus-Negative Solid Tumors
Investigational Product(s), Dose and Mode of Administration, Duration of Treatment with Investigational 
Product(s): 
On the basis of eligibility and tumor type (Epstein Barr Virus [EBV] positive gastric cancer, EBV positive 
nasopharyngeal cancer [NPC], cervical cancer, HPV positive and negative squamous cell cancer of the head and neck 
[SCCHN], anogenital HPV associated cancers [vaginal, vulvar, anal canal, penile], and Polyomavirus positive Merkel 
cell cancer [pMCC]), the study will enroll or randomize subjects into neoadjuvant treatment or recurrent/metastatic 
monotherapy, or assign or randomize into the recurrent/metastatic combination therapies cohorts (A, B, C or D). 


























Research Hypothesis (B):  Treatment with nivolumab alone or in combination with either ipilimumab, BMS-986016
(relatlimab), or daratumumab will lead to clinically meaningful tumor reductions, as measured by objective response 
rate and duration of response, in subjects with metastatic or unresectable tumors.
Primary Objectives  
  
 
 In the metastatic cohort (nivolumab monotherapy), to evaluate the investigator-assessed objective response rate 
(ORR) in subjects with the following diseases:
 






 Metastatic cohort (monotherapy and combination therapies): To evaluate the duration of response, progression-


















Metastatic Cohort (Monotherapy and Combination Therapies)
 To determine the safety and tolerability [defined as toxicity rates (worst CTC grade per subject) of adverse events 
and specific laboratory tests] of nivolumab monotherapy and combination therapy (ipilimumab, BMS-986016, or 
daratumumab) in subjects with metastatic or recurrent viral-mediated tumors.
 
 To investigate the potential association between selected biomarker measures in peripheral blood and tumor 
tissue, including PD-L1, with safety and clinical efficacy measures. 
 To investigate the pharmacodynamic activity of nivolumab monotherapy and combination therapy (ipilimumab, 
BMS-986016, or daratumumab) in the peripheral blood and tumor tissue as measured by gene expression, flow 
cytometry, immunohistochemistry and soluble factor assays. 
 To study the effect of nivolumab monotherapy and combination therapy (ipilimumab, BMS-986016, or 
daratumumab) on the viral antigen specific T cell responsiveness in the peripheral blood. 
 To evaluate the potential association between the number of tumor mutations and neoantigens with clinical 
efficacy measures and determine if tumor antigen-specific T cells are present in the periphery.
 To assess the subject’s overall health status as assessed by the EQ-5D. 
 To evaluate cancer specific health related quality of life as assessed by EORTC QLQ-C30.
 To characterize pharmacokinetics of nivolumab monotherapy and combination therapy (ipilimumab, 
BMS-986016, or daratumumab) and explore exposure-response relationships.
 To characterize the immunogenicity of nivolumab monotherapy and combination therapy (ipilimumab, 
BMS-986016, or daratumumab).
Study Design:  This is an open label, multi-center, phase 1/2 trial to investigate the safety and efficacy of nivolumab 
as a single agent or in combination with either ipilimumab, BMS-986016 (relatlimab, anti-LAG3 antibody), or 
daratumumab in viral positive and viral negative tumor types of the following tumor types: EBV positive gastric 
cancer, EBV positive NPC, cervical cancer, HPV positive and negative SCCHN, anogenital HPV associated cancers 
(vaginal, vulvar, anal canal, penile), and pMCC.
On the basis of eligibility and tumor type, patients will be enrolled into the neoadjuvant or recurrent/metastatic 
monotherapy, or assigned or randomized into the recurrent/metastatic combination therapies cohorts (A, B, C or D). 
Upon approval of Revised Protocol 05, all Metastatic Combination Cohorts A, B, and D will enroll patients 



































Nivo monotherapy 240 mg
Q2 weeks
Until disease progression, toxicity, 
withdrawal of consent, or a maximum 
of 24 months
TUMORS:
• EBV (+) Gastric - N=12
• HPV(+) SCCHN - N=23
• GYN (cervical, vaginal, 
vulvar) - N=23
• MCC - N=23
• NPC  - N=23
Up to 5 weeks
Up to 2 prior treatments
≥ 1 target lesion
ECOG status: 0 or 1
• Imaging every 8 weeks starting at 
Week 8 for the first year of treatment
• Imaging every 12 weeks starting at 
year 2 and beyond
Min 12 weeks
survival
For Subjects with HPV (+) and 
EBV (+):  virus selection required








































iv) Squamous cell carcinoma of the cervix, vagina, vulva, anal canal, and penile (Note: anal canal and 
penile for metastatic combination cohorts only)
(1). For subjects in the neoadjuvant and metastatic (monotherapy and combination) cohorts with 
gynecological tumors, HPV positivity is defined by FDA approved tests (Cobas HPV Test; Digene 
Hybrid Capture 2 High-Risk HPV DNA Test; Cervista™ HPV HR and Genfind™ DNA Extraction 
Kit; Cervista™ HPV 16/18; APTIMA® HPV Assay) or other well validated commercially available 
tests (such as Ventana Inform HPV ISH test) comprising in situ hybridization, real-time PCR, or 
immunohistochemistry (IHC). High-risk HPV positivity includes the following subtypes:  16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. Virus testing will be performed retrospectively 





































c) For subjects in the metastatic (monotherapy and combination) cohorts
i) Progressive metastatic or recurrent disease treated with no more than 2 prior systemic therapies or 
regimens in the metastatic setting. (In combo C, prior I-O therapy is not included in the number of prior 
systemic therapies)
ii) Measurable disease by CT or MRI per RECIST 1.1 criteria (radiographic tumor assessment must be 
performed within 35 days prior to first dose).
iii) Subjects who actively refuse chemotherapy or other standard therapies for the treatment of unresectable 
or metastatic disease (advanced Stage III or Stage IV), despite being informed by the investigator about 
the treatment options may enroll. The subject’s refusal must be thoroughly documented. The investigator 
will discuss each individual subject refusing chemotherapy with the sponsor’s medical monitor or study 






























(3). Histologically confirmed cervical, vulvar, or vaginal cancer, as defined above. If the viral results 








d) For both neoadjuvant and metastatic (monotherapy and combination) cohorts
i) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
ii) Men and women of age 18 or older.
iii) Subject willing to comply to provide tumor tissue for PD-L1 expression analysis and other biomarker 
correlative studies. Biopsy should be excisional, incisional or core needle. Fine needle aspirates are 
prohibited.
Exclusion Criteria:
1. Target Disease Exceptions
a) Active brain metastases or leptomeningeal metastases. Exception: Subjects with brain metastases are eligible 
if these have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for at 
least 4 weeks after treatment is complete and within 28 days prior to first dose of study drug administration. 





There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day 
prednisone equivalents) for at least 2 weeks prior to study drug administration.
2. Medical History and Concurrent Diseases
a) Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk 
associated with study participation or study drug administration, impair the ability of the subject to receive 
protocol therapy, or interfere with the interpretation of study results.
b) Prior malignancy active within the previous 3 years except for locally curable cancers that have been 
apparently cured or successfully resected, such as basal or squamous cell skin cancer, superficial bladder 
cancer, or gastric cancer, or carcinoma in situ of the prostate, cervix, or breast.
c) Subjects with active, known or suspected autoimmune disease. Subjects with skin disorders (such as vitiligo, 
psoriasis, or alopecia), type I diabetes mellitus, residual hypothyroidism only requiring hormone replacement, 
or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
d) Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone 
equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled 
or topical steroids, and adrenal replacement doses are permitted in the absence of active autoimmune disease.
e) Subjects with primary tumor or nodal metastasis fixed to the carotid artery, skull base or cervical spine.
f) Prior therapy with experimental anti-tumor vaccines; any T cell co-stimulation or checkpoint pathways, such 
as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, including ipilimumab; or other 
medicines specifically targeting T cell co-stimulation or checkpoint pathways is also prohibited. Exception: 
Combo C SCCHN prior exposure to anti PD-1/PD-L1/CTLA-4 therapy
g) All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must have resolved to 
Grade 1 (NCI CTCAE version 4) or baseline before administration of study drug. Subjects with toxicities 
attributed to prior anti-cancer therapy which are not expected to resolve and result in long lasting sequelae, 
such as neuropathy after platinum based therapy, are permitted to enroll.
h) Treatment with any chemotherapy, radiation therapy, biologics for cancer, or investigational therapy within 
28 days of first administration of study treatment (subjects with prior cytotoxic or investigational products 
< 4 weeks prior to treatment might be eligible after discussion between investigator and sponsor, if toxicities 





















Study Drug: includes both Investigational [Medicinal] Products (IP/IMP) and Non-investigational [Medicinal] 





































































































































Safety assessments at baseline will include a medical history to be obtained to capture relevant underlying conditions. 
Baseline examinations should include signs and symptoms, weight, height, ECOG Performance Status, BP, HR, 
temperature, and respiratory rate should be performed within 14 days prior to first dose. Concomitant medications 
will also be collected from within 14 days prior to first dose and through the study treatment. Baseline safety laboratory 
assessments should be done within 14 days prior to the first dose. 
Subjects will be evaluated for safety if they have received any study drug. Toxicity assessments will be performed 
continuously during the treatment phase. On-study assessments including weight, height, ECOG Performance Status, 





BP, HR, temperature, respiratory rate, and oxygen saturation by pulse oximetry at rest and after exertion will be 
performed. On-study safety laboratory assessments will also be performed. 
Efficacy: 
Tumor imaging assessments for ongoing study treatment decisions will be completed by the investigator using 
RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria.
Statistical Considerations:






2) Recurrent/metastatic monotherapy cohort:
HPV+ SCCHN, GYN, MCC and NPC tumor types in the recurrent/metastatic cohort will contain 23 subjects. Table 1 
shows the probabilities of observing 0, 1 or 2 responders and  3 responders assuming 5%, 20% and 30% true response 
rate of ORR. Table 2 shows two-sided 95% exact CI using Clopper-Pearson methods based on observed 3, 4, and 
5 responders out of 23 subjects.
Table 3 shows the precision of the 
estimation of ORR based on the two sided 95% exact CI using Clopper-Pearson methods based on 1, 2, 3, 4, and 
5 responders out of 12 subjects. 
Table 1 Probability of Observing Responses Given True ORR for Sample Size 
of 23 Subjects
True response rate of 
ORR
Probability of observing 0, 1 or 2 
responses





Table 2 Two-sided 95% exact CI Using Clopper-Pearson Method 
Based on Number of Observed Responses out of 23 Subjects
The number of observed 
responses
3 4 5
Observed Response Rate 3/23 (13.0%) 4/23 (17.4%) 5/23 (21.7%)
95% exact CI (2.8%, 33.6%) (5.0%, 38.8%) (7.5%, 43.7%)





Table 3 Two-sided 95% Exact CI Using Clopper-Pearson Method 
Based on the Number of Observed Responses out of 12 
Subjects
The number of 
observed responses




































































Metastatic cohort (monotherapy and combination therapies): The objective response rate (ORR). ORR is defined 
as the number of subjects with a best overall response (BOR) of confirmed complete response (CR) or partial response 
(PR) divided by the number of treated subjects. BOR is defined as the best response designation recorded between the 
date of first dose and the date of the initial objectively documented tumor progression per investigator assessment 
using RECIST 1.1 criteria or the date of the last tumor assessment date prior to subsequent therapy. In this study, an 
ORR in excess of 10% will be considered of clinical interest, and an ORR of 25% or greater will be considered of 
strong clinical interest.
Secondary Endpoints:
Metastatic cohort (monotherapy and combination therapies): 
 Duration of response (DOR) is defined as the time from first confirmed response (CR or PR) to the date of the 
initial objectively documented tumor progression as determined per investigator assessment using RECIST 1.1 
criteria or death due to any cause, whichever occurs first. Subjects who did not start subsequent anti-cancer 
therapy and die without a reported prior progression will be considered to have progressed on the date of their 
death. Subjects who did not progress or die will be censored on the date of their last tumor assessment. Subjects 
who did not have any on study tumor assessments and did not die will be censored on the date they were treated. 
Subjects who started any subsequent anti-cancer therapy prior to death and without a prior reported progression 
will be censored at the last tumor assessment prior to or on the date of initiation of the subsequent anti-cancer 
therapy. DOR will only be evaluated in subjects with objective response of CR or PR
 Overall survival (OS) is defined as the time from first dosing date to the date of death. A subject who has not died 
will be censored at last known date alive. 
 Investigator-assessed progression free survival (PFS) is defined as the time from first dosing date to the date of 
the first documented tumor progression, as determined by investigators (per RECIST 1.1), or death due to any 
cause. Subjects who die without a reported prior progression will be considered to have progressed on the date of 
their death. Subjects who did not progress or die will be censored on the date of their last tumor assessment. 
Subjects who did not have any on study tumor assessments and did not die will be censored on the date they were 
treated. Subjects who started any subsequent anti-cancer therapy prior to death and without a prior reported 


















Metastatic cohort (monotherapy and combination therapies): 
 The safety and tolerability objective will be measured by the incidence of adverse events, serious adverse events, 
deaths and laboratory abnormalities.
 
 
 Metastatic cohort (monotherapy and combination therapies): 
 The PK samples collected will be used to determine summary measures of nivolumab, ipilimumab, BMS-986016 
(relatlimab) and daratumumab exposure (see Section 8.4.4 in protocol).
 Exploratory endpoints for pharmacodynamics, outcomes research and immunogenicity are discussed in detail in 
Sections 5.6, 5.7, and 5.8.
Other exploratory endpoints will be discussed in details in the statistical analysis plan.
Analyses:
Analyses for primary endpoints: 
 
 
Metastatic cohort (monotherapy and combination therapies): 
 The investigator assessed ORR in the metastatic cohort will be summarized by binomial response rates and their 
corresponding two-sided 95% exact CIs using Clopper-Pearson method. 
Analyses for secondary endpoints: 
Metastatic cohort (monotherapy and combination therapies):
 Time to event distribution will be estimated using Kaplan Meier techniques. This will be done for PFS (based on 
investigator assessments) and OS. Median PFS or OS along with 95% CI will be constructed based on a log-log 
transformed CI for the survivor function. Rates at some fixed time points will be derived from the Kaplan Meier 
estimate and corresponding confidence interval will be derived based on Greenwood formula for variance 
derivation and on log-log transformation applied on the survivor function. 
 The DOR will be summarized for all treated subjects who achieve confirmed PR or CR using the Kaplan-Meier 
(KM) product-limit method. Median values of DOR, along with two-sided 95% CI using Brookmeyer and 
Crowley method, will also be calculated.
Analyses for exploratory endpoints: 
Methods for exploratory endpoints will be discussed in details in the statistical analysis plan.






Safety analyses will be performed in all treated subjects. Descriptive statistics of safety will be presented using 
NCI CTCAE version 4. All on-study AEs, drug-related, AEs, SAEs and drug-related SAEs will be tabulated using 
worst grade per NCI CTCAE version 4 criteria by system organ class and MedDRA preferred term. On-study lab 
parameters including hematology, chemistry, liver function, thyroid function, and renal function will be summarized 
using worst grade per NCI CTCAE version 4 criteria.
The proportion of subjects in the neoadjuvant cohort with surgery delayed > 4 weeks due to a drug-related AE will be 
reported for each tumor type and the Clopper-Pearson method will be used to estimate the two-sided 95% confidence 
interval.
Pharmacokinetic Analyses
The nivolumab, ipilimumab, BMS-986016 (relatlimab), and daratumumab concentration data obtained in this study 
may be combined with data from other studies in any of the clinical development programs (nivolumab, ipilimumab, 
BMS-986016, and daratumumab) to develop or refine a population PK model. The models may be used to evaluate 
the effects of intrinsic and extrinsic covariates on the PK of nivolumab or other compounds and to determine measures 
of individual exposure (such as steady-state peak, trough, and time-averaged concentration). In addition, model 
determined exposures may be used for exposure-response analyses. If performed, results of population PK and 
exposure response-analyses will be reported separately.
Biomarker Analyses
The pharmacodynamic effects of nivolumab as monotherapy or in combination with ipilimumab, BMS-986016
(relatlimab) or daratumumab on selected biomarkers will be assessed by summary statistics and corresponding 
changes (or percent changes) from baseline tabulated by time and cohort. In addition, the time course of biomarker 
outcomes will be investigated graphically, by summary plots or individual subject plots. If there is an indication of a 
meaningful pharmacodynamic trend, methods such as linear mixed models may be used to characterize the pattern of 
change over time. The potential association between PD-L1 expression level (IHC) and clinical efficacy measures will 
be assessed using Fisher’s exact test or other methodology as appropriate.
Potential associations of various biomarker measures with pharmacokinetic exposure, safety and clinical efficacy 
measures will be investigated based on data availability. Methods such as, but not limited to, logistic regression and 
graphical summaries may be used to assess these associations.
The methodology for additional exploratory biomarker analyses will be described in the statistical analysis plan.
Outcomes Research Analyses
EQ-5D
Subject’s overall health state on a visual analog scale (EQ-VAS) at each assessment time point will be summarized 
using descriptive statistics (N, mean, standard deviation, median, first and third quartiles, minimum, maximum). 
Proportion of subjects reporting problems for the 5 EQ-5D dimensions at each assessment time point will be 
summarized by level of problem. Percentages will be based on number subjects assessed at assessment time point.
A by-subject listing of EQ-5D with the problem levels for each of the 5 dimensions (mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression), health state (5 dimensions digits combined in a 5-digit number) 
and EQ-VAS will be provided. Each dimension has three levels: no problems, some problems, and severe problems.
EORTC QLQ-C30
The analysis of EORTC QLQ-C30 will be performed in all treated subjects who have an assessment at baseline and 
at least one subsequent assessment.
All scales and single items are scored on a categorical scale and linearly transformed to 0-to-100 scales with higher 
scores for a functional scale representing higher levels of functioning, higher scores for the global health status/quality 
of life representing higher levels of global health status/quality of life, and higher scores for a symptom scale 
representing higher level of symptoms.
Baseline and change from baseline in EORTC QLQ-C30 global health status/QoL composite scale data and the 
remaining EORTC QLQ-C30 scale data will be summarized by time point using descriptive statistics for each cohort 





(N, mean, standard deviation, median, first and third quartiles, minimum, maximum). In addition, the percentage of 
subjects demonstrating a clinically meaningful deterioration (defined as a 10 point change from baseline) will be 
presented for each scale at each assessment time point. Percentages will be based on number subjects assessed at 
assessment time point.
Immunogenicity Analyses
Immunogenicity may be reported for anti-drug antibody (ADA) positive status (such as persistent positive, 
neutralizing positive, only last sample positive, baseline positive and other positive) and ADA negative status, relative 
to baseline. Effect of immunogenicity on safety, efficacy, biomarkers and PK may be explored. Additional details will 
be described in the statistical analysis plan.
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1 INTRODUCTION AND STUDY RATIONALE
1.1 Study Rationale
Programmed Cell Death-1 (PD-1; CD279) is a cell surface signaling molecule that delivers 
inhibitory signals that regulate the balance between T cell activation and tolerance by interacting 
with its ligands, PD-L1 (CD274; B7-H1) and PD-L2 (B7-DC/CD273). PD-1 is a 55 kD type I 
transmembrane protein that is a member of the CD28 family of T-cell regulatory receptors, which 
also includes CTLA-4, ICOS, and BTLA.1 PD-1 is primarily expressed on activated T cells, B 
cells, and myeloid cells.2 Its ligands, PD-L1 (B7-H1/CD274) and PD-L2 (B7-DC/CD273), have 
been shown to down-regulate T-cell activation upon binding to PD-1 in both murine and human 
systems.3,4 PD-1 contains an intracellular membrane proximal immunoreceptor tyrosine inhibitory 
motif (ITIM) and a membrane distal immunoreceptor tyrosine-based switch motif (ITSM), that 
when phosphorylated, delivers a negative signal to the lymphocyte by the recruitment of SHP-2 to 
the phosphorylated tyrosine residue in the ITSM in its cytoplasmic region.5,6
Evidence for a negative regulatory role of PD-1 comes from studies of PD-1-deficient mice. PD-1-
deficient mice develop various autoimmune phenotypes, including dilated cardiomyopathy and a 
lupus-like syndrome with arthritis and nephritis.7,8,9 The emergence of these autoimmune 
phenotypes is dependent upon the genetic background of the mouse strain; many of these 
phenotypes emerge at different times and show variable penetrance. In addition to the phenotypes 
of null mutations, PD-1 inhibition by antibody-mediated blockade in several murine models has 
been found to play a role in the development of autoimmune diseases such as encephalomyelitis, 
graft-versus-host disease, and type I diabetes.10,11,12 Taken together, these results suggest that 
PD-1 blockade has the potential to activate anti-self T-cell responses, but these responses are 
variable and dependent upon various host genetic factors. Thus, PD-1 deficiency or inhibition is 
not accompanied by a universal loss of tolerance to self-antigens. 
Preclinical animal models of tumors have shown that blockade of PD-1 by monoclonal antibodies 
(mAbs) can enhance the anti-tumor immune response and result in tumor rejection. This suggests 
that host mechanisms limit the antitumor response.13,14,15,16,17,18
In humans, PD-L1 is constitutively expressed on macrophage-lineage cells, activated T cells, lung, 
vascular endothelial cells, and placental syncytiotrophoblasts.19 Aberrant expression of PD-L1 by 
tumor cells has been reported in a number of human malignancies.20,21,22,23,24,25,26 PD-L1 
expressed by tumor cells has been shown to enhance apoptosis of activated tumor-specific T cells 
in vitro.27 Moreover, the expression of PD-L1 may protect the tumor cells from the induction of 
apoptosis by effector T cells.28 Retrospective analyses of several human tumor types suggest that 
tumor over-expression (as measured by immunohistochemistry) of PD-L1 may permit immune 
evasion by tumors. In renal cell carcinoma, high surface expression levels of PD-L1 on tumor cells 
are related to tumor aggressiveness. Patients with high tumor and/or lymphocyte PD-L1 levels are 
4.5 times more likely to die from their cancer than patients exhibiting low levels of PD-L1 
expression.29





Nivolumab is a fully human, IgG4 (kappa) isotype, mAb that binds to PD-1. Blockade of the PD-1 
pathway by nivolumab was studied using the mixed lymphocyte reaction (MLR). PD-1 blockade 
resulted in a reproducible enhancement of both proliferation and IFN-γ release in the MLR.30 The 
effect of nivolumab on antigen-specific recall response was investigated using a CMV-
restimulation assay with human peripheral blood mononuclear cells (PBMCs) and was evaluated 
by ELISA. These data indicated that nivolumab, versus an isotype-matched control antibody, 
augmented IFN-g secretion from CMV-specific memory T cells in a dose-dependent manner. 
1.1.1 Disease Background
Study CA209358 is an open label, multicenter, Phase 1/2 trial to investigate the safety and efficacy 
of nivolumab as a single agent or in combination with either ipilimumab, relatlimab (anti-LAG3 
antibody), or daratumumab in viral positive and viral negative tumor types - Epstein Barr Virus 
(EBV) positive gastric cancer, EBV positive nasopharyngeal cancer (NPC), cervical cancer, HPV 
positive and negative squamous cell cancer (SCC) of the head and neck (SCCHN), anogenital 
HPV associated cancers (vaginal, vulvar, anal canal, penile), and Polyomavirus positive Merkel 












































































































































Cervical, Vaginal, Vulvar, Anal Canal, and Penile Cancers
In the United States, almost 4900 cases of vulvar cancer are diagnosed each year, with over 1000 of 
those women expected to die from the disease; for cervical cancer in the US there are 12,000 new 
cases of invasive cervical cancer and approximately 4000 cancer-related deaths occur each year.56
HPV infection is associated with the development of cervical, vulvar, anal canal, and penile 
cancers.75 HPV 16 and 18 are the most common subtypes for vulvar, anal canal, and penile cancers; 
HPV 16, 18, 33, 6 and 31 are the 5 most frequently observed HPV types for cervical cancer. 
Whereas cervical cancer HPV infection occurs in nearly 100% of patients76, HPV associated 
squamous vulvar cancer affects younger women77 and is a warty squamous cell compared to 
keratinizing or differentiated. Only 70% of cases are associated with HPV infection.78
Treatment for vulvar or vaginal cancer is typically surgical resection, though chemoradiotherapy 
is another option.79 The 5-year survival for vulvar cancer depends on spread of disease, Local 
86%, Regional 54%, and Distant 16%.80 Treatment of recurrent disease includes surgical 
reexcision or resection and platinum based chemotherapy for metastatic disease. Recurrences are 
more likely local compared to distant (5.7%) and the 5-year survival rate was 60% for perineal 
recurrences, 27% for inguinal and pelvic recurrences, 15% for distant recurrences, and 14% for 
multiple recurrences.81
Treatment for cervical cancer is typically surgery for Stages IA - IIA1 and concurrent 
chemoradiation for Stages IB2 to IVA. The 5-year survival rate for cervical cancer depends on 
stage: IA 93%, IB 80%, IIA 63%, IIB58%, IIIA 35%, IIIB 32%, IVA 16%, and IVB 15%.82
Treatment of recurrent disease is typically with surgery for resectable disease or chemotherapy 
plus bevacizumab, which improved ORR (48% vs 36%) and mOS (17 vs 13.3 months) compared 
to chemotherapy alone.83 After first line chemotherapy, there is no standard of care that has 




































































1.1.2 Infection and Tumorigenesis
The establishment of a virus as the inducer of cellular transformation109 by Petyon Rous in the 
early 20th century paved the way for modern tumor biology. Since Rous’ observation, many 
cancers of different origins have been linked to chronic viral infections that are partly responsible 
for driving tumorigenesis through several mechanisms, including the disruption of tumor
suppressor proteins such as p53 and Rb, activation of cellular proliferation pathways, and 
inhibiting the apoptotic machinery.110 Two major classes of virus, Human Papilloma virus (HPV) 
and Epstein-Barr virus (EBV), are associated with  670,000 oncological cases per year, 
worldwide.110
1.1.2.1 HPV
Promotion of tumorigenesis by HPV is mediated by two key viral proteins, E6 and E7, both of 
which target cell cycle regulation, proliferation, and apoptosis pathways that drive cells toward 
transformation. The viral E6 protein binds to E6-AP, an ubiquitin ligase, resulting in degradation 
of p53 protein.111 In addition, E6, binds to histone acetyltransferases p300, ADA3, and CREB 
binding protein (CBP) preventing acetylation of p53 and inhibiting the transcription of 
p53-responsive genes. E6 has also been shown to inhibit apoptotic signaling by binding tumor 
necrosis factor (TNF)-α receptor (TNFR1), FAS-associated protein with death domain (FADD) 
and caspase 8, and through the degradation of pro-apoptotic BAX and BAK. Direct killing of cells 
through IFN is inhibited by E6 through inhibition of IRF3.112





The HPV protein E7 also targets a tumor suppressor, retinoblastoma (Rb), leading to its 
inactivation and resulting in constitutive activation of E2F-responsive genes. Further disruption of 
cell cycle control by E7 is achieved by inhibition of cyclin-dependent kinase inhibitors. Similar to 
















































1.1.4 Rationale for Immunotherapy in Virus-Associated Tumors
As described above, the adaptive T cell response largely depends upon presentation of antigens by 
MHC in the context of an immune-stimulatory environment. Viral proteins, mutated proteins 
(neoantigens), and spatio-temporally dysregulated self-proteins represent targets of the T cell 
response that have potential to result in tumor-cell clearance. As evidence, T cell responses to viral 
antigens in patients with EBV+ or polyomavirus+ tumors can be identified and T cells against 
tumor neoantigens and self-antigens have been widely reported in the literature.122 Further, overall 
survival of both gastric and Merkel cell carcinoma patients is prognostically associated with the 
presence of tumor infiltrating T cells, suggesting immunosurveillance of tumor growth is taking 
place.123,124
Nonetheless, endogenous immune responses do not cause all tumors to regress. One plausible 
explanation, which has direct therapeutic consequences, is that virus associated tumors express 
PD-1 ligands as an adaptive response to virus antigen-specific cytokine-secreting T cells in the 
tumor microenvironment. Recently published results on HPV+ SCCHN and MCC support this 
notion. A recent review of MCC specimens for PD-L1 expression by tumor cells and tumor 
infiltrating lymphocytes (TILs) found that PD-L1 expression was present in 49% and 55% of 
samples, respectively, and specimens with PD-L1+ tumor cells, 97% (28/29) showed a geographic 
association with immune infiltrates.125 Among specimens with moderate-severe TIL intensities, 
100% (29/29) showed PD-L1 expression by tumor cells, but MCPyV(-) tumor cells were 
uniformly PD-L1(-).





These results demonstrated that virtually all HPV+ SCCHN and a majority of MCV+ MCC are 
PD-L1+ and, when positive, demonstrate focal PD-L1 expression associated with areas of 
lymphocyte infiltration. Conversely, among 8 MCV- MCCs, none expressed PD-L1. 
Taken together, these data suggest that virus associated cancers have distinct patterns of immune 
responses and a distinct tumor immune microenvironment.
1.1.5 Rationale and Aims for Biomarker Assessments
The biological basis of nivolumab, ipilimumab, relatlimab, and daratumumab in the treatment of 
oncological disease is to modulate the immune system to both generate and restore a durable anti-
tumor response leading to clearance of tumor. Clinical data supports the hypothesis that inhibition 
of the PD-1 pathway results in rejection of tumor by the host immune system.
The precise mechanisms by which nivolumab, ipilimumab, relatlimab, and daratumumab exert 
their immune-modulatory and anti-tumor activities is unclear; however, particular cell types, such 
as effector T cells and regulatory T cells, are critical for the anti-tumor response. 
Therefore, the major questions that will be addressed through the conduct of this study are:
 Are tumor and/or viral-specific T cells present at the tumor site prior to nivolumab
monotherapy and in combination with ipilimumab, relatlimab, or daratumumab therapy?
 Do nivolumab monotherapy and in combination with ipilimumab, relatlimab, or daratumumab
alter the frequency and activation state of tumor and/or viral-specific tumor infiltrating T cells?
 Does expression of PD-L1 or PD-L2 on tumor cells prior to therapy correlate with clinical 
efficacy to monotherapy and combination therapies?
 Does the mutational status of tumor cells correlate with clinical efficacy to monotherapy and 
combination therapies?
 Can we define distinct pharmacodynamic markers of monotherapy and combination therapies
in the peripheral compartment?
 How do nivolumab monotherapy and combination with ipilimumab, relatlimab, or 
daratumumab alter the activating and negative costimulatory molecules on immune cells in the 
periphery and at the tumor site? 
 Do non-responding subjects have distinct mechanisms of resistance to study drugs (such as an 
increase in additional negative regulatory proteins, an increase in MDSC or Treg, or loss of 
tumor-associated antigens in the tumor)?
 Is the intratumoral or peripheral T cell repertoire predictive of response to study drugs?
 Does the composition and phenotype of the tumor microenvironment, at baseline, or on 
treatment, correlate with clinical efficacy?
1.1.6 Rationale for Dose Selection for Nivolumab 
Nivolumab is currently approved for the treatment of various tumors, including melanoma, 
adjuvant treatment of melanoma, NSCLC, RCC, classical Hodgkin Lymphoma, SCCHN,
hepatocellular carcinoma, and urothelial carcinoma, using a regimen of either nivolumab 240 
mg Q2W or nivolumab 3 mg/kg Q2W.





The nivolumab dose of 240 mg Q2W or 480 mg Q4W was selected for this study based on clinical 
data and modeling and simulation approaches using PPK and exposure-response analyses 
examining relationships between nivolumab exposures and efficacy and safety responses, using 
data from studies in multiple tumor types with body weight-normalized dosing (mg/kg). Flat 
dosing is expected to reduce prescription dosing errors, shorten pharmacy preparation time, and 
improve ease of administration. Additionally, in case of 480 mg Q4W, extending the dosing 
interval to 4 weeks provided numerous benefits to participants as they would have increased 
flexibility between clinical visits.
Using the PPK and exposure-response models, nivolumab exposures and probabilities of efficacy 
responses and risks of AEs were predicted following nivolumab 480 mg Q4W administration and 
compared to those following nivolumab 3 mg/kg Q2W administration. The overall distributions 
of average nivolumab steady-state exposures (Cav,ss) are comparable following administration with 
either nivolumab 3 mg/kg Q2W or nivolumab 480 mg Q4W over a wide range of body weights. 
Nivolumab 480 mg Q4W administration is predicted to result in approximately 43% greater 
steady-state peak concentrations (Cmax,ss) compared to nivolumab 3 mg/kg Q2W. Although the 
Cmax,ss of nivolumab is expected to be greater following nivolumab 480 mg Q4W compared to 
nivolumab 3 mg/kg Q2W, the predicted Cmax,ss following nivolumab 480 mg Q4W is well below 
the median Cmax,ss achieved following administration of nivolumab 10 mg/kg Q2W, a safe and 
tolerable dose level across a wide body range (35 to 160 kg).
Exposure-safety analysis demonstrated that the exposure margins for safety are maintained 
following nivolumab 480 mg Q4W, and the predicted risks of AEs due to discontinuation or death, 
 Grade 3 AEs, and  Grade 2 immunotherapy-mediated AEs (IMAEs) are predicted to be similar 
following administration of nivolumab 480 mg Q4W relative to nivolumab 3 mg/kg Q2W across 
tumor types. Safety analyses using available data following nivolumab 3 mg/kg Q2W and 
10 mg/kg Q2W administration indicated there were no differences in AE profiles across body-
weight groups. Finally, initial clinical evidence demonstrates that, following administration of 
nivolumab 480 mg Q4W, nivolumab is well tolerated.
Nivolumab 480 mg Q4W is predicted to have approximately 16% lower steady-state trough 
concentrations (Cmin,ss) compared to nivolumab 3 mg/kg Q2W. While these exposures are 
predicted to be lower, they are on the flat part of the exposure-response curves and are not predicted 
to affect efficacy. Exposure-efficacy analyses of multiple PK measures and efficacy endpoints 
indicated that following administration of nivolumab 480 mg Q4W, efficacy is predicted to be 
similar to that following administration of nivolumab 3 mg/kg Q2W across multiple tumor types. 
Based on these data, nivolumab 480 mg Q4W is expected to have similar efficacy and safety 






















































































































































































































































































































































































































































1.1.15 Duration of Treatment with Nivolumab Monotherapy or Combination 
Therapy
The optimal duration of immunotherapy is an important question and continues to be investigated. 
Clinical trials across different tumors types in the nivolumab and ipilimumab development 
program indicate that most of the responses occur early, with a median time to response of 2-4 
months, and emerging data suggests that benefit can be maintained in the absence of continued 
treatment. A recent analysis in a melanoma study suggests the majority of patients who discontinue 
nivolumab and/or ipilimumab for toxicity maintain disease control in the absence of further 





treatment.166 Furthermore, a limited duration of ipilimumab, including only 4 induction doses, 
resulted in long term survival in patients with metastatic melanoma, with a sustained plateau in 
survival starting around 2 years after the start of treatment.167
Accumulating data suggest that 2 years of PD-1 checkpoint inhibitor treatment may be sufficient 
for long term benefit. CA209003, a dose-escalation cohort expansion trial evaluating the safety 
and clinical activity of nivolumab in patients with previously treated advanced solid tumors 
(including 129 subjects with NSCLC), specified a maximum treatment duration of 2 years. Among 
16 subjects with non-small cell lung cancer (NSCLC) who discontinued nivolumab after 
completing 2 years of treatment, 12 subjects were alive >5 years and remained progression-free 
without any subsequent therapy (2) In the CA209003 NSCLC cohort, the overall survival (OS) 
curve begins to plateau after 2 years, with an OS rate of 25% at 2 years and 18% at 3 years.168
These survival outcomes are similar to phase 3 studies in previously treated NSCLC, in which 
nivolumab treatment was continued until progression or unacceptable toxicity (2 year OS rates of 
23% and 29%, and 3 year OS rates of 16%-18% for squamous and non-squamous NSCLC 
respectively).169
Similar results have been reported in clinical studies of pembrolizumab, another PD-1 inhibitor. 
Keynote-010 was a randomized phase 3 trial of pembrolizumab (at either 2 mg/kg or 10 mg/kg 
every 3 weeks) versus docetaxel in subjects with previously treated, PD-L1-positive, advanced 
NSCLC which specified a  maximum treatment duration of 2 years for pembrolizumab. OS was 
significantly longer with both pembrolizumab 2 mg/kg (HR 0.72, p = 0.00017) and pembrolizumab 
10 mg/kg (HR 0.60, p < 0.00001) compared to docetaxel, with an OS plateau developing beyond 
2 years in both pembrolizumab arms. Among 690 patients who received pembrolizumab, 47 
patients completed 2 years of pembrolizumab and stopped treatment. Most were able to maintain 
their response, including those with stable disease, with only 2 patients (4%) having confirmed 
progression after stopping at 2 years.170
Keynote-006 was a randomized phase 3 study of pembrolizumab versus ipilimumab in patients 
with advanced melanoma, which also specified a maximum 2 year duration of pembrolizumab 
treatment. 104 (19%) of 556 patients randomized to pembrolizumab completed 2 years of 
treatment. With a median follow-up of 9 months after completion of pembrolizumab, the estimated 
risk of progression or death was 9% in these patients.171
Taken together, these data suggest that treatment beyond 2 years is unlikely to confer additional 
clinically meaningful benefit and that the risk of progression after discontinuing treatment at 2 
years is low.
In contrast, a shorter duration of nivolumab of only 1 year was associated with increased risk of 
progression in previously treated patients with NSCLC, suggesting that treatment beyond 1 year 
is likely needed. In CA209153, patients with previously treated advanced NSCLC who completed 
1 year of nivolumab therapy were randomized to either continue or stop treatment, with the option 
of retreatment upon progression. Among 163 patients still on treatment at 1 year and without 
progression, those who were randomized to continue nivolumab had significant improvement in 





progression-free survival (PFS) compared to those who were randomized to stop treatment, with 
median PFS (post-randomization) not reached vs 10.3 months, respectively; HR=0.42 (95% CI, 
0.25 to 0.71). With a median follow-up of 14.9 months post-randomization, there also was a trend 
for patients on continued treatment to live longer (OS HR = 0.63 [95% CI: 0.33, 1.20]). Of note,  
the PFS curves in both groups plateau approximately 1 year after randomization (i.e., 2 years after 
treatment initiation), suggesting that there may be minimal benefit in extending treatment beyond 
a total of 2 years.172
Collectively, these data suggest that there is minimal if any benefit derived from continuing I-O 
treatment beyond two years in advanced tumors. However, even though immunotherapy is well 
tolerated, patients will be at risk for additional toxicity with longer term treatment. Therefore, in 
this study, treatment will be given for a maximum of 2 years from the start of study treatment.
1.2 Research Hypothesis
 
Research Hypothesis (B): Treatment with nivolumab alone or in combination with either 
ipilimumab, BMS-986016 (relatlimab), or daratumumab will lead to clinically meaningful tumor 
reductions, as measured by objective response rate and duration of response, in subjects with 




 In the metastatic cohort (nivolumab monotherapy), to evaluate the investigator-assessed 
objective response rate (ORR) in subjects with the following diseases:
 
 Metastatic or recurrent cervical, vaginal, or vulvar cancers
 










 Metastatic cohort (monotherapy and combination therapy): To evaluate the duration of 























 Metastatic Cohort (Monotherapy and Combination Therapy)
 To determine the safety and tolerability [defined as toxicity rates (worst CTC grade per 
subject) of adverse events and specific laboratory tests] of nivolumab monotherapy  
in subjects with 
metastatic or recurrent viral-mediated tumors.
 To investigate the potential association between selected biomarker measures in peripheral 
blood and tumor tissue, including PD-L1, with safety and clinical efficacy measures. 
 To investigate the pharmacodynamic activity of nivolumab monotherapy and combination 
therapy (ipilimumab, daratumumab, or BMS-986016) in the peripheral blood and tumor 
tissue as measured by gene expression, flow cytometry, immunohistochemistry and soluble 
factor assays. 
 To study the effect of nivolumab monotherapy , 
on the viral antigen specific T cell responsiveness in the 
peripheral blood. 
 To evaluate the potential association between the number of tumor mutations and 
neoantigens with clinical efficacy measures and determine if tumor antigen-specific T cells 
are present in the periphery.
 To assess the subject’s overall health status as assessed by the EQ-5D. 
 To evaluate cancer specific health related quality of life as assessed by EORTC QLQ-C30.
 To characterize pharmacokinetics of nivolumab monotherapy  
and explore exposure-response relationships.
 To characterize the immunogenicity of nivolumab monotherapy  
1.4 Product Development Background
Information for nivolumab (BMS-936558, anti-PD-1 antibody), ipilimumab (YERVOY; anti-
CTLA antibody), daratumumab (anti-CD38 antibody) and BMS-986016 (relatlimab, anti-LAG-3 
antibody) is provided in the sections below; additional details are provided in the respective 
Investigator Brochures.
1.4.1 Nivolumab
1.4.1.1 Summary of Nivolumab Clinical Activity in the Metastatic Setting
The PK, clinical activity, and safety of nivolumab have been assessed in approximately 70 clinical 
studies sponsored by BMS, Ono Pharmaceutical Co., Ltd. (ONO), or other partners.
Approximately 12,300 subjects have received nivolumab in single- or multiple-dose Phase 1/2/3 
studies or studies with nivolumab in combination with other therapeutics (ipilimumab, cytotoxic 
chemotherapy, anti-angiogenics, and targeted therapies). 
Nivolumab monotherapy is approved in multiple countries, including the US and EU, for 
unresectable or metastatic melanoma, previously treated metastatic NSCLC, and previously 
treated advanced RCC; it is also approved for the treatment of cHL in the US. In addition, 





nivolumab has been approved for use in combination with ipilimumab for unresectable melanoma 
in multiple countries, including the US and EU.
Nivolumab has demonstrated durable responses exceeding 6 months as monotherapy and in 
combination with ipilimumab in several tumor types, including NSCLC, melanoma, RCC, 
classical Hodgkin’s lymphoma (cHL), small cell lung cancer (SCLC), gastric cancer, urothelial 
cancer, hepatocellular carcinoma, and colorectal cancer. In confirmatory trials, nivolumab as 
monotherapy demonstrated a statistically significant improvement in OS as compared with the 
current standard of care in subjects with advanced or metastatic NSCLC, unresectable or metastatic 
melanoma, advanced RCC, or SCCHN. Nivolumab in combination with ipilimumab improved 
PFS and ORR over ipilimumab alone in subjects with unresectable or metastatic melanoma. 
Additional details on the efficacy profile of nivolumab, including results from clinical studies, are 
available in the nivolumab IB.
1.4.1.2 Summary of Nivolumab Safety in the Metastatic Setting
The overall safety experience with nivolumab, as a monotherapy or in combination with other 
therapeutics, is based on experience in approximately 12,300 subjects treated to date.
For monotherapy, the safety profile is similar across tumor types. There is no pattern in the 
incidence, severity, or causality of AEs to nivolumab dose level. In Phase 3 controlled studies, the 
safety profile of nivolumab monotherapy is acceptable in the context of the observed clinical 
efficacy, and manageable using established safety guidelines. A pattern of immune-related adverse 
events has been defined, for which management algorithms have been developed; these are 
provided in Appendix 2. Most high-grade events were manageable with the use of corticosteroids 
or hormone replacement therapy (endocrinopathies) as instructed in these algorithms. For 
additional material, see the nivolumab Investigator Brochure.
Additional details on the safety profile of nivolumab, including results from other clinical studies, 


























































































































































































































































































1.5 Overall Risk/Benefit Assessment
There is a significant unmet medical need for subjects with virus positive tumors including 
 cervical/vulvar/vaginal/  
 as outlined in Section 1.1. Virus positive tumors may have distinct 
patterns of immune responses and tumor immune microenvironments (Section 1.1.4); therefore, a 
strong rationale exists to support blocking the PD-1 signaling pathway with the goal of improving 
patient outcomes in the metastatic/recurrent settings. In the metastatic setting, subjects with virus-
positive tumors generally have limited treatment options with high mortality rates, and NCCN 
guidelines recommend clinical trials as an option for each of the tumor types in this trial.
Extensive details on the safety profile of nivolumab are available in the Investigator Brochure, and 
will not be repeated herein.
Overall, the safety profile of nivolumab monotherapy as well as in combination with ipilimumab 
is manageable and generally consistent across completed and ongoing clinical trials with no MTD 
reached at any dose tested up to 10 mg/kg. Most AEs were low-grade (Grade 1 to 2) with relatively 
few related high-grade (Grade 3 to 4) AEs. There was no pattern in the incidence, severity, or 
causality of AEs with respect to nivolumab dose level.
A pattern of immune-related adverse events has been defined, for which management algorithms 
have been developed; these are provided in Appendix 2. Most high-grade events were manageable 
with the use of corticosteroids or hormone replacement therapy (endocrinopathies) as instructed 
in these algorithms. 
Additional details on the safety profile of nivolumab, including results from other clinical studies, 





















































A pattern of immune-related adverse events has been defined for treatment with nivolumab 
monotherapy  





 Management algorithms have been developed for these events and are provided in 
Appendix 2. Most high-grade events are manageable with the use of corticosteroids or hormone 
replacement therapy (endocrinopathies) as instructed in these algorithms.
Myocarditis has been observed with nivolumab monotherapy treatment (see nivolumab IB Section 
5.6.2). Given the grade 5 myocarditis event in the CA224020 study, and the known nonclinical 
mouse double LAG-3/PD-1 knockout myocarditis phenotype, increased cardiac surveillance with 
troponin measurements were instituted. As of the clinical cutoff date of 15-Jun-2017 there have 
been four grade 1 myocarditis cases (asymptomatic troponin elevations with imaging correlate of 
myocardial inflammation but without evidence of cardiac dysfunction). Treatment was delayed in 
all cases, and precautionary steroid treatment was given without any of the participants developing 













































It is possible that unforeseen or unanticipated AEs may occur. In order to minimize the overall 
risks to participating subjects, the protocol has inclusion-exclusion criteria appropriate to the 
population, and specific follow-up safety assessments. Routine safety monitoring for all the AEs 
described above will be implemented in the protocol to ensure that we are monitoring the potential 
for overlapping toxicities.
Adverse events and SAEs will continue to be reviewed expeditiously by the Medical Monitor, 

























In summary, based on the manageable safety profile of nivolumab  
 the observed clinical activity of nivolumab  
and the rationale for immune checkpoint inhibition for 
patients with virus-associated tumors, it is felt that the overall benefits to subjects outweigh the 










Depending on the clinical activity, results could form the basis for regulatory filings. Additional 
combination arms based on a nivolumab backbone, and/or expansion of existing cohorts, may be 
added in future amendments. 
2 ETHICAL CONSIDERATIONS
2.1 Good Clinical Practice
This study will be conducted in accordance with Good Clinical Practice (GCP), as defined by the 
International Conference on Harmonisation (ICH) and in accordance with the ethical principles 
underlying European Union Directive 2001/20/EC and the United States Code of Federal 
Regulations, Title 21, Part 50 (21CFR50).
The study will be conducted in compliance with the protocol. The protocol and any amendments 
and the subject informed consent will receive Institutional Review Board/Independent Ethics 
Committee (IRB/IEC) approval/favorable opinion prior to initiation of the study.





All potential serious breaches must be reported to BMS immediately. A serious breach is a breach 
of the conditions and principles of GCP in connection with the study or the protocol, which is 
likely to affect, to a significant degree, the safety or physical or mental integrity of the subjects of 
the study or the scientific value of the study.
Personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks.
This study will not use the services of study personnel where sanctions have been invoked or where 
there has been scientific misconduct or fraud (eg, loss of medical licensure, debarment). 
2.2 Institutional Review Board/Independent Ethics Committee
Before study initiation, the investigator must have written and dated approval/favorable opinion 
from the IRB/IEC for the protocol, consent form, subject recruitment materials 
(eg, advertisements), and any other written information to be provided to subjects. The investigator 
or BMS should also provide the IRB/IEC with a copy of the Investigator Brochure or product 
labeling information to be provided to subjects and any updates. 
The investigator or BMS should provide the IRB/IEC with reports, updates and other information 
(eg, expedited safety reports, amendments, and administrative letters) according to regulatory 
requirements or institution procedures.
2.3 Informed Consent
Investigators must ensure that subjects are clearly and fully informed about the purpose, potential 
risks, and other critical issues regarding clinical studies in which they volunteer to participate. 
In situations where consent cannot be given to subjects, their legally acceptable representatives as 
per country guidelines) are clearly and fully informed about the purpose, potential risks, and other 
critical issues regarding clinical studies in which the subject volunteers to participate. 
BMS will provide the investigator with an appropriate (ie, Global or Local) sample informed 
consent form which will include all elements required by ICH, GCP and applicable regulatory 
requirements. The sample informed consent form will adhere to the ethical principles that have 
their origin in the Declaration of Helsinki.
Investigators must:
1) Provide a copy of the consent form and written information about the study in the language in 
which the subject is most proficient prior to clinical study participation. The language must be 
non-technical and easily understood. 
2) Allow time necessary for subject or subject's legally acceptable representative to inquire about 
the details of the study.
3) Obtain an informed consent signed and personally dated by the subject or the subject's legally 
acceptable representative and by the person who conducted the informed consent discussion. 
4) Obtain the IRB/IEC’s written approval/favorable opinion of the written informed consent form 
and any other information to be provided to the subjects, prior to the beginning of the study, 
and after any revisions are completed for new information.





5) If informed consent is initially given by a subject’s legally acceptable representative or legal 
guardian, and the subject subsequently becomes capable of making and communicating his or 
her informed consent during the study, consent must additionally be obtained from the subject.
6) Revise the informed consent whenever important new information becomes available that is 
relevant to the subject's consent. The investigator, or a person designated by the investigator, 
should fully inform the subject or the subject's legally acceptable representative or legal 
guardian, of all pertinent aspects of the study and of any new information relevant to the 
subject's willingness to continue participation in the study. This communication should be 
documented. 
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules applicable to regulatory requirements, the subjects' signed ICF and, in the 
US, the subjects’ signed HIPAA Authorization.
The consent form must also include a statement that BMS and regulatory authorities have direct 
access to subject records. 
The rights, safety, and well-being of the study subjects are the most important considerations and 
should prevail over interests of science and society.
3 INVESTIGATIONAL PLAN
3.1 Study Design and Duration
This is an open label, multi-center, phase 1/2 trial to investigate the safety and efficacy of 
nivolumab as a single agent or in combination with either ipilimumab, BMS-986016 (relatlimab,
anti-LAG3 antibody), or daratumumab in viral positive and viral negative tumor types of the 
following tumor types: Epstein Barr Virus (EBV) positive gastric cancer, EBV positive 
nasopharyngeal cancer (NPC), cervical cancer, HPV positive and negative squamous cell cancer 
of the head and neck (SCCHN), anogenital HPV associated cancers (vaginal, vulvar, anal canal, 
penile), and Polyomavirus positive Merkel cell cancer (pMCC).
On the basis of eligibility and tumor type, patients will be enrolled into the neoadjuvant or 
recurrent/metastatic monotherapy, or assigned or randomized into the recurrent/metastatic 
combination therapies cohorts (A, B, and D). Upon approval of Revised Protocol 05, all Metastatic 
Combination Cohorts A, B, and D will enroll patients concurrently, and enrollment will be closed 












 Nivolumab administered IV over 30 minutes at 240 mg every 2 weeks for a maximum of 











































Nivo monotherapy 240 mg
Q2 weeks
Until disease progression, toxicity, 
withdrawal of consent, or a maximum 
of 24 months
TUMORS:
• EBV (+) Gastric - N=12
• HPV(+) SCCHN - N=23
• GYN (cervical, vaginal, 
vulvar) - N=23
• MCC - N=23
• NPC  - N=23
Up to 5 weeks
Up to 2 prior treatments
≥ 1 target lesion
ECOG status: 0 or 1
• Imaging every 8 weeks starting at 
Week 8 for the first year of treatment
• Imaging every 12 weeks starting at 
year 2 and beyond
Min 12 weeks
survival
For Subjects with HPV (+) and 
EBV (+):  virus selection required








































All subjects will complete 3 periods of the study: Screening, Treatment, Follow-up, including
survival follow-up. 
Duration of Study: The last visit will be defined as the latest survival visit included in the final 
analysis of OS (ie, the latest subject death, loss to follow up, or withdrawal of consent) for a tumor 
type within each cohort. Additional survival follow-up may continue for up to 5 years from the 
time of this analysis. The study will end once survival follow-up collection has concluded.



























Metastatic monotherapy cohort: Gastric and SCCHN subjects will be tested for viral status prior 
to study drug assignment. Gastric subjects must be EBV positive, and SCCHN subjects must be 
HPV positive to enroll in this cohort. MCC, NPC, and Gyn (cervical, vaginal, vulvar) subjects will 
not require viral screening prior to study entry. With the exception of gastric cancer (n=12), each 
specific tumor type in the metastatic monotherapy cohort will contain 23 subjects. Subjects will 
be treated with nivolumab 240 mg IV every 2 weeks until disease progression, unacceptable 
toxicity, or 24 months of treatment. Viral positivity will be tested retrospectively for MCC, NPC, 


























All subjects (if clinically feasible) in each cohort will receive pre-treatment and on-treatment tumor 
biopsies. Primary analysis for the Neoadjuvant, Metastatic monotherapy, and Metastatic 
combination therapy cohorts will be conducted separately after a minimum of at least six months
after the first treatment of the last patient for a tumor type enrolled in each cohort. All analyses 

































3.1.3 Subjects in the Metastatic Monotherapy Cohort
For subjects without resectable disease, nivolumab will be administered at 240 mg every 2 weeks 
until toxicity, disease progression, withdrawal of consent, or 24 months of treatment, whichever 
comes first. For subjects in the metastatic cohort, radiographic tumor assessments by CT 
(preferred)/MRI will begin 8 weeks ( 1 week) after the start of therapy and will continue every 8
weeks ( 1 week) for the first year of treatment. CT (preferred)/MRI will continue every 12 weeks 
( 2 weeks) for the second year and beyond. Tumor assessments will follow the above schedule 
until disease progression is documented. If the subject discontinues treatment prior to disease 
progression, tumor assessment will continue per protocol as described in Table 5.4.1-1. Disease 
progression is defined by investigator-assessed RECIST 1.1 criteria. The primary endpoint of this 
cohort is objective response rate (ORR) based on investigator assessments, using RECIST 1.1





criteria. Exploratory endpoints include complete and partial remission rates and durations based 
on radiological assessments. Individual tumors types will be analyzed separate from each other.  
In all subjects for each tumor type, biopsy and submission of fresh tumor tissue, or submission of 
archived tumor tissue, is mandatory for all subjects. Subjects with accessible lesions where biopsy 


































3.2 Post Study Access to Therapy
At the conclusion of the study, subjects who continue to demonstrate clinical benefit will be 
eligible to receive BMS supplied study drug for the maximum treatment duration specified in 
Section 3.1. Study drug will be provided via an extension of the study, a rollover study requiring 
approval by responsible health authority and ethics committee or through another mechanism at 
the discretion of BMS. BMS reserves the right to terminate access to BMS supplied study drug if 
any of the following occur: a) the marketing application is rejected by responsible health authority; 
b) the study is terminated due to safety concerns; c) the subject can obtain medication from a 
government sponsored or private health program; or d) therapeutic alternatives become available 
in the local market.
3.3 Study Population
For entry into the study, the following criteria MUST be met.
3.3.1 Inclusion Criteria
1. Signed Written Informed Consent
a) Subjects must have signed and dated an IRB/IEC approved written informed consent form 
in accordance with regulatory and institutional guidelines. This must be obtained before 
the performance of any protocol related procedures that are not part of normal subject care.
b) Subjects must be willing and able to comply with scheduled visits, treatment schedule, 
laboratory tests, and other requirements of the study.
2. Target Population
a) Histopathologic confirmation of the following tumor types
 















 Squamous cell carcinoma of the cervix, vagina, vulva, penile or anal carcinoma
o For subjects in the neoadjuvant and metastatic (monotherapy and combination)
cohorts with gynecological tumors, HPV positivity is defined by FDA approved 
tests (Cobas HPV Test; Digene Hybrid Capture 2 High-Risk HPV DNA Test; 
Cervista™ HPV HR and Genfind™ DNA Extraction Kit; Cervista™ HPV 16/18; 
APTIMA® HPV Assay) or other well validated commercially available tests (such 
as Ventana Inform HPV ISH test) comprising in situ hybridization, real-time PCR, 
or immunohistochemistry (IHC). High-risk HPV positivity includes the following 
subtypes:  16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68. Virus testing will 









































o For subjects in the metastatic cohorts (monotherapy and combination)
 Progressive metastatic or recurrent disease treated with no more than 2 prior systemic 
therapies or regimens in the metastatic setting.
 Measurable disease by CT or MRI per RECIST 1.1 criteria (Appendix 3) (radiographic 
tumor assessment must be performed within 35 days prior to first dose).
 Subjects who actively refuse chemotherapy or other standard therapies for the treatment 
of unresectable or metastatic disease (advanced Stage III or Stage IV), despite being 
informed by the investigator about the treatment options may enroll. The subject’s 
refusal must be thoroughly documented. The investigator will discuss each individual 
subject refusing chemotherapy with the sponsor’s medical monitor or study director to 
confirm eligibility. Written approval from the sponsor’s medical monitor is required 
for eligibility. 






























o Histologically confirmed cervical, vulvar, or vaginal cancer, as defined above. If 
the viral results are known prior to enrollment, and they are viral negative, the 















 metastatic (monotherapy and combination)cohorts
 Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
 Men and women of age 18 or older.
 Subject willing to comply to provide tumor tissue for PD-L1 expression analysis and 
other biomarker correlative studies. See Section 5.6.9 for further details. Biopsy should 
be excisional, incisional or core needle. Fine needle aspirates are prohibited.
o All baseline laboratory requirements will be assessed and should be obtained within 
-14 days of first dose (unless otherwise specified in Table 5.1-1). Screening laboratory 
values must meet the following criteria:
 WBCs  2000/µL
 Neutrophils  1500/µL
 Platelets  100 x 10³/µL
 Hemoglobin  9.0 g/dL
 Creatinine Serum creatinine  1.5 x ULN or creatinine clearance (CrCl) 
 40 mL/minute (using Cockcroft/Gault formula)
 AST  3 x ULN 
 ALT  3 x ULN 
 Total Bilirubin  1.5 x ULN (except subjects with Gilbert Syndrome who can have 
total bilirubin < 3.0 mg/dL)
 Cardiac Troponin T (cTnT) or I (cTnI) ≤ 2 × institutional ULN. Subjects with cTnT or 
cTnI levels between > 1 to 2 × ULN will be permitted if repeat levels within 24 hours 
are ≤ 1 ULN (Combo C only)
o If cTnT or cTnI levels are >1 ULN at 24 hours, the subject may undergo a cardiac 
evaluation and be considered for treatment, following a discussion with the BMS 
Medical Monitor or designee.
o Subject Re-enrollment: This study permits the re-enrollment of a subject that has 
discontinued the study as a pre-treatment failure (ie, subject has not been randomized / has 
not been treated). If re-enrolled, the subject must be re-consented.
o LVEF assessment with documented LVEF ≥ 50% by either TTE or MUGA (TTE preferred 
test) within 6 months from first study drug administration (Combo C only)
3. Age and Reproductive Status
a) Men and women, ages  18 years of age
b) Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours 
prior to the start of study drug.





c) Women must not be breastfeeding
d) WOCBP must agree to follow instructions for method(s) of contraception from the time of 
enrollment for the duration of treatment with study drug(s) plus approximately 5 half-lives 





 WOCBP who are continuously not heterosexually active are 
exempt from contraceptive requirements. However they must still undergo pregnancy 
testing as described in this section.
Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on 
the importance of pregnancy prevention and the implications of an unexpected pregnancy.
Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the 
use of highly effective methods of contraception. Highly effective methods of contraception have 
a failure rate of < 1% when used consistently and correctly.
At a minimum, subjects must agree to the use one highly effective method of contraception as 
listed in Appendix 4.
3.3.2 Exclusion Criteria
 Target Disease Exceptions
a) Active brain metastases or leptomeningeal metastases. Subjects with brain metastases are 
eligible if these have been treated and there is no magnetic resonance imaging (MRI) 
evidence of progression for at least 4 weeks after treatment is complete and within 28 days 
prior to first dose of study drug administration. There must also be no requirement for 
immunosuppressive doses of systemic corticosteroids (>10 mg/day prednisone 
equivalents) for at least 2 weeks prior to study drug administration.
 Medical History and Concurrent Diseases
a) Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may 
increase the risk associated with study participation or study drug administration, impair 
the ability of the subject to receive protocol therapy, or interfere with the interpretation of 
study results.
b) Prior malignancy active within the previous 3 years except for locally curable cancers that 
have been apparently cured or successfully resected, such as basal or squamous cell skin 
cancer, superficial bladder cancer, or gastric cancer, or carcinoma in situ of the prostate, 
cervix, or breast.
c) Subjects with active, known or suspected autoimmune disease. Subjects with skin disorders 
(such as vitiligo, psoriasis, or alopecia), type I diabetes mellitus, hypothyroidism only 





requiring hormone replacement, or conditions not expected to recur in the absence of an 
external trigger are permitted to enroll.
d) Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg 
daily prednisone equivalents) or other immunosuppressive medications within 14 days of 
study drug administration. Inhaled or topical steroids, and adrenal replacement doses are 
permitted in the absence of active autoimmune disease.
e) Subjects with primary tumor or nodal metastasis fixed to the carotid artery, skull base or 
cervical spine.
f) Prior therapy with experimental anti-tumor vaccines; any T cell co-stimulation or 
checkpoint pathways, such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or 
anti-CTLA-4 antibody, including ipilimumab; or other medicines specifically targeting 
T cell co-stimulation or checkpoint pathways is also prohibited. Exception: Combo C
SCCHN prior anti-PD-1/anti-PD-L1/anti-CTLA-4 exposure tumor types.
g) All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must 
have resolved to Grade 1 (NCI CTCAE version 4) or baseline before administration of 
study drug. Subjects with toxicities attributed to prior anti-cancer therapy which are not 
expected to resolve and result in long lasting sequelae, such as neuropathy after platinum 
based therapy, are permitted to enroll.
h) Treatment with any chemotherapy, radiation therapy, biologics for cancer, or 
investigational therapy within 28 days of first administration of study treatment (subjects 
with prior cytotoxic or investigational products < 4 weeks prior to treatment might be 
eligible after discussion between investigator and sponsor, if toxicities from the prior 


















l) Treatment with botanical preparations (eg herbal supplements or traditional Chinese 
medicines) intended for general health support or to treat the disease under study within 2 
weeks prior to randomization/treatment. Refer to Section 3.4.1 for prohibited therapies.
m) For the expansion cohort for subjects with SCC of the cervix and for subjects eligible to 
receive study drug (Combo B) as first-line treatment for their recurrent/metastatic disease, 
must not have been treated previously with chemotherapy except when used concurrently 
with radiation therapy.
 Physical and Laboratory Test Findings
a) Any positive test result for hepatitis B virus (e.g. surface antigen [HBV sAg, Australia 
antigen] positive) or hepatitis C virus (Hepatic C antibody [anti-HCV] positive, except if 
HCV-RNA negative.
b) Known history of testing positive for human immunodeficiency virus (HIV) or known 
acquired immunodeficiency syndrome (AIDS). NOTE: Testing for HIV must be performed 
at sites where mandated locally.
 Allergies and Adverse Drug Reaction
a) History of allergy to study drug components.
b) History of severe hypersensitivity reaction to any monoclonal antibody.
 Sex and Reproductive Status
a) WOCBP who are pregnant or breastfeeding
b) Women with a positive pregnancy test at enrollment or prior to administration of study 
drug
 Other Exclusion Criteria
a) Prisoners or subjects who are involuntarily incarcerated
b) Subjects who are compulsorily detained for treatment of either a psychiatric or physical 
(eg, infectious disease) illness
Eligibility criteria for this study have been carefully considered to ensure the safety of the study 
subjects and that the results of the study can be used. It is imperative that subjects fully meet all 
eligibility criteria.





3.3.3 Women of Childbearing Potential
A women of childbearing potential (WOCBP) is defined as any female who has experienced 
menarche and who has not undergone surgical sterilization (hysterectomy or bilateral 
oophorectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in 
a woman over age 45 years in the absence of other biological or physiological causes. In addition, 
females under the age of 55 years must have a serum follicle stimulating hormone, (FSH) level 
> 40 mIU/mL to confirm menopause.
See Appendix 4 for more details.
3.4 Concomitant Treatments
3.4.1 Prohibited and/or Restricted Treatments
The following medications are prohibited during the study:
 Immunosuppressive agents (except to treat a drug-related adverse event)
 Immunosuppressive doses of systemic corticosteroids (> 10 mg daily prednisone 
equivalent), except as stated in Section 3.4.2 or to treat a drug-related adverse event. 
 Any concurrent antineoplastic therapy (ie, chemotherapy, hormonal therapy, 
immunotherapy, radiation therapy except for palliative radiation therapy described in 
Section 3.4.2 or standard or investigational agents for treatment of cancer).
 Any botanical preparation (eg herbal supplements or traditional Chinese medicines) 
intended to treat the disease under study or provide supportive care. Use of marijuana and 
its derivatives for treatment of symptoms related to cancer or cancer treatment are 
permitted if obtained by medical prescription or if its use (even without a medical 
prescription) has been legalized locally.  
 LAG-3 targeting agents. 
Supportive care for disease-related symptoms may be offered to all subjects on the trial.
3.4.1.1 Restricted Treatments
Restricted therapies are not prohibited but are not recommended; consult BMS medical 
monitor/designee if the following are clearly medically indicated:
 Participants with a condition requiring systemic treatment with either corticosteroids (> 10 
mg daily prednisone equivalent) or other immunosuppressive medications within 14 days 
of randomization are excluded. Inhaled or topical steroids, and adrenal replacement steroid 
doses > 10 mg daily prednisone equivalent, are permitted in the absence of active 
autoimmune disease.
3.4.2 Permitted Therapy
Subjects are permitted the use of topical, ocular, intra-articular, intranasal, and inhalational 
corticosteroids (with minimal systemic absorption). Adrenal replacement steroid doses including 
doses > 10 mg daily prednisone are permitted. A brief (less than 3 weeks) course of corticosteroids 
for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, 
delayed-type hypersensitivity reaction caused by a contact allergen) is permitted.





Oral Prophylaxis for herpes zoster reactivation is recommended during the Treatment Phase. 
Initiate antiviral prophylaxis within 1 week after starting daratumumab, and continue for 3 months 
following treatment discontinuation (Combo D only).
Subjects must receive pre-infusion and post-infusion medications with each dose of daratumumab, 
per the daratumumab Investigators Brochure; additional details are provided in Section 4.7.7.  
Palliative (limited-field) radiation therapy and palliative surgical resection are permitted if the 
following criteria are met:
 The subject is considered to have progressed at the time of palliative therapy and meets 
criteria to continue with treatment beyond progression (Section 4.7.8).
 The case is discussed with the BMS medical monitor. 
 Palliative therapy must be clearly documented as such in the study record.
The potential for overlapping toxicities with radiotherapy and nivolumab alone or in combination 
with either ipilimumab, BMS-986016 (relatlimab), or daratumumab currently is not known. 
Therefore, palliative radiotherapy is not recommended while receiving study drug. If palliative 
radiotherapy is required, then study drug should be withheld for at least 1 week before, during and 
1 week after radiation. Subjects should be closely monitored for any potential toxicity during and 
after receiving radiotherapy, and AEs considered related to radiotherapy should resolve to Grade 
 1 prior to resuming study drug. 
Only non-target lesions included in the planned radiation field or CNS lesions may receive 
palliative radiotherapy. Details of palliative radiotherapy should be documented in the source 
records and electronic case report form (eCRF). Details in the source records should include: dates 
of treatment, anatomical site, dose administered and fractionation schedule, and adverse events. 
Subjects receiving limited field palliative radiation therapy will be considered to have unequivocal 
progression of disease in the non-target lesion. Symptoms requiring palliative radiotherapy should 
be evaluated for objective evidence of disease progression. Administration of additional study drug
to subjects who received limited field palliative radiation should follow guidelines specified in 
Section 4.7.8 Treatment Beyond Disease Progression.
3.4.3 Surgical Resection Following Initial Response
Investigators may choose to resect solitary lesions in subjects with residual disease and render the 
subject free of macroscopic disease. Subjects treated in this study may have lesions surgically 
resected only following consultation with the Medical Monitor and following the Week 25 tumor 
imaging assessments. If additional tumor shrinkage is noted compared to the tumor imaging 
assessments at Week 17, it is highly encouraged that surgical resection be delayed until subsequent 
scans fail to demonstrate further shrinkage. Subjects with a confirmed PR who go on to have 
surgical resection of remaining disease will be considered a PR. Subjects with SD who go on to 
have surgical resection of remaining disease will be considered a SD. Subjects may continue 
treatment after surgery. Tumor tissue of any resected solitary lesion should be submitted to BMS 
(see Section 5.6.9). Detailed instructions of the obtaining, processing, labeling, handling, storage 





and shipment of these specimens will be provided in a separate Procedure Manual at the time of 
study initiation.
3.4.4 Other Restrictions and Precautions
Participants with a condition requiring systemic treatment with either corticosteroids (> 10 mg 
daily prednisone equivalent) or other immunosuppressive medications within 14 days of treatment 
assignment are excluded. Inhaled or topical steroids, and adrenal replacement steroid doses 
> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
It is the local imaging facility’s responsibility to determine, based on subject attributes (eg, allergy 
history, diabetic history and renal status), the appropriate imaging modality and contrast regimen 
for each subject. Imaging contraindications and contrast risks should be considered in this 
assessment. Subjects with renal insufficiency should be assessed as to whether or not they should 
receive contrast and if so, what type and dose of contrast is appropriate. Specific to MRI, subjects 
with severe renal insufficiency (ie, estimated glomerular filtration rate (eGFR) 
< 30 mL/min/1.73m2) are at increased risk of nephrogenic systemic fibrosis. MRI contrast should 
not be given to this subject population. In addition, subjects are excluded from MRI if they have 
tattoos, metallic implants, pacemakers, etc.
The ultimate decision to perform MRI in an individual subject in this study rests with the site 




























3.5 Discontinuation of Subjects following any Treatment with Study Drug
Subjects MUST discontinue investigational product (and non-investigational product at the 
discretion of the investigator) for any of the following reasons:
 Subject’s request to stop study treatment
 Any clinical adverse event (AE), laboratory abnormality or intercurrent illness which, in 
the opinion of the investigator, indicates that continued participation in the study is not in 
the best interest of the subject
 Termination of the study by Bristol-Myers Squibb (BMS)
 Loss of ability to freely provide consent through imprisonment or involuntarily
incarceration for treatment of either a psychiatric or physical (eg, infectious disease) illness
 For discontinuation criteria related to nivolumab-and/or ipilimumab, BMS-986016
(relatlimab) or daratumumab-related adverse events, please refer to Section 4.7.6. 
Follow-up begins when the decision to discontinue a subject from study therapy is made 
(no further treatment with study therapy).
 Subjects will have two follow-up visits for safety. Follow-up visit 1, 35 days from the last 
dose or from the date decision is made to discontinue subject from the study (only 
applicable for early treatment discontinuation) ( 7 days) and follow-up visit 2 80 days 
( 7 days) after follow-up visit 1. After follow-up visit 2, subjects will be followed every 
3 months for ongoing drug-related adverse events until resolved, return to baseline or 
deemed irreversible, or until lost to follow-up, withdrawal of study consent, or start of a 
subsequent anti-cancer therapy.
 Subjects who discontinue study therapy for reasons other than disease progression will 
continue to have radiographic assessments as per defined schedule until disease 
progression, lost to follow-up, or withdrawal of study consent.
 PK and immunogenicity samples will be collected at the first 2 follow-up visits.
In the case of pregnancy, the investigator must immediately notify the BMS Medical 
Monitor/designee of this event. In most cases, the study drug will be permanently discontinued in 
an appropriate manner. Please contact the Sponsor or designee within 24 hours of awareness of 
the pregnancy. If the investigator determines a possible favorable benefit/risk ratio that warrants 
continuation of study drug, a discussion between the investigator and the BMS Medical 
Monitor/designee must occur.





All subjects who discontinue study drug should comply with protocol specified follow-up 
procedures as outlined in Section 5. The only exception to this requirement is when a subject 
withdraws consent for all study procedures including post-treatment study follow-up or loses the 
ability to consent freely (ie, is imprisoned or involuntarily incarcerated for the treatment of either 
a psychiatric or physical illness).
If study drug is discontinued prior to the subject’s completion of the study, the reason for the 
discontinuation must be documented in the subject’s medical records and entered on the 
appropriate case report form (CRF) page.
This study will end when analysis of the primary endpoint is complete. Additional survival analysis 
may be conducted for up to 5 years beyond analysis of the primary endpoint.
3.6 Post Study Drug Study Follow-up
In this study, overall survival is a key endpoint of the study. Post study follow-up is of critical 
importance and is essential to preserving subject safety and the integrity of the study. Subjects who 
discontinue study drug must continue to be followed for collection of outcome and/or survival 
follow-up data as required and in line with Section 5 until death or the conclusion of the study.
BMS may request that survival data be collected on all treated/randomized subjects outside of the 
protocol defined window (refer to Section 5.1). At the time of this request, each subject will be 
contacted to determine their survival status unless the subject has withdrawn consent for all 
contacts or is lost to follow-up.
3.6.1 Withdrawal of Consent
Subjects who request to discontinue study drug will remain in the study and must continue to be 
followed for protocol specified follow-up procedures. The only exception to this is when a subject 
specifically withdraws consent for any further contact with him/her or persons previously 
authorized by subject to provide this information. Subjects should notify the investigator of the 
decision to withdraw consent from future follow-up in writing, whenever possible. The 
withdrawal of consent should be explained in detail in the medical records by the investigator, as 
to whether the withdrawal is from further treatment with study drug only or also from study 
procedures and/or post treatment study follow-up, and entered on the appropriate CRF page. In the
event that vital status (whether the subject is alive or dead) is being measured, publicly available 
information should be used to determine vital status only as appropriately directed in accordance 
with local law.
3.6.2 Lost to Follow-up
All reasonable efforts must be made to locate subjects to determine and report their ongoing status. 
This includes follow-up with persons authorized by the subject as noted above. Lost to follow-up 
is defined by the inability to reach the subject after a minimum of three documented phone calls, 
faxes, or emails as well as lack of response by subject to one registered mail letter. All attempts 
should be documented in the subject’s medical records. If it is determined that the subject has died, 
the site will use permissible local methods to obtain the date and cause of death.





If investigator’s use of third-party representative to assist in the follow-up portion of the study has 
been included in the subject’s informed consent, then the investigator may use a Sponsor-retained 
third-party representative to assist site staff with obtaining subject’s contact information or other 
public vital status data necessary to complete the follow-up portion of the study. The site staff and 
representative will consult publicly available sources, such as public health registries and 
databases, in order to obtain updated contact information. If after all attempts, the subject remains 
lost to follow-up, then the last known alive date as determined by the investigator should be 











Table 4.-1: Product Description: Treatment Period
Product Description / 
































a May be labeled as either “BMS-936558-01” or “Nivolumab”
 
 






An investigational product, also known as investigational medicinal product in some regions, is 
defined as a pharmaceutical form of an active substance or placebo being tested or used as a 
reference in a clinical study, including products already with a marketing authorization but used 
or assembled (formulated or packaged) in a way different from the authorized form, or used for an 
unauthorized indication, or when used to gain further information about the authorized form.
The investigational product should be stored in a secure area according to local regulations. It is 
the responsibility of the investigator to ensure that investigational product is only dispensed to 
study subjects. The investigational product must be dispensed only from official study sites by 
authorized personnel according to local regulations. 
In this protocol, the investigational product is: nivolumab for the neoadjuvant and metastatic 
monotherapy cohorts.
For the metastatic combination therapy cohort, the investigational products are nivolumab and 
ipilimumab for combination therapy Combo A and B, nivolumab and BMS-986016 (relatlimab)
for combination therapy Combo C, and nivolumab and daratumumab for combination therapy 
Combo D.
4.2 Non-investigational Product
Other medications used as support or escape medication for preventative, diagnostic, or therapeutic 
reasons, as components of the standard of care for a given diagnosis, may be considered as non-
investigational products. 
Standard of care treatment will be procured by the investigator.
4.3 Storage and Dispensing
The product storage manager should ensure that the study drug is stored in accordance with the 
environmental conditions (temperature, light, and humidity) as determined by BMS. If concerns 
regarding the quality or appearance of the study drug arise, the study drug should not be dispensed 
and contact BMS immediately.
Study drug not supplied by BMS will be stored in accordance with the package insert.
Investigational product documentation (whether supplied by BMS or not) must be maintained that 
includes all processes required to ensure drug is accurately administered. This includes 
documentation of drug storage, administration and, as applicable, storage temperatures, 
reconstitution, and use of required processes (eg, required diluents, administration sets).
Infusion-related supplies (eg, IV bags, in-line filters, 0.9% sodium chloride injection, 5% dextrose 
injection) will not be supplied by the sponsor and should be purchased locally if permitted by local 
regulations.
Please refer to the current version of the Investigator Brochure and/or pharmacy reference sheets 
for complete storage, handling, dispensing, and infusion information for nivolumab, ipilimumab, 
BMS-986016 (relatlimab), and daratumumab.





Nivolumab is to be administered as an IV infusion. Nivolumab infusion must be promptly followed 































































   
 





















4.4 Method of Assigning Subject Identification
The subject number will be assigned through an interactive response technology (IRT) system
once the subject has signed the informed consent form and is registered. Every subject that signs 
the informed consent form must be assigned a subject number in IRT. Specific instructions for 
using IRT will be provided to the investigational site in a separate document.
The investigator or designee will register the subject for enrollment by following the enrollment 
procedures established by BMS. The following information is required for enrollment:
 Confirm that informed consent was obtained
 Date of birth
 Gender at birth
 Subject Identification Method
 Which cohort the subject will be enrolled (Neoadjuvant or Metastatic)
 Tumor type for subject





Once enrolled subjects have met all eligibility criteria the IRT must be contacted again for 
treatment assignment, drug vial  
and to confirm that the Cohort/Tumor Type that the 
subject would qualify for is not closed for the study. 
 
The following information is required for drug vial assignment:
 Subject number











If the Cohort/Tumor Type that the subject would qualify for has already met the maximum number 
of subjects, the subject will not be able to enter the treatment phase of the study and will be 
considered an enrollment failure.
The exact procedures for using the IRT will be detailed in the IRT manual.
4.5 Selection and Timing of Dose for Each Subject



































































































































Metastatic Monotherapy Cohort subjects will receive treatment with nivolumab on Day 1 of a 






































Treatment compliance will be monitored by drug accountability as well as the subject’s medical 
record and eCRF.
4.7.1 Premedications
Antiemetic medications should not be routinely administered prior to dosing of nivolumab, 
ipilimumab, and BMS-986016 (relatlimab). See Section 4.7.7 for subsequent premedication 
recommendations following a study drug-related infusion reaction.
 





4.7.2 Management Algorithms for Immuno-oncology Agents
Immuno-oncology (I-O) agents are associated with adverse events that can differ in severity and
duration than adverse events caused by other therapeutic classes. Nivolumab, ipilimumab, 
BMS-986016 (relatlimab), and daratumumab are considered immuno-oncology agents in this 
protocol. Early recognition and management of adverse events associated with immuno-oncology 
agents may mitigate severe toxicity. Management algorithms have been developed to assist 








The safety management algorithms are provided in Appendix 2 of this protocol.
4.7.3 Dose Delay Criteria
Study drug administration (nivolumab, ipilimumab, and BMS-986016) should be delayed for the 
following:
 Grade 2 non-skin, drug-related adverse event, except for fatigue.
 Grade 3 skin, drug-related adverse event
 Grade 2 drug-related creatinine, AST, ALT, and/or total bilirubin
 Grade 3 drug-related fatigue, nausea, vomiting, and anemia (Combination Cohort C only)
 Grade 3 drug-related laboratory abnormality, with the following exceptions:
 Grade 3 lymphopenia or asymptomatic amylase or lipase does not require a dose delay
 Grade  AST, ALT, or total bilirubin will require dose discontinuation (Section 4.7.6)
 All troponin elevations require a dose delay to allow for prompt cardiac evaluation (Combo C
only)
 Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of
the investigator, warrants delaying the dose of study drug.
 Subjects receiving ipilimumab or BMS-986016 in combination with nivolumab that have drug-
related toxicities that meet the criteria for dose delay, should have both drugs (nivolumab and
either ipilimumab, or BMS-986016) delayed until retreatment criteria are met.
 Subjects who require delay of study treatment should be re-evaluated weekly or more











































There will be no dose reductions for nivolumab,
4.7.5 Criteria to Resume Dosing
Subjects may resume treatment with study drug when the drug-related AE(s) resolve(s) to Grade 1 
or baseline, with the following exceptions:
 Subjects may resume treatment in the presence of Grade 2 fatigue.
 Subjects who have not experienced a Grade 3 drug-related skin AE may resume treatment in 
the presence of Grade 2 skin toxicity.
 For participants with Grade 2 AST, ALT and/or Total Bilirubin Abnormalities, dosing may 
resume when laboratory values return to baseline and management with corticosteroids, if 
needed, is complete.
 Drug-related pulmonary toxicity, diarrhea, or colitis must have resolved to baseline before 
treatment is resumed. Subjects with persistent Grade 1 pneumonitis after completion of a 
steroid taper over at least 1 month may be eligible for retreatment if discussed with and 
approved by the BMS Medical Monitor.
 Subjects who received systemic corticosteroids for management of any drug-related toxicity 
must be off corticosteroids or have tapered down to an equivalent dose of prednisone 
 10 mg/day.
 Drug-related endocrinopathies adequately controlled with only physiologic hormone 
replacement may resume treatment after consultation with the BMS Medical Monitor. Adrenal 
insufficiency requires discontinuation regardless of control with hormone replacement.





 Troponin elevations will require the participant to undergo a cardiac evaluation. Following this 























Treatment with study drug should be permanently discontinued for the following:
 Any Grade 2 drug-related uveitis or eye pain or blurred vision that does not respond to 
topical therapy and does not improve to Grade 1 severity within the re-treatment period OR 
requires systemic treatment
 Any Grade 3 non-skin, drug-related adverse event lasting > 7 days or recurs, with the 
following exceptions for laboratory abnormalities, diarrhea, colitis, neurologic toxicity, drug-
related uveitis, pneumonitis, bronchospasm, hypersensitivity reactions, myocarditis, infusion 
reactions, and endocrinopathies:
 Grade 3 drug-related diarrhea, colitis, neurologic toxicity, uveitis, pneumonitis, 
bronchospasm, myocarditis, hypersensitivity reaction, or infusion reaction of any duration 
requires discontinuation





 Grade 3 drug-related endocrinopathies, adequately controlled with only physiologic 
hormone replacement do not require discontinuation. Adrenal insufficiency requires 
discontinuation regardless of control with hormone replacement.
 Grade 3 drug-related laboratory abnormalities do not require treatment discontinuation 
except:
 Grade 3 drug-related thrombocytopenia > 7 days or associated with bleeding requires 
discontinuation
 Any drug-related liver function test (LFT) abnormality that meets the following criteria 
require discontinuation: 
o Grade  3 drug-related AST, ALT or Total Bilirubin requires discontinuation.  
Note: * In most cases of Grade 3 AST or ALT elevation, study drug(s) will be 
permanently discontinued. If the investigator determines a possible favorable 
benefit/risk ratio that warrants continuation of study drug(s), a discussion between 
the investigator and the BMS Medical Monitor/designee must occur.
o Concurrent AST or ALT > 3 x ULN and total bilirubin > 2x ULN
 Any Grade 4 drug-related adverse event or laboratory abnormality (including but not limited 
to creatinine, AST, ALT, or Total Bilirubin), except for the following events, which do not 
require discontinuation:
 Grade 4 neutropenia  7 days
 Grade 4 lymphopenia or leukopenia or asymptomatic amylase or lipase
 Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with clinical 
sequelae and are corrected with supplementation/appropriate management within 72 hours 
of their onset
 Grade 4 drug-related endocrinopathy adverse events such as hyper- or hypothyroidism, or 
glucose intolerance, which resolve or are adequately controlled with physiologic hormone 
replacement (steroids, thyroid hormones) or glucose-controlling agents, respectively, may 







 Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 






















Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of the 
Investigator, presents a substantial clinical risk to the participant with continued nivolumab dosing.
4.7.7 Treatment of Study Drug-related Infusion Reactions
Since nivolumab, ipilimumab, and BMS-986016 (relatlimab) contain only human 
immunoglobulin protein sequences, it is unlikely to be immunogenic and induce infusion or 
hypersensitivity reactions. However, if such a reaction were to occur, it might manifest with fever, 
chills, rigors, headache, rash, pruritus, arthralgias, hypo- or hypertension, bronchospasm, or other 
symptoms. All Grade 3 or 4 infusion reactions should be reported within 24 hours to the BMS 
Medical Monitor and reported as an SAE if criteria are met. Infusion reactions should be graded 






Treatment recommendations are provided below and may be modified based on local treatment 
standards and guidelines as appropriate:





For Grade 1 symptoms: (Mild reaction; infusion interruption not indicated; intervention not 
indicated)
 Remain at bedside and monitor subject until recovery from symptoms. The following 
prophylactic premedications are recommended for future infusions: diphenhydramine 
50 mg (or equivalent) and/or paracetamol 325 to 1000 mg (acetaminophen) at least 
30 minutes before additional study drug administrations.
For Grade 2 symptoms: (Moderate reaction requires therapy or infusion interruption but responds 
promptly to symptomatic treatment [eg, antihistamines, non-steroidal anti-inflammatory drugs, 
narcotics, corticosteroids, bronchodilators, IV fluids]; prophylactic medications indicated for  24 
hours).
 Stop the infusion, begin an IV infusion of normal saline, and treat the subject with 
diphenhydramine 50 mg IV (or equivalent) and/or paracetamol 325 to 1000 mg 
(acetaminophen); remain at bedside and monitor subject until resolution of symptoms. 
Corticosteroid or bronchodilator therapy may also be administered as appropriate. If the 
infusion is interrupted, then restart the infusion at 50% of the original infusion rate when 
symptoms resolve; if no further complications ensue after 30 minutes, the rate may be
increased to 100% of the original infusion rate. Monitor subject closely. If symptoms recur 
then no further study drug will be administered at that visit. Administer diphenhydramine 
50 mg IV, and remain at bedside and monitor the subject until resolution of symptoms. The 
amount of study drug infused must be recorded on the electronic case report form (eCRF). 
The following prophylactic premedications are recommended for future infusions: 
 Diphenhydramine 50 mg (or equivalent) and/or paracetamol 325 to 1000 mg 
(acetaminophen) should be administered at least 30 minutes before additional nivolumab 
administrations. If necessary, corticosteroids (recommended dose: up to 25 mg of 
IV hydrocortisone or equivalent) may be used.
For Grade 3 or Grade 4 symptoms: (Severe reaction, Grade 3: prolonged [ie, not rapidly 
responsive to symptomatic medication and/or brief interruption of infusion]; recurrence of 
symptoms following initial improvement; hospitalization indicated for other clinical sequelae [eg, 
renal impairment, pulmonary infiltrates]). Grade 4: (life-threatening; pressor or ventilatory support 
indicated).
 Immediately discontinue infusion of study drug. Begin an IV infusion of normal saline, 
and treat the subject as follows. Recommend bronchodilators, epinephrine 0.2 to 1 mg of a 
1:1,000 solution for subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 solution 
injected slowly for IV administration, and/or diphenhydramine 50 mg IV with 
methylprednisolone 100 mg IV (or equivalent), as needed. Subject should be monitored 
until the investigator is comfortable that the symptoms will not recur. Study drug will be 
permanently discontinued. Investigators should follow their institutional guidelines for the 
treatment of anaphylaxis. Remain at bedside and monitor subject until recovery from 
symptoms. 





In the case of late-occurring hypersensitivity symptoms (eg, appearance of a localized or 















































4.7.8 Treatment Beyond Disease Progression
Accumulating clinical evidence indicates some subjects treated with immune system stimulating 
agents may develop progression of disease (by conventional response criteria) before 
demonstrating clinical objective responses and/or stable disease. This phenomenon was observed 
in approximately 10% of subjects in the Phase 1 study of nivolumab and also with ipilimumab 
monotherapy.186 Two hypotheses have been put forth to explain this phenomenon. First, enhanced 
inflammation within tumors could lead to an increase in tumor size which would appear as 
enlarged index lesions and as newly visible small non-index lesions. Over time, both the malignant 
and inflammatory portions of the mass may then decrease leading to overt signs of clinical 
improvement. Alternatively, in some individuals, the kinetics of tumor growth may initially 
outpace anti-tumor immune activity. With sufficient time, the anti-tumor activity will dominate 
and become clinically apparent. Therefore, subjects will be allowed to continue study therapy after 





initial investigator-assessed RECIST 1.1 defined progression as long as they meet the following 
criteria:
1) Investigator-assessed clinical benefit, and do not have rapid disease progression
2) Tolerance of study drug as defined by the investigator
3) Stable performance status
4) Treatment beyond progression will not delay an imminent intervention to prevent serious 
complications of disease progression (eg, CNS metastases)
5) Subject provides a new written informed consent prior to receiving any additional study drug 
using an ICF describing any reasonably foreseeable risks or discomforts, or other alternative 
treatment options
The assessment of clinical benefit should take into account whether the subject is clinically 
deteriorating and unlikely to receive further benefit from continued treatment. 
Patients enrolled to the nivolumab monotherapy, the nivolumab plus ipilimumab, nivolumab plus 
BMS-986016 (relatlimab), or the nivolumab plus daratumumab combination arms may be allowed 
to continue treatment beyond initial progression for up to a maximum of 24 months from the date 
of first dose. In this instance, subjects may continue therapy with assigned treatment.
All decisions to continue treatment beyond initial progression must be discussed with the BMS 
Medical Monitor and documented in the study records. Subjects will be re-consented with an 
ICF describing any reasonably foreseeable risks or discomforts.
Subjects should discontinue study therapy upon further evidence of further progression, defined 
as an additional 10% or greater increase in tumor burden volume from time of initial progression 
(including all target lesions and new measurable lesions).
New lesions are considered measurable at the time of initial progression if the longest diameter is 
at least 10 mm (except for pathological lymph nodes, which must have a short axis of at least 
15 mm). Any new lesion considered non-measurable at the time of initial progression may become 
measurable and therefore included in the tumor burden measurement if the longest diameter 
increases to at least 10 mm (except for pathological lymph nodes, which must have an increase in 
short axis to at least 15 mm).
For statistical analyses that include the investigator-assessed progression date, subjects who 
continue treatment beyond initial investigator-assessed, RECIST 1.1-defined progression will be 
considered to have investigator-assessed progressive disease at the time of the initial progression 
event.
4.8 Destruction of Study Drug
For this study, study drugs (those supplied by BMS or sourced by the investigator) such as partially 
used study drug containers, vials and syringes may be destroyed on site. 





Any unused study drugs can only be destroyed after being inspected and reconciled by the 
responsible Study Monitor unless study drug containers must be immediately destroyed as required 
for safety, or to meet local regulations (eg, cytotoxics or biologics). 
On-site destruction is allowed provided the following minimal standards are met:
 On-site disposal practices must not expose humans to risks from the drug.
 On-site disposal practices and procedures are in agreement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
 Written procedures for on-site disposal are available and followed. The procedures must be 
filed with the site’s SOPs and a copy provided to BMS upon request.
 Records are maintained that allow for traceability of each container, including the date 
disposed of, quantity disposed, and identification of the person disposing the containers. The 
method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal vendor 
must be documented.
 Accountability and disposal records are complete, up-to-date, and available for the Monitor to 
review throughout the clinical trial period.
If conditions for destruction cannot be met the responsible Study Monitor will make arrangements 
for return of study drug.
It is the investigator’s responsibility to arrange for disposal of all empty containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, local, 
and institutional guidelines and procedures, and provided that appropriate records of disposal are 
kept.
4.9 Return of Study Drug
If study drug will not be destroyed upon completion or termination of the study, all unused and/or 
partially used study drug that was supplied by BMS must be returned to BMS. The return of study 
drug will be arranged by the responsible Study Monitor. 
It is the investigator’s responsibility to arrange for disposal of all empty containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, local, 
and institutional guidelines and procedures, and provided that appropriate records of disposal are 
kept.





5 STUDY ASSESSMENTS AND PROCEDURES
5.1 Flow Chart/Time and Events Schedule






Informed Consent X Register in Interactive Response Technology (IRT) system to obtain subject 
number.
Pre-screening informed consent will be obtained to perform viral testing for 
Gastric and SCCHN subjects. Register subject in IRT. Once viral status is 
confirmed positive, informed consent will be obtained for full eligibility 
assessments. See Viral Testing row below in this table for additional details. 
Inclusion/Exclusion Criteria X All inclusion/exclusion criteria should be assessed at screening and confirmed 
prior to first dose
Medical History X
Serious Adverse Event Assessment X Serious Adverse Events from time of consent. See Section 6.
Prior Systemic Therapy X
Safety Assessments
Physical Examination X Within 14 days prior to first dose
Physical Measurements X Include Height and Weight
Within 14 days prior to first dose
Vital Signs X Temperature, BP and HR 
Within 72 hours of first dose
Performance Status (ECOG) X
Within 14 days prior to first dose














ECG X Within 14 days prior to first dose
Assessment of Signs and Symptoms X After obtaining Informed Consent, assess all signs and symptoms within 14 days 
prior to first dose.
Concomitant Medication Collection X Within 14 days prior to first dose
Laboratory Tests X CBC with differential and platelet count, Chemistry panel including LDH, AST, 
ALT, ALP, T.Bili, BUN or serum urea level, creatinine, Ca, Mg, Na, K, Cl, P, 
glucose, bicarbonate or total CO2 (if locally available), albumin, amylase, lipase, 
TSH (reflex to free T3, free T4 for abnormal TSH result), hepatitis B surface 
antigen (HBV sAg, Australia antigen), and hepatitis C antibody (HCV Ab or 
RNA)
Within 14 days prior to first dose.
Viral Testing X See Section 5.6.1.






 See the Efficacy/Biomarker Assessment section of this table for additional 
information regarding other tumor types. 
Pregnancy Test X Serum or urine pregnancy testing to be done at screening visit and repeated within 
24 hours of first dose.












Spiral CT/MRI of Chest, Abdomen, Pelvis, and any other 
known sites of disease 
X Should be performed within 35 days prior to first dose.
Additional sites of known or suspected disease (including CNS) should be imaged 
at the screening visit and at subsequent on-study assessments. 
Collection of tumor tissue X For both the Neoadjuvant and Metastatic Cohorts: Submission of tumor tissue is 
mandatory. A fresh biopsy is preferred. An archived sample of an FFPE tumor 
tissue block or 15 unstained slides collected as a standard of care procedure within 
90 days prior to obtaining informed consent is acceptable for metastatic cohorts. 
Fresh Biopsies are mandatory for neoadjuvant cohort patients.
Fresh biopsy samples should be excisional, incisional, or core needle. Fine needle 
aspirates are not acceptable. Tumor biopsies should be placed in formalin for IHC 
of tumor and TIL, RNALater for gene expression, and media for flow cytometry 
analysis (neo-adjuvant cohort only) as described in the laboratory manual.
If HPV viral status of the gynecological (cervical, vaginal, vulvar) or anogenital 
HPV associated tumor types (anal canal, penile) is not available, a fresh collection 
of tumor cells will be required. Please see laboratory manual for details.
See Section 5.6.9 for Biomarker Sampling Schedules.
Record Historic mutation/markers of interest X  
Cervical, Vaginal, Vulvar, :  HPV status











Phone calls to IRT X Phone calls must be made to IRT as follows:
 For subject number assignment at the time of pre-screening informed consent 
is obtained (Gastric and SCCHN patients)
 For subject number assignment at the time informed consent is obtained.
 Prior to dosing for study drug vial assignment (call should be made within 
5 days prior to dosing).
 Confirmation of viral status will be required prior to study drug assignment for 
EBV gastric cancer (metastatic monotherapy cohort only) and HPV SCCHN 
tumor types in the neoadjuvant and metastatic cohorts (monotherapy or 
Combos A and C).
 If SCCHN subjects decline pre-screening informed consent or are unwilling to 
undergo viral testing, they are eligible to enroll in Combo D. However, viral 
status should be determined retrospectively.
a Within 35 days prior to first dose










Each Cycle (every 
2 Weeks) on 
Day 1 ( 3 days)
Notes
Safety Assessments





 Neurological exam for subjects with brain metastases
Within 72 hours prior to dosing
Vital Signs X X Temperature, BP, and HR prior to dosing and at any time a subject has 
any new or worsening respiratory symptoms. 
Obtain vital signs within 72 hours prior to dosing.
Physical Measurements X X Includes Weight and ECOG performance status
See Appendix 1 for ECOG scale
Obtain physical measurements within 72 hrs prior to dosing.
Adverse Events Assessment ------ Continuously ------- Assessed using NCI CTCAE version 4.
Review of Concomitant Medications X X
Laboratory Tests X X On-study local laboratory assessments should be done within 72 hours
prior to dosing for every cycle and include: CBC with differential and 
platelet count, BUN or serum urea level, serum creatinine, sodium, 
potassium, calcium, magnesium, phosphorus, chloride, bicarbonate or 
total CO2 (if locally available), amylase, lipase, glucose, AST, ALT, 
total bilirubin, alkaline phosphatase, LDH, albumin.
Labs required prior to first dose do not have to be repeated if screening 
labs were performed within 14 days prior to first dose.
Thyroid Function Testing See Note TSH (reflex to free T3 and free T4 if abnormal result) to be performed 
every 6 weeks ( 1 week).










Each Cycle (every 
2 Weeks) on 
Day 1 ( 3 days)
Notes
Pregnancy Test X See Note Serum or urine within 24 hours prior to first dose and then at least once 
every 4 weeks (+/- 1 week) regardless of dosing schedule.
Efficacy/Biomarker Assessments
Radiographic Tumor Assessment
Spiral CT/MRI of Chest, Abdomen, Pelvis, and
any other known sites of disease
See Table 5.4.1-1 for imaging frequency.
See Appendix 3 (RECIST 1.1 Guidelines) for details regarding imaging methodology 
requirements and assessments
Collection of Tumor Tissue Collection of tumor tissue (FFPE tumor tissue block or 15 unstained slides) for determination of PD-L1 
expression and other exploratory biomarker analysis.
Biopsy samples should be excisional, incisional, or core needle. Tumor biopsies should be placed in 
formalin for IHC of tumor and TIL and RNALater for gene expression.





See Table 5.6.9-2 for Biomarker Sampling Schedule
PK and Immunogenicity Assessments
PK samples See Table 5.5-1 of PK and Immunogenicity Sampling
Immunogenicity samples See Table 5.5-1 of PK and Immunogenicity Sampling
Outcomes Research Assessments
EORTC QLQ-C30 X See note Assessments to be collected every 4 cycles for the first 17 cycles:
Day 1 (prior to dosing) of Cycles 5, 9, 13, 17
every 6 cycles thereafter:
Day 1 (prior to dosing) of Cycles 23, 29, 35+.
EQ-5D X See note










Each Cycle (every 
2 Weeks) on 
Day 1 ( 3 days)
Notes
Clinical Drug Supplies
Administer Study Drug X X First dose to be administered within 5 days of study drug assignment.
Confirmation of viral status will be required prior to study drug 
assignment for EBV gastric cancer and HPV SCCHN tumor types in the 
metastatic cohort.





























































































































































































































































































































































































































Table 5.1-5: Eligibility Assessments and On-Treatment Assessments - Subjects Receiving Study Drug Post-












Inclusion/Exclusion Criteria X Eligibility must be assessed within 72 hours per inclusion/exclusion criteria 
for metastatic subjects as defined in Section 3.3, with the following 
exceptions/specificities:
 Subjects who completed the neoadjuvant portion of the study must 
have developed unresectable recurrent or metastatic disease within 1 
year of surgery or chemotherapy/radiation completion to be eligible. 
 Exclusion criterion ‘2.f’ regarding prior therapies is not applicable.
Subjects who meet discontinuation criteria at Cycle 1 Day 1 are not eligible 
to receive nivolumab. See Section 3.5 for discontinuation criteria. 
Safety Assessments





Neurological exam for subjects with brain metastases
Within 72 hours prior to dosing
Vital Signs X X Temperature, BP, and HR prior to dosing and at any time a subject has any 
new or worsening respiratory symptoms. 
Obtain vital signs within 72 hours prior to dosing.
Physical Measurements X X Includes Weighta and ECOG performance status
See Appendix 1 for ECOG scale





Table 5.1-5: Eligibility Assessments and On-Treatment Assessments - Subjects Receiving Study Drug Post-











Obtain physical measurements within 72 hrs. prior to dosing.
Adverse Events Assessment ------- Continuously ------- Assessed using NCI CTCAE version 4.
Review of Concomitant Medications X X
Laboratory Tests X X On-study local laboratory assessments should be done within 72 hours prior 
to dosing for every cycle and include: CBC with differential and platelet 
count, BUN or serum urea level, serum creatinine, sodium, potassium, 
calcium, magnesium, phosphorus, chloride, bicarbonate or total CO2 (if 
locally available), amylase, lipase, glucose, AST, ALT, total bilirubin, 
alkaline phosphatase, LDH, albumin.
Thyroid Function Testing See Note TSH (reflex to free T3 and free T4 if abnormal result) to be performed every 
6 weeks ( 1 week).
Pregnancy Test X See Note Serum or urine within 24 hours prior to first dose and then at least once 
every 4 weeks (+/- 1 week) regardless of dosing schedule.





Table 5.1-5: Eligibility Assessments and On-Treatment Assessments - Subjects Receiving Study Drug Post-













Spiral CT/MRI of Chest, Abdomen, Pelvis, and 
any other known sites of disease
See Note See Table 5.4.1-1 for imaging frequency
See Appendix 3 (RECIST 1.1 Guidelines) for details regarding imaging 
methodology requirements and assessments
Should be performed within 35 days prior to first dose or restarting 
nivolumab.
Additional sites of known or suspected disease (including CNS) should be 
imaged at the screening visit and at subsequent on-study assessments.





See Note See Note See Table 5.6.9-4 for Biomarker Sampling Schedule
PK and Immunogenicity Assessments
PK samples See Note See Table 5.5-3 of PK and Immunogenicity Sampling
Immunogenicity samples See Note See Table 5.5-3 of PK and Immunogenicity Sampling
Outcomes Research Assessments
EORTC QLQ-C30 X See Note Assessments to be collected every 4 cycles for the first 17 cycles;
Day 1 (prior to dosing) of Cycles 5, 9, 13, 17
every 6 cycles thereafter;
Day 1 (prior to dosing) of Cycles 23, 29, 35+.
EQ-5D X See Note





Table 5.1-5: Eligibility Assessments and On-Treatment Assessments - Subjects Receiving Study Drug Post-












Administer Study Drug X X Within 5 days from vial allocation, the subject must receive the first dose of 
study drug. Subjects may be dosed no less than 12 days between doses and 
no more than 3 days from the scheduled dose
a Dosing calculations should be based on the body weight assessed at baseline. It is not necessary to re-calculate subsequent doses if the participant weight is 
within 10% of the weight used to calculate the previous dose. All doses should be rounded up or to the nearest milligram per institutional standard.





Table 5.1-6: Follow-Up Assessments - All Subjects (CA209358)
Procedure X, Follow-Up
a
Visits X01 and 
X02
Follow-Up Assessments 
for Neoadjuvant Cohort 
Subjects









Targeted Physical Examination X Lymph node areas (eg, submandibular, 
cervical, supraclavicular, axillary, or inguinal 
lymph node), and abdominal organs 
(eg, spleen, liver).
To assess for potential late emergent study drug 
related issues
Adverse Events Assessment X X NSAEs and SAEs must be collected up to 100 
days after study drug discontinuation. SAEs 
that relate to any later protocol specified 
procedure must be collected.
Review of Medical History and 
Subsequent Cancer Therapy 
Information 
X X X
Laboratory Tests X CBC with differential and platelet count, BUN
or serum urea level, serum creatinine, sodium, 
potassium, calcium, magnesium, phosphorus, 
chloride, bicarbonate or total CO2 (if locally 
available), amylase, lipase, glucose, AST, 
ALT, total bilirubin, alkaline phosphatase, 
LDH, albumin..
Thyroid Function Testing X TSH (reflex to free T3 and free T4 if abnormal 
result)
Pregnancy Test X Serum or urine





Table 5.1-6: Follow-Up Assessments - All Subjects (CA209358)
Procedure X, Follow-Up
a
Visits X01 and 
X02
Follow-Up Assessments 
for Neoadjuvant Cohort 
Subjects












See Note X See note Only for subjects without progression and no 
longer on study therapy
See Table 5.4.1-1 for Spiral CT/MRI. For 
subjects in the neoadjuvant cohort, 
radiographic tumor assessment should be at 4 
mo, 8 mo and 12 mo post-surgery.b
Subjects with a history of brain metastasis may 
have surveillance MRI approximately every 12 
weeks or sooner if clinically indicated
Outcomes Research Assessments
EORTC QLQ-C30 X
EQ-5D X X EQ-5D during the survival follow-up will be 
assessed during a clinic visit or via a phone 
contact
Pharmacokinetic/Immunogenicity Assessments
PK Samples X See Table 5.5-1, Table 5.5-2, Table 5.5-3, 
Table 5.5-4, Table 5.5-5, and Table 5.5-8 for PK 
and Immunogenicity SamplingImmunogenicity samples X





Table 5.1-6: Follow-Up Assessments - All Subjects (CA209358)
Procedure X, Follow-Up
a
Visits X01 and 
X02
Follow-Up Assessments 
for Neoadjuvant Cohort 
Subjects








Additional Exploratory Biomarker Testing
Serum See Note.
Collection of Biomarker samples at time of 
progression is optional.
See Table 5.6.9-1, Table 5.6.9-2, and Table 







Survival Status X X X Every 3 months after X02; may be 
accomplished by visit or phone contact, to 
update survival information and assess 
subsequent anti-cancer therapy.
a X visits occur as follows: X01 = 35 days  7 days from last dose or from the date decision is made to discontinue subject from the study (only applicable for 
early treatment discontinuation), X02 = 80 days  7 days from X01. Neoadjuvant cohort subjects will have these visits labeled as E01 (35 days +/ 7 days from 
last dose) and E02 (80 days +/ 7 days) visits in the CRF. For neoadjuvant cohort subjects receiving nivolumab as part of the post-standard of care, X01 and X02 
visits will be completed after the last dose
b Follow-Up Assessments for Neoadjuvant Cohort Subjects, 4, 8, and 12 Months Post-Surgery, may occur 7 days from scheduled time point.
4 Month Post-Surgery may occur weeks from scheduled time point. Neoadjuvant Cohort. E02 and E03 follow-up can occur at the same time.
c S, Survival Follow-Up visits continue every 3 months after X visits.





5.1.1 Retesting During Screening or Lead-in Period
Retesting of laboratory parameters and/or other assessments within any single Screening period 
will be permitted (in addition to any parameters that require a confirmatory value).
Any new result will override the previous result (ie, the most current result prior to treatment) and 
is the value by which study inclusion will be assessed, as it represents the subject’s most current, 
clinical state.
5.2 Study Materials
 NCI CTCAE version 4
 BMS-936558 (nivolumab) Investigator Brochure
 Pharmacy Binder
 Laboratory manuals for collection and handling of blood (including biomarker and 
immunogenicity) and tissue specimens
 Site manual for operation of interactive response technology system, including enrollment 
worksheets
 Manual for entry of local laboratory data
 Pregnancy Surveillance Forms
 Serious Adverse Events (or eSAE) case report forms
 EORTC QLQ-C30 and EQ-5D questionnaires
 CT/MRI/PET Subject Scanning Guide 
 CT-MRI Subject Data Transmittal Form
 PET-CT Subject Data Transmittal Form
5.3 Safety Assessments
At baseline, a medical history will be obtained to capture relevant underlying conditions. The 
baseline examinations should include signs and symptoms, weight, height, ECOG Performance 
Status, BP, HR, temperature, and respiratory rate should be performed within 14 days prior to first 
dose except where noted in Table 5.1-1. Concomitant medications will also be collected from 
within 14 days prior to first dose and through the study treatment period (See Table 5.1-1, Table 
5.1-2, Table 5.1-3, Table 5.1-4, and Table 5.1-5). 
Baseline safety laboratory assessments should be done within 14 days prior to the first dose and 
include: CBC with differential and platelet count, Chemistry panel including LDH, AST, ALT, 
ALP, T.Bili, BUN or serum urea level, creatinine, Ca, Mg, Na, K, Cl, P, glucose, bicarbonate or 
total CO2 (if locally available), albumin, amylase, lipase, TSH (reflex to free T3, free T4 for 
abnormal TSH result), hepatitis B surface antigen (HBV sAg, Australia antigen), and hepatitis C 
antibody (HCV Ab, RNA) (see Table 5.1-1). Pregnancy testing for WOCBP (done locally) to be 
done within 24 hours prior to first dose, and then every 4 weeks ( 1 week) regardless of dosing 
schedule, and at each safety follow up visit.  







Determination of safety lab results is required prior to dosing. If there are delays with obtaining 
results for certain tests, please contact the medical monitor to determine clinical significance.
Subjects will be evaluated for safety if they have received any study drug. Toxicity assessments 
will be performed continuously during the treatment phase. During the safety follow-up phase 
(Table 5.1-6) toxicity assessments should be done in person. Once subjects reach the survival 
follow-up phase, either in-person visits or documented telephone calls to assess the subject’s status 
are acceptable.
Adverse events and laboratory values will be graded according to the NCI-CTCAE version 4.
On-study weight and ECOG performance status should be assessed at each on-study visit prior to 
nivolumab dosing. On treatment vital signs may be performed within 72 hours prior to dose. In 
addition, vital signs can also be taken as per institutional standard of care prior to; during and after 
the infusion. The start and stop time of the nivolumab infusion should be documented. Physical 
examinations are to be performed at treatment visits as clinically indicated. If there are any new or 
worsening clinically significant changes since the last exam, report changes on the appropriate 
non-serious or serious adverse event page.
Additional measures, including non-study required laboratory tests, should be performed as 
clinically indicated or to comply with local regulations. Laboratory toxicities (eg, suspected drug 
inducted liver enzyme elevations) will be monitored during the follow-up phase via on site/local 
labs until all study drug related toxicities resolve, return to baseline or are deemed irreversible.
Some of the previously referred to assessments may not be captured as data in the eCRF. They are 
intended to be used as safety monitoring by the treating physician. Additional testing or 
assessments may be performed as clinically necessary or where required by institutional or local 
regulations.
5.4 Efficacy Assessments
5.4.1 Imaging Assessments for the Study
Any incidental findings of potential clinical relevance that are not directly associated with the 
objectives of the protocol should be evaluated and handled by the Study Investigator as per 
standard medical/clinical judgment.
Study evaluations will take place in accordance with the flow charts in Section 5.1, Table 5.4.1-1, 
Table 5.4.1-2, and Appendix 3. For the Neoadjuvant cohort, any images obtained prior to Month 4 
as standard of care should also be assessed.
In addition to chest, abdomen, and pelvis, all known sites of disease should be assessed at baseline. 
Subsequent assessments should include chest, abdomen, and pelvis, and all known sites of disease 
and should use the same imaging method as was used at baseline. Baseline MRI for brain should 
be done for known or suspected disease. 





Tumor imaging assessments for ongoing study treatment decisions will be completed by the 
investigator using RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria, see 
Appendix 3.
All study images will be submitted to an imaging core laboratory for review. Sites should be 
trained prior to sending in the first image. Image acquisition guidelines and submission process 
will be outlined in the CA209358 Imaging Manual to be provided by the core imaging laboratory.
Table 5.4.1-1: Schedule of Spiral CT/MRI Tumor Assessments for Metastatic 
Cohorts (Monotherapy and Combination Therapy), and Subjects 
Treated with Study Drug Post-Standard of Care Adjuvant 
Treatment
Time On Study Assessment Frequency
Assessment Week
(Day 1 of Week Shown)
Assessment 
Window
Metastatic Cohort Subjects 
During First Year of Treatment
At screening (within 35 days of 
first dose), then every 8 weeks
Screening, 8, 16, 24, 32, 
40, 48
 1 week
Metastatic Cohort Subjects 
During Second Year of Treatment 
and Beyond




For Subjects Treated with Study 
Drug Post-Standard of Care
During Second Year of Treatment 
and Beyond






For the Metastatic Cohorts (monotherapy and combination therapy), baseline tumor assessments 
should be performed within 35 days prior to the first dose. Subjects will then be evaluated for 





tumor response beginning 8 weeks from the date of first dose ( 1 wk.), then every 8 weeks 
( 1 wk.) thereafter up to 48 weeks, then it will be every 12 weeks ( 2 weeks) until disease 









5.4.2 Primary Efficacy Assessment
The investigator objective response rate (ORR) of nivolumab monotherapy is the primary endpoint 
among all treated subjects in the recurrent/metastatic monotherapy cohort. The investigator 
objective response rate (ORR) of nivolumab combination therapy (ipilimumab, BMS-986016, 
daratumumab) is the primary endpoint among all treated subjects in the recurrent/metastatic 
combination cohort for combination therapies, Combo A, B, C and D.
ORR is defined as the number of subjects with a best overall response (BOR) of confirmed 
complete response (CR) or partial response (PR) divided by the number of all treated subjects. 
BOR is defined as the best response designation recorded between the date of first dose and the 
date of the initial objectively documented tumor progression per investigator assessment using 
RECIST 1.1 criteria or the date of subsequent therapy, whichever occurs first.
5.4.3 Secondary Efficacy Assessments
Not applicable
5.5 Pharmacokinetic Assessments
Samples for pharmacokinetic and immunogenicity assessments will be collected for all subjects 
receiving nivolumab as a monotherapy or in combination with ipilimumab, BMS-986016
(relatlimab), or daratumumab. Table 5.5-1, Table 5.5-2, and Table 5.5-3 list the sampling schedule 
to be followed for pharmacokinetics and immunogenicity of nivolumab. Table 5.5-4 and Table 
5.5-5 list the sampling schedule to be followed for pharmacokinetics and immunogenicity of 
nivolumab and ipilimumab. Table 5.5-6 lists the sampling schedule to be followed for 
pharmacokinetics and immunogenicity of nivolumab and BMS-986016 (relatlimab). Table 5.5-7
and Table 5.5-8 list the sampling schedule to be followed for pharmacokinetics and 
immunogenicity of nivolumab and daratumumab, respectively, for nivolumab and daratumumab 
combination cohort. All time points in nivolumab/ipilimumab and nivolumab/BMS-986016 
(relatlimab) combination cohorts are relative to the start of nivolumab infusion. In the 
nivolumab/daratumumab combination cohort, daratumumab will be administered after nivolumab 





and predose sample for daratumumab should be drawn with a window of -2 hours before the start 
of daratumumab dosing. Daratumumab post-dose samples should be drawn within 2 hours after 
the end of the infusion. All on-treatment PK time points are intended to align with days on which 
nivolumab is administered. If it is known that a dose is going to be delayed, then the predose 
sample should be collected just prior to the delayed dose. However, if a predose sample is 
collected, but the dose is subsequently delayed, an additional predose sample should not be 
collected. 
The exact dates and times of blood sampling must be recorded. Refer to the Laboratory Manual 
for sample collection requirements. Collected samples must be stored under the specified and 
controlled conditions for the temperatures indicated in the Laboratory Manual. Additional 
information about the collection, handling, and shipment of biological samples can be found in the 
Laboratory Manual.




(Relative to Start 
of Infusion/Event)
Time 










Cycle 1 Day 1 (Week 1 Day 1) predosea 00:00 X X
Cycle 5 Day 1(Week 9 Day 1) predosea 00:00 X X
Cycle 7 Day 1 (Week 13 Day 
1)
predosea 00:00 X X
Day 1 of every 8th cycle (every 
16 weeks) until discontinuation 
of study treatmentb
predosea 00:00 X X
First 2 Follow-up visits- X01 & 
X02
X X
a Predose samples should be taken just prior to the administration (preferably within 30 minutes). If the infusion is 
delayed and a pre-dose sample was already collected, there is no need to collect an additional pre-dose sample.
b For subjects during second year of treatment and beyond, PK collections will occur every 24 weeks instead of every 
16 weeks.












Table 5.5-3: Pharmacokinetic and Immunogenicity Sampling Schedule (Subjects 

















Cycle 1 Day 1 (Week 1 Day 1)a predoseb 00:00 X X
Cycle 5 Day 1(Week 9 Day 1) predoseb 00:00 X X
Cycle 7 Day 1(Week 13 Day 1) predoseb 00:00 X X
Day 1 of every 8th cycle (every 
16 weeks) until discontinuation 
of study treatmentc
predoseb 00:00 X X
First 2 Follow-up visits- X01 & 
X02
X X
a The day subjects start study drug after standard of care will be considered Cycle 1 Day 1 (Week 1 Day 1).
b Predose samples should be taken just prior to the administration (preferably within 30 minutes). If the infusion is 
delayed and a pre-dose sample was already collected, there is no need to collect an additional pre-dose sample. 
c For subjects during second year of treatment and beyond, PK collections will occur every 24 weeks instead of every 
16 weeks.





















































































































5.5.1 Pharmacokinetic Sample Analysis
Serum samples will be analyzed for nivolumab,  
 by a validated method. In addition, selected samples may be analyzed 
by an exploratory analytical method that measures nivolumab,





for technology exploration purposes; exploratory results will not be 
reported.
5.6 Biomarker Assessments
Peripheral blood and tumor tissue will be collected prior to therapy and at selected time points on 
treatment as outlined in the Biomarker Sampling Schedule in Table 5.6.9-1, Table 5.6.9-2, Table 
5.6.9-3, and Table 5.6.9-4 unless restricted by local requirements. Detailed instructions of the 
obtaining, processing, labeling, handling, storage and shipment of specimens will be provided in 
a separate Procedure Manual at the time of study initiation.



















Cervical, vaginal, vulvar, anal canal and penile: HPV positivity is defined by FDA approved tests 
(Cobas HPV Test; Digene Hybrid Capture 2 High-Risk HPV DNA Test; Cervista™ HPV HR and 
Genfind™ DNA Extraction Kit; Cervista™ HPV 16/18; APTIMA® HPV Assay) or other well 
validated commercially available tests (such as Ventana Inform HPV ISH test) comprising in situ 
hybridization, real-time PCR, or immunohistochemistry (IHC). High-risk HPV positivity includes 
the following subtypes:  16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. Virus testing will 





be performed retrospectively only if results from prior accepted testing are not available. If the 



















































Tumor tissue specimen requirements for the Metastatic Cohort (Monotherapy and 
Combination Therapy) are as follows:
 At Baseline (Prior to first dose of study drug): Biopsy and submission of fresh tumor tissue, or
submission of archived tumor tissue, is mandatory for all subjects. Biopsy is indicated for 
subjects with accessible lesions where biopsy is deemed safe by the Investigator. 
 An on-treatment biopsy and submission of fresh tumor tissue is mandatory for subjects in each 
tumor type in the metastatic cohort to ensure an adequate number of paired samples to perform 
meaningful analyses to support biomarker objectives. Subjects with accessible lesions where 
biopsy is deemed safe by the Investigator should undergo biopsy per protocol.
 All other time points where tumor tissue collections are indicated, aside from baseline and the 
one mandatory on-treatment biopsy, are described in Table 5.6.9-2 and Table 5.6.9-3.





Tumor tissue specimen requirements for Subjects Treated with Study Drug Post-Standard 
of Care are as follows:
 At Cycle 1 Day 1 biopsy and submission of fresh tumor tissue is strongly encouraged for 
subjects with accessible lesions where biopsy is deemed safe by the Investigator.
 All other time points where tumor tissue collections are indicated, aside from Cycle 1 Day 1, 
are described in Table 5.6.9-4.
Submission of fresh tumor tissue collected via biopsy is required for TILs isolation for ex-vivo 
functional assays (RPMI media preparation), and also for gene expression profiling (RNALater 
samples). Please refer to Central Lab Manual for detailed sample requirements.
Submission of tissue samples (FFPE tumor tissue block or slides) is required for characterization 
of tumor infiltrating lymphocytes (TILs) and tumor, utilizing immunohistochemistry (IHC) 
methods. A minimum of 1 FFPE tumor tissue block (preferred) OR minimum of 15 FFPE 
unstained sections are required for this purpose. Tissue for this purpose may be obtained during 
the screening phase, prior to resection, or collected as a standard of care procedure within 90 days 
prior to obtaining informed consent, and is mandatory. Please refer to Central Lab Manual for 
detailed sample requirements.
Tissue for protocol purposes should be obtained via excision, incision or core needle. Fine needle 
aspirates are prohibited.
Tumor samples obtained from bone metastases are not considered acceptable for PD-L1 testing 
because the PD-L1 assay does not include a decalcification step. For any cases where the only 
tumor tissue available is from a bone metastasis lesion, please discuss further with the study 
Medical Monitor.
All subjects may volunteer to undergo tumor biopsies at any time during therapy, if clinically 
indicated. When tumor biopsy is performed during these times, submission of tumor biopsy is 
strongly encouraged.
All tumor tissue sample submission upon progression is optional, and can be taken within 7 days 
at the discretion of the investigator.
Tumor-Based Biomarker Measures
Tumor biopsy specimens will be obtained from consenting subjects prior to administration of study 
drug to characterize immune cell populations and expression of selected tumor markers. Tumor 
biopsy collection and submission is mandatory for subjects with accessible lesions prior to therapy. 
Tumor tissue (obtained during the screening phase or collected as a standard of care procedure 
within 90 days prior to obtaining informed consent) will be provided for biomarker analysis if 
accessible and deemed safe by the investigator. For subjects where tumor tissue cannot be provided
due to issues related to safety, the reason must be clearly documented in the medical record AND 
the BMS Medical Monitor must be contacted. Archival tissue should be submitted for these 
subjects. Submission of archival tissue is also encouraged for all subjects, irrespective of whether 
fresh biopsy tissue is available. 





For cases when a complete response occurs, and an on-treatment biopsy is required but not 
feasible, these cases must be clearly documented in the medical record AND the BMS Medical 
Monitor must be contacted.
A tumor biopsy sample of subjects that have confirmed progression is optional, but strongly 
encouraged for the purposes of understanding mechanisms of resistance to therapy. 
Biopsy samples may be used for the following assessments:
Characterization of tumor infiltrating lymphocytes (TILs) and tumor. Immunohistochemistry 
(IHC) will be used to assess the number and composition of immune infiltrates in order to define 
the immune cell subsets present within formalin-fixed, paraffin-embedded (FFPE) tumor tissue 
before and after exposure to therapy. These IHC analyses may include, but not necessarily be 
limited to, the following markers: PD-L1, PD-L2, PD-1, LAG3, IDO, GITR, T cell and 
macrophage markers. For the neo-adjuvant arm only TILs may also be assessed in fresh baseline 
biopsies and surgical resections by cytometry. Analysis of cytokines including but not limited to 
IFN-g, IL-4, IL-13, IL-10, IL-17, and IL-32g may be done with multiplex qRT-PCR and/or 
amplified in situ hybridization (ISH) using fixed tumor tissue. 
Tumor genotyping, mutational analysis, and tumor antigen profiling
RNA and DNA from tumor samples may be analyzed using whole-exome and transcriptome 
sequencing or another technology to determine the number of mutations found within a given 
sample relative to a normal host tissue, such as adjacent non-transformed cells or PBMC. 
Mutations that are detected will be analyzed for their ability to bind the MHC I and MHC II 
proteins using prediction algorithms. Evaluating the ability of tumor mutations to bind MHC 
molecules will provide evidence that these mutations are serving as antigens that are recognized 
the immune system and are potential rejection antigens. 
In addition to viral positivity, chromosomal translocations, aberrant expressions, and epigenetic 
modifications within tumor cells may be characterized and explored by IHC and RNA/DNA 
analysis of tumor biopsies. Associations of altered tumor cell genetic structure with nivolumab 
efficacy will be performed. This includes, but is not limited to, assessments of 9p24 copy number 
alterations.
Characterization of T cell repertoire. As described above, DNA sequencing may be performed 
on pre- and post-treatment tumor tissue to assess the composition of the T cell repertoire. DNA 
may be isolated from either the FFPE tumor block or from RNAlater, or equivalent preparations.  
Gene expression profiling. Tumor biopsies that are collected in RNAlater or equivalent fixative 
maybe examined for mRNA and miRNA gene expression by nanostring, RNAseq, microarray, 
and/or quantitative real-time polymerase chain reaction (qPCR) to detect expression of selected 
immune related genes and regulatory pathways.
Ex vivo Functional Assays. To explore whether nivolumab may restore T cell activation and 
function, Tumor infiltrating Lymphocytes (TILs) will be isolated. Assays for phenotypic 





characteristic as well as functional status of effector T cells may be performed, including but not 
limited to, flow cytometry and peptide restimulation.
























Table 5.6.9-2: CA209358 Biomarker Sampling Schedule (Metastatic Monotherapy Cohorts and Metastatic Cohort 
Combo A and B)
Collection Time
a Serum Plasma















Week 1 Day 1 X X X X X X X









   





Week 7 Day 1 X X X X X
   
CR Evaluation X X X (optional)e X










a Serum, PBMC, Plasma, and whole blood samples may be obtained  3 days of the indicated time except for Cycle 1 Day 1 samples which must be collected 
prior to treatment.
b Submission of fresh tumor tissue is required for gene expression profiling (RNALater samples).
c For Monotherapy
d For cervical cancer and anogenital HPV associated tumors (vulvar/vaginal/anal canal/penile) only
e All subjects may volunteer to undergo tumor biopsies at any time during therapy if clinically indicated. When tumor biopsy is performed, submission of tumor 
biopsy is strongly encouraged. 





f All sample submission upon progression is optional and can be taken at any time after progression at the discretion of the investigator.
Submission of tissue samples (FFPE tumor tissue block or slides) is required for characterization of tumor infiltrating lymphocytes (TILs) and tumor, utilizing 
immunohistochemistry (IHC) methods. Tissue for this purpose may be obtained during the screening phase, prior to resection, or collected as a standard of care 
procedure within 90 days prior to obtaining informed consent. On-treatment tumor biopsies are mandatory. On-treatment tumor biopsy may be collected +/- 7 
days.






















Table 5.6.9-4: CA209358 Biomarker Sampling Schedule (Subjects Treated with Study Drug Post-Standard of Care)
Collection Time













Cycle 1 Day 1 X X X X
b X X
Cycle 2 Day 1 X X X
Cycle 3 Day 1 X X
Cycle 4 Day 1 X X X X X
CR Evaluation X X X (optional)
c X
During Treatment (when 
clinically indicated)c
Xc
Upon Progressiond X (optional) X (optional) X (optional) X (optional) X (optional) X (optional)
a Serum, PBMC and whole blood samples may be obtained  3 days of the indicated time except for Cycle 1 Day 1 samples which must be collected prior to 
treatment.
b Submission of tumor tissue is strongly encouraged, if feasible.
c All subjects may volunteer to undergo tumor biopsies at any time during therapy if clinically indicated. When tumor biopsy is performed, submission of tumor 
biopsy is strongly encouraged.
d All sample submission upon progression is optional and can be taken at any point after progression at the discretion of the investigator.





5.7 Outcomes Research Assessments
The Outcomes research data including health related quality of life and subject reported symptom 
burden provide a more complete understanding of the impact of treatment by incorporating the 
subjects’ perspective. These data offer insights into the subject experience that may not be captured 
through physician reporting. Generic health related quality of life scales provide data necessary in 
calculating utility values for health economic models. 
The EQ-5D will be collected in order to assess the impact of study drug on generic health related 
quality of life and the data will be used for populating health economic models most notably, cost 
effectiveness analysis. The EQ-5D descriptive system comprises the following five dimensions: 
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 
three levels: no problems, some problems, and severe problems.
The EORTC QLQ-C30 will be collected in order to assess cancer specific health related quality of 
life. The combination of the generic scale for general health status and economic evaluation and
the cancer specific scale will provide a robust outcomes research package.
The EORTC QLQ-C30 is one the most commonly used QoL instrument in oncology studies. The 
EORTC QLQ-C30 is a 30-item instrument comprising six functional scales (physical functioning, 
cognitive functioning, emotional functioning, role functioning, social functioning and global 
quality of life) as well as nine symptom scales (fatigue, pain, nausea/vomiting, dyspnea, insomnia, 
appetite loss, constipation, diarrhea, and financial difficulties). Except for the overall health status 
and global quality of life items, responses for all items are 4-point categorical scales ranging from 
1 (Not at all) to 4 (Very much). The overall health status/quality of life responses are 7-point Likert 
scales. General health status will be measured using the EQ-5D. The EQ-5D is a standardized 
instrument for use as a measure of self-reported general health status. The EQ-5D comprises 5 
dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety) and a visual analog 
rating scale (VAS). The utility data generated from the EQ-5D is recommended for and commonly 
used in cost effectiveness analysis.
5.8 Immunogenicity Assessments
Serum samples collected at time points identified from Table 5.5-1 to Table 5.5-8 will be analyzed 
by validated immunoassay methods. Additional characterization (ie, neutralizing antibodies) for 
any detected anti-drug antibodies (ADA) response to study drug may also be performed. All 
samples collected for detection of anti-drug antibodies will also be assessed for the respective 
serum drug concentrations to enable interpretation of the antibody data. All on-treatment PK time 
points are intended to align with days on which nivolumab is administered. If it is known that a 
dose is going to be delayed, then the predose sample should be collected just prior to the delayed 
dose. However, if a predose sample is collected, but the dose is subsequently delayed, an additional 
predose sample should not be collected. Selected serum samples may be analyzed by an 
exploratory method that measures anti-nivolumab, anti-ipilimumab, anti-BMS-986016
(relatlimab), or anti-daratumumab antibodies for technology exploration purposes; exploratory 
results will not be reported.





In addition, serum samples designated for PK or biomarker assessments may also be used for
immunogenicity analysis if required (eg, if there is insufficient volume for complete
immunogenicity assessment or to follow up on suspected immunogenicity related AE).
6 ADVERSE EVENTS
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a 
preexisting medical condition in a clinical investigation subject administered study drug and that 
does not necessarily have a causal relationship with this treatment. An AE can therefore be any 
unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of study drug, whether or not considered related to the study 
drug.
The causal relationship to study drug is determined by a physician and should be used to assess all 
adverse events (AE).The causal relationship can be one of the following:
Related: There is a reasonable causal relationship between study drug administration and 
the AE.
Not related: There is not a reasonable causal relationship between study drug 
administration and the AE.
The term “reasonable causal relationship” means there is evidence to suggest a causal relationship. 
Adverse events can be spontaneously reported or elicited during open-ended questioning, 
examination, or evaluation of a subject. (In order to prevent reporting bias, subjects should not be 
questioned regarding the specific occurrence of one or more AEs.)
6.1 Serious Adverse Events
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: 
 results in death
 is life-threatening (defined as an event in which the subject was at risk of death at the time of 
the event; it does not refer to an event which hypothetically might have caused death if it were 
more severe)
 requires inpatient hospitalization or causes prolongation of existing hospitalization (see NOTE
below)
 results in persistent or significant disability/incapacity
 is a congenital anomaly/birth defect 
 is an important medical event (defined as a medical event(s) that may not be immediately life-
threatening or result in death or hospitalization but, based upon appropriate medical and 
scientific judgment, may jeopardize the subject or may require intervention [eg, medical, 
surgical] to prevent one of the other serious outcomes listed in the definition above.) Examples 
of such events include, but are not limited to, intensive treatment in an emergency room or at 
home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in 
hospitalization.) Potential drug induced liver injury (DILI) is also considered an important 
medical event. (See Section 6.6 for the definition of potential DILI.)





Suspected transmission of an infectious agent (eg, pathogenic or nonpathogenic) via the study drug 
is an SAE.
Although pregnancy, overdose, cancer, and potential drug induced liver injury (DILI) are not 
always serious by regulatory definition, these events must be handled as SAEs, (See Section 6.1.1
for reporting pregnancies).
Any component of a study endpoint that is considered related to study therapy (eg, death is an 
endpoint, if death occurred due to anaphylaxis, anaphylaxis must be reported) should be reported 
as SAE (see Section 6.1.1 for reporting details).
NOTE: 
The following hospitalizations are not considered SAEs in BMS clinical studies: 
 a visit to the emergency room or other hospital department < 24 hours, that does not result 
in admission (unless considered an important medical or life-threatening event)
 elective surgery, planned prior to signing consent
 admissions as per protocol for a planned medical/surgical procedure
 routine health assessment requiring admission for baseline/trending of health status 
(eg, routine colonoscopy)
 medical/surgical admission other than to remedy ill health and planned prior to entry into 
the study. Appropriate documentation is required in these cases
 admission encountered for another life circumstance that carries no bearing on health status 
and requires no medical/surgical intervention (eg, lack of housing, economic inadequacy, 
caregiver respite, family circumstances, administrative reason).
 Admission for administration of anticancer therapy in the absence of any other SAEs 
(applies to oncology protocols)
6.1.1 Serious Adverse Event Collection and Reporting
Sections 5.6.1 and 5.6.2 in the Investigator Brochure (IB) represent the Reference Safety 
Information to determine expectedness of serious adverse events for expedited reporting. 
Following the subject’s written consent to participate in the study, all SAEs, whether related or not 
related to study drug, must be collected, including those thought to be associated with protocol-
specified procedures. All SAEs must be collected that occur during the screening period and within
100 days of the last dose of study drug. For participants assigned to treatment and never treated 
with study drug, SAEs should be collected for 30 days from the date of treatment assignment. If 
applicable, SAEs must be collected that relate to any later protocol-specified procedure (eg, a 
follow-up skin biopsy). 
The investigator should report any SAE that occurs after these time periods and that is believed to 
be related to study drug or protocol-specified procedure. 
An SAE report should be completed for any event where doubt exists regarding its seriousness. 





If the investigator believes that an SAE is not related to study drug, but is potentially related to the 
conditions of the study (such as withdrawal of previous therapy or a complication of a study 
procedure), the relationship should be specified in the narrative section of the SAE Report Form.
SAEs, whether related or not related to study drug, and pregnancies must be reported to BMS 
(or designee) within 24 hours of awareness of the event. SAEs must be recorded on the SAE Report 
Form; pregnancies on a Pregnancy Surveillance Form (electronic or paper forms). The preferred 
method for SAE data reporting collection is through the eCRF. The paper SAE/pregnancy 
surveillance forms are only intended as a back-up option when the eCRF system is not functioning. 
In this case, the paper forms are to be transmitted via email or confirmed facsimile (fax) 
transmission to:
SAE Email Address: Refer to Contact Information list.
SAE Facsimile Number: Refer to Contact Information list.
For studies capturing SAEs through electronic data capture (EDC), electronic submission is the 
required method for reporting. The paper forms should be used and submitted immediately, only 
in the event the electronic system is unavailable for transmission. When paper forms are used, the 
original paper forms are to remain on site.
SAE Telephone Contact (required for SAE and pregnancy reporting): Refer to Contact
Information list.
If only limited information is initially available, follow-up reports are required. (Note: Follow-up 
SAE reports should include the same investigator term(s) initially reported.) 
If an ongoing SAE changes in its intensity or relationship to study drug or if new information 
becomes available, a follow-up SAE report should be sent within 24 hours to the BMS (or 
designee) using the same procedure used for transmitting the initial SAE report.
All SAEs should be followed to resolution or stabilization.
6.2 Nonserious Adverse Events
A nonserious adverse event is an AE not classified as serious.
6.2.1 Nonserious Adverse Event Collection and Reporting
The collection of nonserious AE information should begin at initiation of study drug. Nonserious 
AE information should also be collected from the start of a placebo lead-in period or other 
observational period intended to establish a baseline status for the subjects.
Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they 
become serious (see Section 6.1.1). Follow-up is also required for nonserious AEs that cause 
interruption or discontinuation of study drug and for those present at the end of study treatment as 
appropriate. All identified nonserious AEs must be recorded and described on the nonserious AE 
page of the CRF (paper or electronic). 
Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or 
immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor 





progression) have been ruled out. IMAEs can include events with an alternate etiology which were 
exacerbated by the induction of autoimmunity. Information supporting the assessment will be 
collected on the participant’s case report form.
All non-serious adverse events (not only those deemed to be treatment-related) should be collected 
continuously during the treatment period and for a minimum of 100 days following the last dose 
of study treatment.
Every adverse event must be assessed by the investigator with regard to whether it is considered 
immune-mediated. For events which are potentially immune-mediated, additional information will 
be collected on the subject’s case report form.
Completion of supplemental CRFs may be requested for AEs and/or laboratory abnormalities that 
are reported/identified during the course of the study.
6.3 Laboratory Test Result Abnormalities
The following laboratory test result abnormalities should be captured on the nonserious AE CRF 
page or SAE Report Form (paper or electronic) as appropriate:
 Any laboratory test result that is clinically significant or meets the definition of an SAE 
 Any laboratory test result abnormality that required the subject to have study drug discontinued 
or interrupted
 Any laboratory test result abnormality that required the subject to receive specific corrective 
therapy.
It is expected that wherever possible, the clinical rather than laboratory term would be used by the 
reporting investigator (eg, anemia versus low hemoglobin value).
6.4 Pregnancy
If, following initiation of the study drug, it is subsequently discovered that a study subject is 
pregnant or may have been pregnant at the time of study exposure, including during at least 
approximately 5 half-lives after product administration plus 30 days, the investigator must 
immediately notify the BMS Medical Monitor/designee of this event and complete and forward a 
Pregnancy Surveillance Form to BMS Designee within 24 hours of awareness of the event and in 
accordance with SAE reporting procedures described in Section 6.1.1.
In most cases, the study drug will be permanently discontinued in an appropriate manner (eg, dose 
tapering if necessary for subject safety).
In the rare event that the benefit of continuing study drug is thought to outweigh the risk, after 
consultation with BMS, the pregnant subject may continue study drug after a thorough discussion 
of benefits and risk with the subject
The investigator must immediately notify the BMS (or designee) Medical Monitor of this event 
and complete and forward a Pregnancy Surveillance Form to BMS (or designee) within 24 hours 
of awareness of the event and in accordance with SAE reporting procedures described in 
Section 6.1.1. 





Follow-up information regarding the course of the pregnancy, including perinatal and neonatal 
outcome and, where applicable, offspring information must be reported on the Pregnancy 
Surveillance Form.
Any pregnancy that occurs in a female partner of a male study participant should be reported to 
BMS. Information on this pregnancy will be collected on the Pregnancy Surveillance Form.
6.5 Overdose
All occurrences of overdose must be reported as SAEs (see Section 6.1.1 for reporting details).
6.6 Potential Drug Induced Liver Injury (DILI)
Wherever possible, timely confirmation of initial liver-related laboratory abnormalities should 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meeting 
the defined criteria, must be reported as SAEs (see Section 6.1.1 for reporting details).
Potential drug induced liver injury is defined as: 
1. AT (ALT or AST) elevation > 3 times upper limit of normal (ULN)
AND
2. Total bilirubin > 2 times ULN, without initial findings of cholestasis (elevated serum alkaline 
phosphatase),
AND
3. No other immediately apparent possible causes of AT elevation and hyperbilirubinemia, 
including, but not limited to, viral hepatitis, pre-existing chronic or acute liver disease, or the 
administration of other drug(s) known to be hepatotoxic.
6.7 Other Safety Considerations
Any significant worsening noted during interim or final physical examinations, electrocardiogram, 
x-ray filming, any other potential safety assessment required or not required by protocol should 
also be recorded as a nonserious or serious AE, as appropriate, and reported accordingly. 




8.1 Sample Size Determination











2) Recurrent/metastatic monotherapy cohort:
HPV+ SCCHN, GYN, MCC and NPC tumor types in the recurrent/metastatic cohort will contain 
approximately 23 subjects. Table 8.1-1 shows the probabilities of observing 0, 1 or 2 responders 
and  3 responders assuming 5%, 20% and 30% true response rate of ORR. Table 8.1-2 shows the 
two-sided 95% exact CI using Clopper-Pearson methods based on observed 3, 4 and 5 responders 
out of 23 subjects.
EBV+ Gastric tumor type will contain approximately 12 subjects, due to the low prevalence. Table 
8.1-5 shows the precision of the estimation of ORR based on the two sided 95% exact CI using 
Clopper-Pearson methods based on 1, 2, 3, 4 and 5 responders out of 12 subjects.
Table 8.1-1: Probability of Observing Responses Given True ORR for Sample 
Size of 23 Subjects
True ORR Probability of observing 0, 1 or 2 
responses





Table 8.1-2: Two-sided 95% Exact CI Using Clopper-Pearson Method Based on 
Number of Observed Responses out of 23 Subjects
The number of observed 
responses
3 4 5
Observed Response Rate 3/23 (13.0%) 4/23 (17.4%) 5/23 (21.7%)




































































8.2 Populations for Analyses
The analysis populations will be by cohort (neoadjuvant and metastatic), tumor type, and 
combination regimen. The following populations will be defined, and their specific applications 
will be documented in detail in the statistical analysis plan:
 All Enrolled Subjects: All subjects who signed an informed consent form and were registered 
into the IRT.
 All Treated Subjects: All enrolled subjects who received at least one dose of study drug.
 All Response Evaluable Subjects: All treated subjects in recurrent/metastatic cohorts 
(monotherapy and combination therapy) who have a BOR of CR, PR, SD, Non-CR/Non-
PD or PD, and target lesion(s) assessed at baseline, and one of the following: i) at least one 
on-study time point (before sub-sequent therapy) with all baseline target lesion(s) assessed; 
ii) clinical progression or death before any on-study tumor assessment.
 All Evaluable Neoadjuvant Subjects: All treated subjects in neoadjuvant cohorts who have 
available paired tissue samples at Screening and Day 29.
 Outcome Research Subjects: All treated subjects who have an assessment at baseline and at 
least one post-baseline assessment.
 Pharmacokinetic Subjects: All subjects who receive at least one dose of study drug and have 
available serum concentration data.





 Immunogenicity Subjects: All treated subjects with baseline and at least 1 post-baseline 
immunogenicity assessment for nivolumab, ipilimumab and BMS-986016 (relatlimab); All 
treated subjects with at least 1 post-baseline immunogenicity assessment for daratumumab. 







Metastatic cohorts (monotherapy and combination therapies): 
 The investigator-assessed objective response rate (ORR). ORR is defined as the number of 
subjects with a best overall response (BOR) of confirmed complete response (CR) or partial 
response (PR) divided by the number of treated subjects. BOR is defined as the best response 
designation recorded between the date of first dose and the date of the initial objectively 
documented tumor progression per investigator assessment using RECIST 1.1 criteria or the 
date of the last tumor assessment date prior to subsequent therapy. In this study, an ORR in 
excess of 10% will be considered of clinical interest, and an ORR of 25% or greater will be 
considered of strong clinical interest.  
8.3.2 Secondary Endpoint(s)
Metastatic cohorts (monotherapy and combination therapies):
 Duration of response (DOR) is defined as the time from first confirmed response (CR or PR) 
to the date of the initial objectively documented tumor progression as determined per 
investigator assessment using RECIST 1.1 criteria or death due to any cause, whichever occurs 
first. Subjects who did not start subsequent anti-cancer therapy and die without a reported prior 
progression will be considered to have progressed on the date of their death. Subjects who did 
not progress or die will be censored on the date of their last tumor assessment. Subjects who 
did not have any on study tumor assessments and did not die will be censored on the date they 
were treated. Subjects who started any subsequent anti-cancer therapy prior to death and 
without a prior reported progression will be censored at the last tumor assessment prior to or
on the date of initiation of the subsequent anti-cancer therapy. DOR will only be evaluated in 
subjects with objective response of CR or PR.
 Overall survival (OS) is defined as the time from first dosing date to the date of death. A subject 
who has not died will be censored at last known date alive. 
 Investigator-assessed progression free survival (PFS) is defined as the time from first dosing 
date to the date of the first documented tumor progression, as determined by investigators (per 





RECIST 1.1), or death due to any cause. Subjects who did not start subsequent anti-cancer 
therapy and die without a reported prior progression will be considered to have progressed on 
the date of their death. Subjects who did not progress or die will be censored on the date of 
their last tumor assessment. Subjects who did not have any on study tumor assessments and 
did not die will be censored on the date they were treated. Subjects who started any subsequent 
anti-cancer therapy prior to death and without a prior reported progression will be censored at 















Metastatic cohorts (monotherapy and combination therapies):
 The safety and tolerability objective will be measured by the incidence of adverse events, 
serious adverse events, deaths and laboratory abnormalities.
 
 
 Metastatic cohorts (monotherapy and combination therapies):
 The PK samples collected will be used to determine summary measures of nivolumab,
ipilimumab, BMS-986016 (relatlimab), and daratumumab exposures (see Section 8.4.4)
 Exploratory endpoints for pharmacodynamics, outcomes research and immunogenicity are 
discussed in detail in Sections 5.6, 5.7 and 5.8.
Other exploratory endpoints will be discussed in detail in the statistical analysis plan.






All analyses for neoadjuvant cohort will be performed as it completes safety follow-up. All 
analyses for each metastatic cohort (nivolumab monotherapy or combo A, B, C, or D) will be 
performed as it completes efficacy follow-up. All analyses will be performed independently by 
cohort, by tumor type, and regimen.
The randomization of the patients with metastatic cervical cancer and anogenital HPV associated 
(vulvar/vaginal/anal canal/penile) tumor types to combo A, B, or D is for administration purposes, 
not for comparison. Analyses will be done for each dosing schema separately. 
8.4.1 Demographics and Baseline Characteristics
Demographic and baseline laboratory results will be summarized using descriptive statistics for all 
treated subjects.
8.4.2 Efficacy Analyses
8.4.2.1 Primary Endpoint Methods
 
 
Metastatic cohort (monotherapy and combination therapies):
 The investigator assessed ORR in the metastatic cohort will be summarized by binomial 
response rates and their corresponding two-sided 95% exact CIs using Clopper-Pearson 
method. 
8.4.2.2 Secondary Endpoints Methods
Metastatic cohort (monotherapy and combination therapies):
 Time to event distribution will be estimated using Kaplan Meier techniques. This will be done 
for PFS (based on investigator assessments) and OS. Median PFS or OS along with 95% CI 
will be constructed based on a log-log transformed CI for the survivor function. Rates at some 
fixed time points will be derived from the Kaplan Meier estimate and corresponding 
confidence interval will be derived based on Greenwood formula for variance derivation and 
on log-log transformation applied on the survivor function. 
 The DOR will be summarized for all treated subjects who achieve confirmed PR or CR using 
the Kaplan-Meier (KM) product-limit method. Median values of DOR, along with two-sided 
95% CI using Brookmeyer and Crowley method, will also be calculated.
8.4.2.3 Exploratory Endpoints Methods
Methods for exploratory endpoints will be discussed in detail in the statistical analysis plan.






Safety analyses will be performed in all treated subjects. Descriptive statistics of safety will be 
presented using NCI CTCAE version 4. All on-study AEs, drug-related, AEs, SAEs and 
drug-related SAEs will be tabulated using worst grade per NCI CTCAE version 4 criteria by 
system organ class and MedDRA preferred term. On-study lab parameters including hematology, 
chemistry, liver function, thyroid function, and renal function will be summarized using worst 
grade per NCI CTCAE version 4 criteria.
The proportion of subjects in the neoadjuvant cohort with surgery delayed > 4 weeks due to a drug-
related AE will be reported for each tumor type and the Clopper-Pearson method will be used to 
estimate the two-sided 95% confidence interval.
8.4.4 Pharmacokinetic Analyses
The nivolumab, ipilimumab, BMS-986016 (relatlimab), and daratumumab concentration data 
obtained in this study may be combined with data from other studies in any of the clinical 
development programs (nivolumab, ipilimumab, BMS-986016, and daratumumab) to develop or 
refine a population PK model. The models may be used to evaluate the effects of intrinsic and 
extrinsic covariates on the PK of nivolumab or other compounds and to determine measures of 
individual exposure (such as steady-state peak, trough, and time-averaged concentration). In 
addition, model determined exposures may be used for exposure-response analyses. If performed, 
results of population PK and exposure response-analyses will be reported separately.
8.4.5 Biomarker Analyses
The pharmacodynamic effects of nivolumab as monotherapy or in combination with ipilimumab,
BMS-986016 (relatlimab), or daratumumab on selected biomarkers will be assessed by summary 
statistics and corresponding changes (or percent changes) from baseline tabulated by time and 
cohort. In addition, the time course of biomarker outcomes will be investigated graphically, by 
summary plots or individual subject plots. If there is an indication of a meaningful 
pharmacodynamic trend, methods such as linear mixed models may be used to characterize the 
pattern of change over time. The potential association between PD-L1 expression level (IHC) and 
clinical efficacy measures will be assessed using Fisher’s exact test or other methodology as 
appropriate.
Potential associations of various biomarker measures with pharmacokinetic exposure, safety and 
clinical efficacy measures will be investigated based on data availability. Methods such as, but not 
limited to, logistic regression and graphical summaries may be used to assess these associations.
The methodology for additional exploratory biomarker analyses will be described in the statistical 
analysis plan. 
8.4.6 Outcomes Research Analyses
8.4.6.1 EQ-5D
Subject’s overall health state on a visual analog scale (EQ-VAS) at each assessment time point 
will be summarized using descriptive statistics (N, mean, standard deviation, median, first and 





third quartiles, minimum, maximum). Proportion of subjects reporting problems for the 5 EQ-5D 
dimensions at each assessment time point will be summarized by level of problem. Percentages 
will be based on number subjects assessed at assessment time point.
A by-subject listing of EQ-5D with the problem levels for each of the 5 dimensions (mobility, self-
care, usual activities, pain/discomfort and anxiety/depression), health state (5 dimensions digits 
combined in a 5-digit number) and EQ-VAS will be provided. Each dimension has three levels: 
no problems, some problems, and severe problems.
8.4.6.2 EORTC QLQ-C30
The analysis of EORTC QLQ-C30 will be performed in all treated subjects who have an 
assessment at baseline and at least one subsequent assessment.
All scales and single items are scored on a categorical scale and linearly transformed to 0-to-100 
scales with higher scores for a functional scale representing higher levels of functioning, higher 
scores for the global health status/quality of life representing higher levels of global health 
status/quality of life, and higher scores for a symptom scale representing higher level of symptoms.
Baseline and change from baseline in EORTC QLQ-C30 global health status/QoL composite scale 
data and the remaining EORTC QLQ-C30 scale data will be summarized by time point using 
descriptive statistics for each cohort (N, mean, standard deviation, median, first and third quartiles, 
minimum, maximum). In addition, the percentage of subjects demonstrating a clinically 
meaningful deterioration (defined as a 10 point change from baseline) will be presented for each 




Immunogenicity may be reported for ADA positive status (such as persistent positive, neutralizing
positive, only last sample positive, baseline positive and other positive) and ADA negative status, 
relative to baseline. Effect of immunogenicity on safety, efficacy, biomarkers and PK may be 
explored. Additional details will be described in the SAP.
8.5 Interim Analyses
Under the circumstance that data of some tumor types mature faster than others or a strong signal 
is observed in some tumor types, interim analyses may be performed prior to the completion of 
the study in order to facilitate program decisions and to support presentations or publication. These 
interim analyses will not impact the study duration and the trial will continue as planned.
9 STUDY MANAGEMENT
9.1 Compliance
9.1.1 Compliance with the Protocol and Protocol Revisions
The study shall be conducted as described in this approved protocol. All revisions to the protocol 
must be discussed with, and be prepared by, BMS. The investigator should not implement any 





deviation or change to the protocol without prior review and documented approval/favorable 
opinion from the IRB/IEC of an amendment, except where necessary to eliminate an immediate 
hazard(s) to study subjects. 
If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior to 
obtaining IRB/IEC approval/favorable opinion, as soon as possible the deviation or change will be 
submitted to:
 IRB/IEC for review and approval/favorable opinion
 BMS
 Regulatory Authority(ies), if required by local regulations
Documentation of approval signed by the chairperson or designee of the IRB(s)/IEC(s) must be 
sent to BMS.
If an amendment substantially alters the study design or increases the potential risk to the subject: 
(1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review and 
approval/favorable opinion; (2) the revised form must be used to obtain consent from subjects 
currently enrolled in the study if they are affected by the amendment; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment.
If the revision is done via an administrative letter, investigators must inform their IRB(s)/IEC(s).
9.1.2 Monitoring
BMS representatives will review data centrally to identify potential issues to determine a schedule 
of on-site visits for targeted review of study records. 
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity. On site they will review study records and directly compare them 
with source documents, discuss the conduct of the study with the investigator, and verify that the 
facilities remain acceptable. Certain CRF pages and/or electronic files may serve as the source 
documents.
In addition, the study may be evaluated by BMS internal auditors and government inspectors who 
must be allowed access to CRFs, source documents, other study files, and study facilities. BMS 
audit reports will be kept confidential.
The investigator must notify BMS promptly of any inspections scheduled by regulatory authorities, 
and promptly forward copies of inspection reports to BMS. 
9.1.2.1 Source Documentation
The Investigator is responsible for ensuring that the source data are accurate, legible,
contemporaneous, original and attributable, whether the data are hand-written on paper or entered 
electronically. If source data are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electronically via computerized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such systems must be compliant with all 
applicable laws and regulations governing use of electronic records and/or electronic signatures. 





Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), 
adverse event tracking/reporting, protocol required assessments, and/or drug accountability 
records).
When paper records from such systems are used in place of electronic format to perform regulated 
activities, such paper records should be certified copies. A certified copy consists of a copy of 
original information that has been verified, as indicated by a dated signature, as an exact copy 
having all of the same attributes and information as the original. 
9.1.3 Investigational Site Training
Bristol-Myers Squibb will provide quality investigational staff training prior to study initiation. 
Training topics will include but are not limited to: GCP, AE reporting, study details and procedure, 
electronic CRFs, study documentation, informed consent, and enrollment of WOCBP.
9.2 Records
9.2.1 Records Retention
The investigator must retain all study records and source documents for the maximum period 
required by applicable regulations and guidelines, or institution procedures, or for the period 
specified by BMS, whichever is longer. The investigator must contact BMS prior to destroying 
any records associated with the study.
BMS will notify the investigator when the study records are no longer needed.
If the investigator withdraws from the study (eg, relocation, retirement), the records shall be 
transferred to a mutually agreed upon designee (eg, another investigator, IRB). Notice of such 
transfer will be given in writing to BMS.
9.2.2 Study Drug Records
It is the responsibility of the investigator to ensure that a current disposition record of study drug 
(inventoried and dispensed) is maintained at the study site to include investigational product. 
Records or logs must comply with applicable regulations and guidelines and should include:
 amount received and placed in storage area
 amount currently in storage area
 label identification number or batch number 
 amount dispensed to and returned by each subject, including unique subject identifiers
 amount transferred to another area/site for dispensing or storage
 nonstudy disposition (eg, lost, wasted) 
 amount destroyed at study site, if applicable
 amount returned to BMS
 retain samples for bioavailability/bioequivalence, if applicable 
 dates and initials of person responsible for Investigational Product dispensing/accountability, 
as per the Delegation of Authority Form.





BMS will provide forms to facilitate inventory control if the investigational site does not have an 
established system that meets these requirements.
9.2.3 Case Report Forms
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other data pertinent to the investigation on each individual treated 
or entered as a control in the investigation. Data that are derived from source documents and 
reported on the CRF must be consistent with the source documents or the discrepancies must be 
explained. Additional clinical information may be collected and analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
For sites using the BMS electronic data capture tool, electronic CRFs will be prepared for all data 
collection fields except for fields specific to SAEs and pregnancy, which will be reported on the 
paper or electronic SAE form and Pregnancy Surveillance form, respectively. Spaces may be left 
blank only in those circumstances permitted by study-specific CRF completion guidelines 
provided by BMS. 
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules in accordance with the applicable regulatory requirement(s).
The investigator will maintain a signature sheet to document signatures and initials of all persons 
authorized to make entries and/or corrections on CRFs. 
The completed CRF, including any paper or electronic SAE/pregnancy CRFs, must be promptly 
reviewed, signed, and dated by the investigator or qualified physician who is a subinvestigator and 
who is delegated this task on the Delegation of Authority Form. For electronic CRFs, review and 
approval/signature is completed electronically through the BMS electronic data capture tool. The 
investigator must retain a copy of the CRFs including records of the changes and corrections.
Each individual electronically signing electronic CRFs must meet BMS training requirements and 
must only access the BMS electronic data capture tool using the unique user account provided by 
BMS. User accounts are not to be shared or reassigned to other individuals.
9.3 Clinical Study Report and Publications
A Signatory Investigator must be selected to sign the clinical study report. 
For this protocol, the Signatory Investigator will be selected as appropriate based on the following 
criteria:
 External Principal Investigator designated at protocol development
 Subject recruitment (eg, among the top quartile of enrollers)
 Involvement in trial design
The data collected during this study are confidential and proprietary to BMS. Any publications or 
abstracts arising from this study must adhere to the publication requirements set forth in the clinical 
trial agreement (CTA) governing [Study site or Investigator] participation in the study. These 





requirements include, but are not limited to, submitting proposed publications to BMS at the 
earliest practicable time prior to submission or presentation and otherwise within the time period 
set forth in the CTA.





10 GLOSSARY OF TERMS
Term Definition
Complete Abstinence If one form of contraception is required, Complete 
Abstinence is defined as complete avoidance of heterosexual 
intercourse and is an acceptable form of contraception for all 
study drugs. Female subjects must continue to have 
pregnancy tests. Acceptable alternate methods of highly 
effective contraception must be discussed in the event that 
the subject chooses to forego complete abstinence.
If two forms of contraception is required, Complete 
abstinence is defined as complete avoidance of heterosexual 
intercourse and is an acceptable form of contraception for all 
study drugs. Subjects who choose complete abstinence are 
not required to use a second method of contraception, but 
female subjects must continue to have pregnancy tests. 
Acceptable alternate methods of highly effective 
contraception must be discussed in the event that the subject 
chooses to forego complete abstinence.
Expanded definition Complete abstinence as defined as 
complete avoidance of heterosexual intercourse is an 
acceptable form of contraception for all study drugs. This
also means that abstinence is the preferred and usual lifestyle 
of the patient. This does not mean periodic abstinence (eg, 
calendar, ovulation, symptothermal, profession of abstinence 
for entry into a clinical trial, post-ovulation methods) and 
withdrawal, which are not acceptable methods of 
contraception. Subjects who choose complete abstinence are 
not required to use a second method of contraception, but 
female subjects must continue to have pregnancy tests. 
Acceptable alternate methods of highly effective 
contraception must be discussed in the event that the subject 
chooses to forego complete abstinence





11 LIST OF ABBREVIATIONS
Term Definition
AE adverse event
ACLS advanced cardiac life support
AI accumulation index
AI_AUC AUC Accumulation Index; ratio of AUC(TAU) at steady state to 
AUC(TAU) after the first dose
AI_Cmax Cmax Accumulation Index; ratio of Cmax at steady state to Cmax after 
the first dose
AI_Ctau Ctau Accumulation Index; ratio of Ctau at steady state to Ctau after the 
first dose
ALT alanine aminotransferase
ANC absolute neutrophil count
ANOVA analysis of variance
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
AT aminotransaminases
AUC area under the concentration-time curve
AUC(INF) area under the concentration-time curve from time zero extrapolated to 
infinite time
AUC(0-T) area under the concentration-time curve from time zero to the time of the 
last quantifiable concentration
AUC(TAU) area under the concentration-time curve in one dosing interval
A-V atrioventricular
-HCG beta-human chorionic gonadotrophin
BA/BE bioavailability/bioequivalence
%BE percent biliary excretion
BID, bid bis in die, twice daily
BLQ below limit of quantification 
BMI body mass index
BMS Bristol-Myers Squibb
BP blood pressure
BRt Total amount recovered in bile






%BRt Total percent of administered dose recovered in bile
BUN blood urea nitrogen
C Celsius
C12 concentration at 12 hours
C24 concentration at 24 hours
Ca++ calcium
Cavg average concentration
CBC complete blood count
Cexpected-tau expected concentration in a dosing interval
CFR Code of Federal Regulations 




CLD Dialysate clearance of drug from plasma/serum
CLNR nonrenal clearance
CLR renal clearance
CLT total body clearance
CLT/F (or CLT) apparent total body clearance
CLT/F/fu or 
CLT/fu
Apparent clearance of free drug or clearance of free if (if IV)
cm centimeter
Cmax, CMAX maximum observed concentration
Cmin, CMIN trough observed concentration
CNS Central nervous system
CRC Clinical Research Center
CRF Case Report Form, paper or electronic
Ct Expected concentration at a certain time, usually at the end of an 
expected future dosing interval (eg, concentration at 24 hours, 
concentration at 12 hours, etc.)
Ctau Concentration in a dosing interval (eg, concentration at 24 hours, 
concentration at 12 hours, etc.)






Ctrough Trough observed plasma concentration




DRt Total amount recovered in dialysate
%DRt Total percent of administered dose recovered in dialysate
DSM IV Diagnostic and Statistical Manual of Mental Disorders (4th Edition)
EA extent of absorption
ECG electrocardiogram
eCRF Electronic Case Report Form
EDC Electronic Data Capture
EEG electroencephalogram
eg exempli gratia (for example)
ESR Expedited Safety Report
F bioavailability
Fb fraction of bound drug
FDA Food and Drug Administration
FI fluctuation Index ([Cmax-Ctau)/Cavg])
FRt total amount recovered in feces
%FRt total percent of administered dose recovered in feces
FSH follicle stimulating hormone
%FE percent fecal excretion
fu fraction of unbound drug
g gram
GC gas chromatography
GCP Good Clinical Practice
G criteria adjusted R2 value of terminal elimination phase
GGT gamma-glutamyl transferase
GFR glomerular filtration rate
h hour






HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HCO3- bicarbonate
HIV Human Immunodeficiency Virus
HR heart rate
HRT hormone replacement therapy
ICD International Classification of Diseases
ICH International Conference on Harmonisation
ie id est (that is)
IEC Independent Ethics Committee
Ig immunoglobulin
IMP investigational medicinal products
IND Investigational New Drug Exemption
IO immuno-oncology
IRB Institutional Review Board
IRT Interactive Response Technology
IU International Unit
IV intravenous
K slope of the terminal phase of the log concentration-time curve
K3EDTA potassium ethylenediaminetetraacetic acid
K+ potassium
kg kilogram
z terminal disposition rate constant
L liter










Lz_Start The time point starting the log-linear elimination phase defining the
terminal half life
Lz_End The time point ending the log-linear elimination phase defining the 
terminal half life
Lz_N Number of time points in the log-linear elimination phase defining the 
terminal half life




MIC minimum inhibitory concentration
min minute
mL milliliter
mmHg millimeters of mercury
MR_AUC(0-T) Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for 
molecular weight
MR_AUC(INF) Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for 
molecular weight
MR_AUC(TAU) Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for 
molecular weight
MR_Cmax Ratio of metabolite Cmax to parent Cmax, corrected for molecular 
weight
MR_Ctau Ratio of metabolite Ctau to parent Ctau, corrected for molecular weight
MRT mean residence time
MS mass spectrometry
MTD maximum tolerated dose
g microgram




NIMP non-investigational medicinal products 
NSAID nonsteroidal anti-inflammatory drug






NSCLC non-small cell lung cancer
pAUCe Extrapolated partial AUC from last quantifiable concentration to infinity
Pb percent of bound drug
PD pharmacodynamics
PK pharmacokinetics
PO per os (by mouth route of administration)
PT prothrombin time
PTT partial thromboplastin time
Pu percent of unbound drug
QC quality control
QD, qd quaque die, once daily
R2 coefficient of determination
RBC red blood cell
RCC renal cell carcinoma
SAE serious adverse event
SCC squamous cell cancer
SCLC small cell lung cancer
SD standard deviation
SEB staphylococcal enterotoxin B
SOC standard of care





TAO Trial Access Online, the BMS implementation of an EDC capability
T-HALF Half life
T-HALFeff_AUC Effective elimination half-life that explains the degree of AUC 
accumulation observed
T-HALFeff_Cmax Effective elimination half-life that explains the degree of Cmax 
accumulation observed)






TID, tid ter in die, three times a day
TIL tumor infiltrating lymphocytes
Tmax, TMAX time of maximum observed concentration
TR_AUC(0-T) AUC(0-T) treatment ratio
TR_AUC(INF) AUC(INF) treatment ratio
TR_Cmax Cmax treatment ratio
UR urinary recovery
%UR percent urinary recovery
URt total amount recovered in urine
%URt total percent of administered dose recovered in urine
UV ultraviolet
Vss/F (or Vss) apparent volume of distribution at steady state
Vz Volume of distribution of terminal phase (if IV and if multi-exponential 
decline)
W washout
WBC white blood cell
WHO World Health Organization
WOCBP women of childbearing potential
x g times gravity






1 Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of 
the PD 1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation 
of lymphocyte activation. J Exp Med 2000;192(7):1027-34.
2 Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. 
Trends Immunol. 2001; 22: 265-8.
3 Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al., PD-L2 is a 
second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261-268.
4 Carter LL, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, et al. PD-1:PD-L inhibitory pathway 
affects both CD4+ and CD8+ T cells and is overcome by IL-2. Eur J Immunol. 2002;32(3):634-
43.
5 Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor 
tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, 
but only receptor ligation prevents T cell activation. J Immunol. 2004; 173: 945-54.
6 Sheppard KA, Fitz LJ, Lee JM, et al. PD-1 inhibits T-cell receptor induced phosphorylation of 
the ZAP70/CD3zeta signalosome and downstream signaling to PKC-theta. FEBS Letters. 
2004; 574: 37-41.
7 Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by 
disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 
1999; 11:141-51.
8 Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 
receptor-deficient mice. Science. 2001; 291: 319-22.
9 Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible 
for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003; 9: 1477-83.
10 Salama AD, Chitnis T, Imitola J, et al. Critical role of the programmed death-1 (PD-1) pathway 
in regulation of experimental autoimmune encephalomyelitis. J Exp Med. 2003; 198: 71-8.
11 Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 
engagement accelerates graft-versus-host disease lethality by an IFN--dependent mechanism. 
J Immunol. 2003; 171: 1272-7.
12 Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, et al. The programmed 
death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J 
Exp Med. 2003 Jul 7;198(1):63-9.





13 Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly 
immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol. 2004; 17: 
133-44.
14 Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from 
host immune system and tumor immunotherapy by PD-1 blockade. Proc Natl Acad Sci USA. 
2002; 99: 12293-7.
15 Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cell 
immunotherapy for squamous cell carcinoma. Cancer Res. 2003; 63: 6501-5.
16 Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: 
a potential mechanism of immune evasion. Nat Med. 2002; 8: 793-800.
17 Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies
potentiates cancer therapeutic immunity. Cancer Res. 2005 Feb 1;65(3):1089-96.
18 Blank C, Brown I Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumor 
rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004; 64: 1140-45.
19 Keir M, Butte M, Freeman G, Sharpe A. PD-1 and its ligands in tolerance and immunity. Ann 
Rev Immunol. 2008;26:677-704.
20 Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells 
and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin 
Cancer Res. 2004; 10: 5094-100.
21 Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma 
subjects: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad 
Sci USA. 2004; 101: 17174-9.
22 Ohigashi Y, Sho M, Yamada Y et al. Clinical significance of programmed death-1 ligand-1 
and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 
2005; 11: 2947-53.
23 Tsushima F, Tanaka K, Otsuki N, et al. Predominant expression of B7-H1 and its 
immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol. 2006; 42: 268-74.
24 Thompson RH, Weber WS, Cheville JC, et al. B7-H1 glycoprotein blockade: a novel strategy 
to enhance immunotherapy in subjects with renal cell carcinoma. Urology. 2005; 66: 10-4.
25 Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory molecule B7-H1 in primary and 
metastatic clear cell renal cell carcinoma. Cancer. 2005; 104: 2084-91.
26 Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med. 
2003; 81: 281-7.





27 Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor 
tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, 
but only receptor ligation prevents T cell activation. J Immunol. 2004; 173: 945-54.
28 Azuma T, Yao S, Zhu G, et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. 
Blood. 2008; 111: 3635-43.
29 Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma 
subjects: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad 
Sci USA. 2004; 101: 17174-9.
30 Effect of MDX-1106 on CD4+ T cells during an allogeneic mixed lymphocyte reaction (MLR) 
(Medarex Study No. MDX-1106-026-R). Bristol-Myers Squibb Pharmaceutical Research 
Institute; 2006. Document Control No. 930046581.
31 Ferlay J, Soerjomataram I, Ervik M. et al. GLOBOCAN 2012 v1.0, cancer incidence and 
mortality worldwide. IARC Cancer Base 11, http://globocan.iarc.fr, Accessed on 13 August 
2014.
32 Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2011, 
National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on 
November 2013 SEER data submission, posted to the SEER web site, April 2014.
33 Karpeh MS, Leon L, Klimstra D, et al. Lymph node staging in gastric cancer: islocation 
important than number? An analysis of 1038 patients. Ann Surg 2000;232:362-371.
34 The Cancer Genome Atlas Network. Comprehensive molecular characterization of gastric 
adenocarcinoma. Nature 2014;513:202–209.
35 Murphy G, Pfeiffer R, Camargo MC, et al. Meta-analysis shows that prevalence of Epstein-
Barr virus-positive gastric cancer differs based on sex and anatomic location. 
Gastroenterology. 2009; 137:824-33. 
36 WHO Classification of Tumours of the Digestive System 4th edition (International Agency for 
Research on Cancer, 2010).
37 Carmargo MC, Kim WH, Chiaravalli AM, et al. Improved survival of gastric cancer with 
tumor Epstein-Barr virus positivity: an international pooled analysis. Gut. 2014;63:236-43.
38 Lee JH, Kim SH, Han SH, et al. Clinicopathological and molecular characteristics of Epstein-
Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol 2009; 
24:354-65.
39 Atula S, Auvinen E, Grenman R, et al. Human papillomavirus and Epstein-Barr virus in 
epithelial carcinomas of the head and neck region. Anticancer Res 1997; 17:4427.
40 Pathmanathan R, Prasad U, Sadler R, et al. Clonal proliferations of cells infected with Epstein-
Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995; 
333:693.





41 Chien YC, Chen JY, Liu MY, et al. Serologic markers of Epstein-Barr virus infection and 
nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001; 345:1877.
42 Pathology and genetics of head and neck tumors. In: World Health Organization Classification 
of Tumours, Barnes L, Eveson JW, Reichart P, Sidransky D (Eds), IARC Press, Lyon 2005.
43 Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation 
complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J 
Clin Oncol 2006; 24:5414-18.
44 Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in 
patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350:2461-70.
45 Lin JC, Wang WY, Liang WM, et al. Long-term prognostic effects of plasma epstein-barr virus 
DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma 
patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1342-
8.
46 Lee AW, Sze WM, Au JS, et al. Treatment results for nasopharyngeal carcinoma in the modern 
era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005;61:1107-16.
47 Jin Y, Cai XY, Shi YX, et al. Comparison of five cisplatin-based regimens frequently used as 
the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 
2012;138:1717-25. 
48 Chua DT, Sham JS, Au GK. A phase II study of capecitabine in patients with recurrent and 
metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral 
Oncol. 2003;39:361-6.
49 Poon D, Chowbay B, Cheung YB, et al. Phase II study of irinotecan (CPT-11) as salvage 
therapy for advanced nasopharyngeal carcinoma. Cancer. 2005;103:576-81.
50 Ngeow J, Lim WT, Leong SS, et al. Docetaxel is effective in heavily pretreated patients with 
disseminated nasopharyngeal carcinoma. Ann Oncol. 2011;22(3):718-22.
51 Chen C, Wang FH, Wang ZQ, et al. Salvage gemcitabine-vinorelbine chemotherapy in patients 
with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral 
Oncol. 2012;48):1146-51. 
52 Yau TK, Shum T, Lee AW, et al. A phase II study of pemetrexed combined with cisplatin in 
patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol. 2012;48:441-4.
53 Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer. Lancet 2008;371:1695-
709.
54 Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for 
head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. 
MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. 
Lancet 2000;355:949-55.





55 Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014 ;64:9-29.
56 Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck 
cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 
2009;92:4-14.
57 Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation 
therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable 
squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.
58 Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell 
carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
59 Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally 
advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and 
relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21-8.
60 Gold KA, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and 
neck. Cancer 2009;115:922-35.
61 Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus-
related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 
2008;26:612-9.
62 Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human 
papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck 
cancers. J Natl Cancer Inst 2008;100:407-20.
63 Argiris A, Heron DE, Smith RP, et al. Induction Docetaxel, Cisplatin, and Cetuximab Followed 
by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in 
Patients With Locally Advanced Head and Neck Cancer. J Clin Oncol 2010;28:5294-300.
64 Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without 
concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 
1998;338:1798-804.
65 Gilbert J, Li Y, Pinto HA, et al. Phase II trial of taxol in salivary gland malignancies (E1394): 
a trial of the Eastern Cooperative Oncology Group. Head Neck 2006;28:197-204.
66 Leon X, Hitt R, Constenla M, et al. A retrospective analysis of the outcome of patients with 
recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a 
platinum-based chemotherapy. Clin Oncol (R Coll Radiol) 2005;17:418-24.
67 http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125084s046LBL.pdf Accessed on 
23 Sept 2103
68 Price KAR and Cohen EE. Current Treatment Options for Metastatic Head and Neck Cancer. 
Curr Treat Options Oncol 2012;13:35-46.





69 Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised phase II study comparing 
docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 
2004;40:2071-6. 
70 Knoedler M, Gauler TC, Gruenwald V, et al. Phase II Study of Cetuximab in Combination 
with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the 
Head and Neck after Platinum-Containing Therapy: A Multicenter Study of the 
ArbeitsgemeinschaftInternisticshceOnkologie. Oncology 2013;84:284-89. 
71 Vermorken JB, Trigo J, Hitt R, et al. Open-Label, Uncontrolled, Multicenter Phase II Study to 
Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent 
and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to 
Platinum-Based Therapy. JCO 2007;25:2171-77.
72 Ang KK, Harris J, Wheeler R, et al. Human Papillomavirus and Survival of Patients with 
Oropharyngeal Cancer. NEJM 2010;363:24-35.
73 Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with 
docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-15.
74 Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-
positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer 
Inst 2008;100:261-9.
75 Insinga RP, Liaw KL, Johnson LG, et al. A systematic review of the prevalence and attribution 
of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in 
the United States. Cancer Epidemiol Biomarkers Prev. 2008l;17:1611-22. 
76 Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause 
of invasive cervical cancer worldwide. J Pathol. 1999;189:12-9.
77 Iwasawa A, Nieminen P, Lehtinen M, et al. Human papillomavirus in squamous cell carcinoma 
of the vulva by polymerase chain reaction. J. Obstet Gynecol. 1997;89:81-4.
78 http://www.cdc.gov/cancer/hpv/statistics/index.htm Accessed on 26 Dec 2014. 
79 Shylasree TS, Bryant A, Howells RE. Chemoradiation for advanced primary vulvar cancer. 
Cochrane Database Syst Rev. 2011;(4):CD003752. 
80 http://www.cancer.org/cancer/vulvarcancer/detailedguide/vulvar-cancer-survival-rates 
Accessed on 26 Dec 2014.
81 Maggino T, Landoni F, Sartori E, et al. Patterns of recurrence in patients with squamous cell 
carcinoma of the vulva. A multicenter CTF Study. Cancer. 2000;89:116-22.
82 http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-survival Accessed 
on 26 Dec 2014. 
83 Tewari KS1, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced 
cervical cancer. N Engl J Med. 2014;370:734-43.





84 Cancer Facts & Figures 2016. American Cancer Society. Available at 
http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-
047079.pdf. Accessed: Sept 6, 2016.
85 Palefsky JM. Anal human papillomavirus infection and anal cancer in HIV-positive 
individuals: an emerging problem. AIDS. 1994;8(3):283-95.
86 Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of 
anal cancer. N Engl J Med. 1997;337 (19):1350-8.
87 SEER Stat Fact Sheets: Anal Cancer. NIH Surveillance, Epidemiology and End Results 
Program. Available at http://seer.cancer.gov/statfacts/html/anus.html.; Accessed: Sept. 6, 
2016.
88 Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D. Anal 
cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and 
follow-up. Ann Oncol. 2014;40(10):1165-76.
89 Long AP, Kroon BK, Gallee MP, et al. Pelvic lymph node dissection for penile carcinoma: 
extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement 
and survival. J Urol. 2007;177(3):947-52.
90 Leijte JA, Kirrander P, Antonini N, Windahl T, Horenblas S. Recurrence patterns of squamous 
cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 
700 patients. Eur Urol. 2008;54(1):161-8. Epub 2008 Apr 15.
91 Connell CF, Berger NA. Management of advanced squamous cell carcinoma of the penis. Urol 
Clin North Am. 1994;21(4):745-56.
92 Nicholson S, Hall E, Harland SJ, et al. Phase II trial of docetaxel, cisplatin and 5FU 
chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). Br J Cancer. 
2013;109(10):2554-9. Epub 2013 Oct 29.
93 Haas GP, Blumenstein BA, Gagliano RG, et al. Cisplatin, methotrexate and bleomycin for the 
treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol. 
1999;161(6):1823-5.
94 Theodore C, Skoneczna I, Bodrogi I, et al. A phase II multicentre study of irinotecan (CPT 11) 
in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma 
(EORTC PROTOCOL 30992). Ann Oncol. 2008;19(7):1304-1307.
95 Di Lorenzo G, Federico P, Buonerba C, et al. Paclitaxel in pretreated metastatic penile cancer: 
final results of a phase 2 study. Eur Urol. 2011;60(6):1280-4.
96 Wang J, Pettaway CA, Pagliaro LC. Treatment for Metastatic Penile Cancer After First-line 
Chemotherapy Failure: Analysis of Response and Survival Outcomes. Urology. 
2015;85(5):1104-10.





97 Albores-Saavedra J, Batich K, Chable-Montero F, et al. Merkel cell carcinoma demographics, 
morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol. 
2010;27:20-7.
98 Lemos BD, Storer BE, Iyer JG, et al. Pathologic nodal evaluation improves prognostic 
accuracy in merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus 
staging system. J Am Acad Dermatol 2010;63:751–61.
99 Howard RA, Dores GM, Curtis RE, et al. Merkel cell carcinoma and multiple primary cancers. 
Cancer Epidemiol Biomarkers Prev 2006;15:1545–9.
100 Ascoli V, Minelli G, Kanieff M, et al. Merkel cell carcinoma: A population-based study on 
mortality and the association with other cancers. Cancer Causes Control 2011;22:1521–7.
101 Gass JK, Chan SK, Rytina E, et al. Multiple primary malignancies in patients with merkel cell 
carcinoma. J Eur Acad Dermatol Venereol 2010;24:601–3.
102 Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel 
cell carcinoma. Science 2008;319:1096-100.
103 Sastre-Garau X, Peter M, Avril MF, et al. Merkel cell carcinoma of the skin: pathological and 
molecular evidence for a causative role of MCV in oncogenesis. J Pathol. 2009;218(1):48-56.
104 Mojica P, Smith D, Ellenhorn JD. Adjuvant radiation therapy is associated with improved 
survival in Merkel cell carcinoma of the skin. Clin Oncol 2007;25:1043-47. 
105 http://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf Accessed on 7 October 2014.
106 Crown J, Lipzstein R, Cohen S, et al. Chemotherapy of metastatic Merkel cell cancer. Cancer 
Invest. 1991;9:129-32.
107 Pectasides D, Moutzourides G, Dimitriadis M, et al. Chemotherapy for Merkel cell carcinoma 
with carboplatin and etoposide. Am J Clin Oncol. 1995 Oct;18:418-20.
108 Redmond J, Perry J, Sowray P, et al. Chemotherapy of disseminated Merkel-cell carcinoma. 
Am J Clin Oncol. 1991;14:305-7.
109 Rous P. A transmissible avian neoplasm. (sarcoma of the common fowl.). The Journal of 
experimental medicine 1910;12:696-705.
110 Martin D, Gutkind JS. Human tumor-associated viruses and new insights into the molecular 
mechanisms of cancer. Oncogene 2008;27 Suppl 2:S31-42.
111 Scheffner M, Huibregtse JM, Vierstra RD, et al. The HPV-16 E6 and E6-AP complex functions 
as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75:495-505.
112 Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. 
Nature reviews Cancer 2010;10:550-60.





113 Saha A, Robertson ES. Impact of EBV essential nuclear protein EBNA-3C on B-cell 
proliferation and apoptosis. Future microbiology 2013;8:323-52.
114 Herrero JA, Mathew P, Paya CV. LMP-1 activates NF-kappa B by targeting the inhibitory 
molecule I kappa B alpha. Journal of virology 1995;69:2168-74.
115 Dyson N, Bernards R, Friend SH, et al. Large T antigens of many polyomaviruses are able to 
form complexes with the retinoblastoma protein. Journal of virology 1990;64:1353-6.
116 Treisman R, Novak U, Favaloro J, et al. Transformation of rat cells by an altered polyoma 
virus genome expressing only the middle-T protein. Nature 1981;292:595-600.
117 Shuda M, Kwun HJ, Feng H, et al. Human Merkel cell polyomavirus small T antigen is an 
oncoprotein targeting the 4E-BP1 translation regulator. The Journal of clinical investigation 
2011;121:3623-34.
118 Lyngaa R, Pedersen NW, Schrama D, et al. T-cell responses to oncogenic merkel cell 
polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors. 
Clinical cancer research: an official journal of the American Association for Cancer Research 
2014;20:1768-78.
119 Li J, Zeng XH, Mo HY, et al. Functional inactivation of EBV-specific T-lymphocytes in 
nasopharyngeal carcinoma: implications for tumor immunotherapy. PloS one 2007;2:e1122.
120 Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple 
inhibitory receptors during chronic viral infection. Nature immunology 2009;10:29-37.
121 Carthon BC, Wolchok JD, Yuan J, Kamat A, et al. Preoperative CTLA-4 blockade: tolerability 
and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010 
May 15;16(10):2861-71. doi: 10.1158/1078-0432.CCR-10-0569. Epub 2010 May 11.
122 Lyngaa R1, Pedersen NW, Schrama D, et al. T-cell responses to oncogenic merkel cell 
polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors. 
Clin Cancer Res. 2014 Apr 1;20(7):1768-78.
123 Feichtenbeiner A1, Haas M, Büttner M, et al. Critical role of spatial interaction between CD8⁺
and Foxp3⁺ cells in human gastric cancer: the distance matters. Cancer Immunol Immunother. 
2014 Feb;63(2):111-9.
124 Paulson KG, Iyer JG, Simonson WT, et al. CD8+ lymphocyte intratumoral infiltration as a 
stage-independent predictor of Merkel cell carcinoma survival: a population-based study. Am 
J Clin Pathol. 2014 Oct;142(4):452-8.
125 Lipson EJ, Vincet JG, Loyo M, et al. Expression in the merkel cell carcinoma 
microenvironment: Association with inflammation, merkel cell polyomavirus, and overall 
survival. Cancer Immunol Res 2013;1:1–10. 
126 Bristol-Myers Squibb Investigator Brochure: Ipilimumab, BMS-734016, MDX010. 





127 Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands 
infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
PNAS 2010; 107: 4275-80.
128 Sznol M, Kluger HM, Callahan MK, et al. Survival, response duration, and activity by BRAF 
mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and 
ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol, 2014. 32:5s 
(suppl; abstr LBA9003).
129 Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in 
untreated melanoma. N Engl J Med 2015; 372:2006-2017.
130 Scott JA, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung 
cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancel Oncol 2016; 
17:883-895.
131 Investigator Brochure, Anti-PD-1 Human Monoclonal Antibody, BMS-936558, Version No. 
12, 21-Jul-2014.
132 Triebel F, Jitsukawa S, Baixeras E, et al. LAG-3, a novel lymphocyte activation gene closely 
related to CD4. J. Exp. Med. 1990; 171:1393–1405.
133 Workman CJ, Wang Y, El Kasmi KC, et al. LAG-3 regulates plasmacytoid dendritic cell 
homeostasis. J Immunol;182(4):1885-91.
134 Workman CJ, Vignali DA. Negative regulation of T cell homeostasis by lymphocyte activation 
gene-3 (CD223). J. Immunol. 2005; 174:688–695.
135 Camisaschi C, Casati C, Rini F, et al. LAG-3 expression defines a subset of CD4(+) CD25 
(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol. 2010; 
184:6545-6551.
136 Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004; 
21:503–513.
137 Grosso JF, Kelleher CC, Harris TJ, et al. LAG-3 regulates CD8+T cell accumulation and 
effector function in murine self- and tumor-tolerance systems. J. Clin. Invest. 2007; 117:3383–
3392.
138 Lyford-Pike S, Peng S, Young GD, et al. Evidence for a Role of the PD-1: PD-L1 Pathway in 
Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma. Cancer 
Res. 2013 Mar 15;73(6):1733-41.
139 Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 
synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 
2012;72:917-927.
140 Okazaki T, Okazaki IM, Wang J, et al. PD-1 and LAG-3 inhibitory co-receptors act 
synergistically to prevent autoimmunity in mice. J Exp Med. 2011; 208:395-407.





141 Bettini M, Szymczak-Workman AL, Forbes K, et al. Cutting edge: accelerated autoimmune 
diabetes in the absence of LAG-3. J Immunol. 2011;187:3493-3498.
142 Goding SR, Wilson KA, Xie Y, et al. Restoring Immune Function of Tumor-Specific CD4+ T 
Cells during Recurrence of Melanoma. J Immunol. 2013 Mar 27.
143 Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1-specific 
CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl 
Acad Sci U S A. 2010;107:7875-7880.
144 Gandhi MK, Lambley E, Duraiswamy J, et al. Expression of LAG-3 by tumor-infiltrating 
lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-
cell function in Hodgkin lymphoma patients. Blood. 2006;108:2280-2289.
145 Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early 
lethality in mice deficient in CTLA-4. Science 1995;270:985-988.
146 Grosso JF, Goldberg MV, Getnet D, et al. Functionally distinct LAG-3 and PD-1 subsets on 
activated and chronically stimulated CD8 T cells. J Immunol. 2009; 182:6659-6669.
147 Saloura V, Zuo Z, Koeppen H, et.al. Correlation of T-cell inflamed phenotype with 
mesenchymal subtype, expression of PD-L1, and other immune checkpoints in head and neck 
cancer. J Clin Oncol 32:5s, 2014 (suppl; abstr 6009).
148 Uozaki H, Fukayama M. Epstein-Barr virus and gastric carcinoma--viral carcinogenesis 
through epigenetic mechanisms. Int J Clin Exp Pathol 2008;1(3):198-216.
149 Sittig SP, Køllgaard T, Grønbæk K, et.al. Clonal expansion of renal cell carcinoma-infiltrating 
T lymphocytes. Oncoimmunology 2013, 2:E26014.
150 Giraldo NA, Becht E, Pagès F, Skliris G, et.al. Orchestration and Prognostic Significance of 
Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. 
Clin Cancer Res. 2015, 21:3031-3040.
151 D'Incecco A, Andreozzi M, Ludovini V, et.al. PD-L1 and PD-1 expression in molecularly 
selected non-small-cell lung cancer (NSCLC) patients. Journal of Thoracic Oncology (2014) 
9 (Supplement 9): S7-S52.
152 Herbst RS, Gordon MS, Fine GD, et al. A study of MPDL3280A, an engineered PD-L1 
antibody in patients with locally advanced or metastatic tumors. J Clin Oncol 2013;31(suppl; 
abstr 3000).
153 Investigator Brochure, Anti-Lag3 Human Monoclonal Antibody, BMS-986016, Version 
No. 4, 30 Aug 2016.
154 BMS-986016 Investigator Brochure, Version 4. Bristol-Myers Squibb Company; 2016. 
Document Control No. 930071620.





155 de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 
monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J 
Immunol. 2011;186(3):1840-1848.
156 Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis contributes to 
the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple 
myeloma. MAbs. 2015;7(2):311-321.
157 Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy 
in multiple myeloma. N Engl J Med. 2015;373(13): 1207-1219.
158 Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-
refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 
2016;387(10027):1551-1560.
159 McKeage K. Daratumumab: first global approval. Drugs. 2016;76(2):275-281.
160 Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and 
receptors. Leuk.Res. 2001;25:1-12
161 Vaisitti T, Aydin S, Rossi D et al. CD38 increases CXCL12-mediated signals and homing of 
chronic lymphocytic leukemia cells. Leukemia. 2010;24:958-969.
162 Malavasi F, Deaglio S, Damle R et al. CD38 and chronic lymphocytic leukemia: a decade later. 
Blood. 2011;118:3470-3478.
163 Overdijk MB, Verploegen S, Marijn B et al. Phagocytosis is a mechanism of action for 
daratumumab. ASH Annual Meeting Abstracts 2012;120:4054.
164 Jansen JHM, Boross P, Overdijk MB et al. Daratumumab, a human CD38 antibody induces 
apoptosis of myeloma tumor cells via fc receptor-mediated crosslinking. ASH Annual Meeting 
Abstracts 2012;120:2974
165 Krejcik J, Casneuf T, Nijhof IS et al. Daratumumab depletes CD38+ immune-regulatory cells, 
promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 2016. pii: 
blood-2015-12-687749. [Epub ahead of print].
166 Schadendorf D et al Efficacy and quality of life outcomes in patients with advanced melanoma 
(MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to 
toxicity in a phase III trial (CheckMate 067). 2016 Annual Meeting of the European 
Association of Dermato-Oncology; August 31-September 3, 2016; Vienna, Austria.
167 Schadendorf D, et al. Pooled Analysis of Long-Term Survival Data from Phase II and Phase 
III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015; 33: 1889-
94.
168 Brahmer J, et al. Five-year follow-up from the CA209-003 study of nivolumab in previously 
treated advanced non-small cell lung cancer: clinical characteristics of long-term survivors. 
Oral presentation presented at: American Association for Cancer Research (AACR) Annual 
Meeting; April 1-5, 2017; Washington, DC, USA.





169 Felip E et al., Three-year follow-up from Checkmate 017/057: Nivolumab versus docetaxel in 
patients with previously treated advanced non-small lung cancer (NSCLC). Poster discussion 
presentation at the European Society of Medical Oncology Annual Meeting. 2017 Sep 8-12; 
Madrid, Spain. Poster 1301PD
170 Herbst RS et al. KEYNOTE-010: Durable clinical benefit in patients with previously treated, 
PD-L1-expressing NSCLC who completed pembrolizumab. Poster presentation at the World 
Conference on Lung Cancer 2016 Dec 4-7; Vienna, Austria.
171 Robert, C et al. Long-term outcomes in patients with ipilimumab-naive advanced melanoma 
in the phase 3 KEYNOTE-006 study who completed pembrolizumab treatment; Journal of 
Clinical Oncology 2017 35:15_suppl, 9504-9504
172 Spigel DR, et al. Randomized results of continuous vs 1-year fixed-duration in patients with 
advanced non-small cell lung cancer. Oral presentation at the European Society of Medical 
Oncology Annual Meeting. 2017 Sep 8-12; Madrid, Spain.
173 Robert C, Thomas L, Bondarenko et al. Ipilimumab plus dacarbazine for previously untreated 
metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-26.
174 Hodi FS, O'Day SJ, McDermott DF, et al. Improved Survival with Ipilimumab in Patients with 
Metastatic Melanoma; N Engl J Med. 2010 Aug 19;363(8):711-23.
175 Lokhorst H., Laubach JP, Nahi, H, Plesner T, Gimsing P, Hansson M, et al. Dose-dependent 
efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory 
multiple myeloma (RR MM). J Clin Oncol 2014. 32:5s, 8513. 2014. 
176 Lonial S, Usmani S, Singha UK, Chari A, Bahlis NJ. Phase II study of daratumumab (DARA) 
monotherapy in patients with = 3 lines of prior therapy or double refractory multiple myeloma 
(MM): 54767414MMY2002 (Sirius). J Clin Oncol. 2015;33 (supplement):LBA8512
177 Nijhof IS, Groen RW, Noort WA et al. Preclinical evidence for the therapeutic potential of 
CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to 
lenalidomide and bortezomib. Clin.Cancer Res. 2014;21(12):2802-10.
178 Nijhof IS, Noort W, van Bueren J, et al. CD38-targeted immunochemotherapy of multiple 
myeloma: preclinical evidence for its combinatorial use in lenalidomide and bortezomib 
refractory/intolerant mm patients. Blood 2013;122:277.
179 van der Veer MS, de WM, van KB et al. Towards effective immunotherapy of myeloma: 
enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 
monoclonal antibody daratumumab. Haematologica. 2011;96:284-290.
180 Plesner T, Arkenau T, Lokhorst H et al. Preliminary safety and efficacy data of daratumumab
in combination with lenalidomide and dexamethasone in relapsed or refractory multiple 
myeloma. Blood 2013;122:1986.
181 Plesner T., Arkenau T, Lokhorst, H et al. Safety and efficacy of daratumumab with 
lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. Blood 
2014;124(21):84. 





182 Dimopoulos M, Oriol A, Nahi H, San Miguel JF, Bahlis NJ, Rabin N, and Orlowski R. An 
open-label, randomized phase 3 study of daratumumab, lenalidomide, and dexamethasone 
(DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple 
myeloma (RRMM): POLLUX. Haematologica 2016;EHA Abstr LB2238.
183 Palumbo A, Chanan-Khan A, Weisel K, Nooka, AK, and Masszi T. Phase III randomized 
controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib 
and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma 
(RRMM): CASTOR study. J Clin Oncol 2016;ASCO Abstr LBA4.
184 DARZALEX [package insert]. Janssen Biotech, Inc, Horsham PA; 2017.
185 Chapuy CI, Nicholson RT, Aguad MD et al: Resolving the daratumumab interference with 
blood compatibility testing. Transfusion 2015;55;1545–1554.
186 Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced 
melanoma. NEJM 2013;369:122-133.
187 Manuel M, Tredan O, Bachelot T, et al. Lymphopenia combined with low TCR diversity 
(divpenia) predicts poor overall survival in metastatic breast cancer patients. 
Oncoimmunology. 2012;1(4):432-440.





APPENDIX 1 ECOG PERFORMANCE STATUS
ECOG PERFORMANCE STATUSa
0 Fully active, able to carry on all pre-disease performance without restriction
1
Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, eg, light house work, office work
2
Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and 
about more than 50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5 Dead
a Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, and Carbone PP. Toxicity and Response 
Criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
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APPENDIX 3 RECIST 1.1 GUIDELINES
1 EVALUATION OF LESIONS
At baseline, tumor lesions/lymph nodes will be categorized measurable or non-measurable as 
follows:
1.1 Measurable
Tumor lesions: Must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:
1. 10 mm by CT scan (CT scan slice thickness no greater than 5 mm)
2. 10 mm caliper measurement by clinical exam (lesions which cannot be accurately measured 
with calipers should be recorded as non-measurable)
3. 20 mm by chest x-ray
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph 
node must be  15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm).
Lymph nodes merit special mention since they are normal anatomical structures which may be 
visible by imaging even if not involved by tumor. Pathological nodes which are defined as 
measurable and may be identified as target lesions must meet the criterion of a short axis of 
 15 mm by CT scan. Only the short axis of these nodes will contribute to the baseline sum. The 
short axis of the node is the diameter normally used by radiologists to judge if a node is involved 
by solid tumor. Nodal size is normally reported as two dimensions in the plane in which the 
image is obtained (for CT scan this is almost always the axial plane; for MRI the plane of 
acquisition may be axial, sagittal or coronal). The smaller of these measures is the short axis. For 
example, an abdominal node which is reported as being 20 mm x 30 mm has a short axis of 
20 mm and qualifies as a malignant, measurable node. In this example, 20 mm should be 
recorded as the node measurement. All other pathological nodes (those with short axis  10 mm 
but < 15 mm) should be considered non-target lesions. Nodes that have a short axis < 10 mm are 
considered non-pathological and should not be recorded or followed.
1.2 Non-Measurable
All other lesions are considered non-measurable, including small lesions (longest diameter 
< 10mm or pathological lymph nodes with  10 to < 15 mm short axis) as well as truly 
non-measurable lesions. Lesions considered truly non-measurable include: leptomeningeal 
disease, ascites, pleural or pericardial effusion, inflammatory breast disease, lymphangitic 
involvement of skin or lung, abdominal masses/abdominal organomegaly identified by physical 
exam that is not measurable by reproducible imaging techniques.





2 BASELINE DOCUMENTATION OF ‘TARGET’ AND ‘NON-TARGET’ 
LESIONS
When more than one measurable lesion is present at baseline all lesions up to a maximum of five 
lesions total (and a maximum of two lesions per organ) representative of all involved organs 
should be identified as target lesions and will be recorded and measured at baseline (this means 
in instances where patients have only one or two organ sites involved a maximum of two and 
four lesions respectively will be recorded).
Target lesions should be selected on the basis of their size (lesions with the longest diameter), be 
representative of all involved organs, but in addition should be those that lend themselves to 
reproducible repeated measurements. It may be the case that, on occasion, the largest lesion does 
not lend itself to reproducible measurement in which circumstance the next largest lesion which 
can be measured reproducibly should be selected.
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be 
included in the sum, then as noted above, only the short axis is added into the sum. The baseline 
sum diameters will be used as reference to further characterize any objective tumor regression in 
the measurable dimension of the disease.
All other lesions (or sites of disease) including pathological lymph nodes should be identified as 
non-target lesions and should also be recorded at baseline. Measurements are not required and 
these lesions should be followed as ‘present’, ‘absent’, or in rare cases ‘unequivocal progression’ 
(more details to follow). In addition, it is possible to record multiple nontarget lesions involving 
the same organ as a single item on the case record form (eg, ‘multiple enlarged pelvic lymph 
nodes’ or ‘multiple liver metastases’).
3 RESPONSE CRITERIA
3.1 Evaluation of Target Lesions
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to < 10 mm.
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking 
as reference the baseline sum diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that 
is the smallest on study). In addition to the relative increase of 20%, the sum must 
also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of 
one or more new lesions is also considered progression).
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on study.





3.1.1 Special Notes on the Assessment of Target Lesions
3.1.1.1 Lymph nodes
Lymph nodes identified as target lesions should always have the actual short axis measurement 
recorded (measured in the same anatomical plane as the baseline examination), even if the nodes 
regress to below 10 mm on study. This means that when lymph nodes are included as target 
lesions, the ‘sum’ of lesions may not be zero even if complete response criteria are met, since a 
normal lymph node is defined as having a short axis of < 10 mm. Case report forms or other data 
collection methods may therefore be designed to have target nodal lesions recorded in a separate 
section where, in order to qualify for CR, each node must achieve a short axis < 10 mm. For PR, 
SD and PD, the actual short axis measurement of the nodes is to be included in the sum of target 
lesions.
3.1.1.2 Target lesions that become ‘too small to measure’
While on study, all lesions (nodal and non-nodal) recorded at baseline should have their actual 
measurements recorded at each subsequent evaluation, even when very small (eg, 2 mm). 
However, sometimes lesions or lymph nodes which are recorded as target lesions at baseline 
become so faint on CT scan that the radiologist may not feel comfortable assigning an exact 
measure and may report them as being ‘too small to measure’. When this occurs it is important 
that a value be recorded on the case report form. If it is the opinion of the radiologist that the 
lesion has likely disappeared, the measurement should be recorded as 0 mm. If the lesion is 
believed to be present and is faintly seen but too small to measure, a default value of 5 mm 
should be assigned (Note: It is less likely that this rule will be used for lymph nodes since they 
usually have a definable size when normal and are frequently surrounded by fat such as in the 
retroperitoneum; however, if a lymph node is believed to be present and is faintly seen but too 
small to measure, a default value of 5 mm should be assigned in this circumstance as well). This 
default value is derived from the 5 mm CT slice thickness (but should not be changed with 
varying CT slice thickness). The measurement of these lesions is potentially non-reproducible, 
therefore providing this default value will prevent false responses or progressions based upon 
measurement error. To reiterate, however, if the radiologist is able to provide an actual measure, 
that should be recorded, even if it is below 5 mm.
3.1.1.3 Lesions that split or coalesce on treatment
When non-nodal lesions ‘fragment’, the longest diameters of the fragmented portions should be 
added together to calculate the target lesion sum. Similarly, as lesions coalesce, a plane between 
them may be maintained that would aid in obtaining maximal diameter measurements of each 
individual lesion. If the lesions have truly coalesced such that they are no longer separable, the 
vector of the longest diameter in this instance should be the maximal longest diameter for the 
‘coalesced lesion’.





3.2 Evaluation of Non-Target Lesions
This section provides the definitions of the criteria used to determine the tumor response for the 
group of non-target lesions. While some non-target lesions may actually be measurable, they 
need not be measured and instead should be assessed only qualitatively at the time points 
specified in the protocol.
Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor 
marker level. All lymph nodes must be non-pathological in size (< 10mm short 
axis). 
Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor 
marker level above the normal limits.
Progressive Disease (PD): Unequivocal progression (see comments below) of existing 
non-target lesions. (Note: the appearance of one or more new lesions is also 
considered progression).
3.2.1 Special Notes on Assessment of Progression of Non-Target Disease
The concept of progression of non-target disease requires additional explanation as follows:
3.2.1.1 When the patient also has measurable disease
In this setting, to achieve ‘unequivocal progression’ on the basis of the non-target disease, there 
must be an overall level of substantial worsening in non-target disease such that, even in 
presence of SD or PR in target disease, the overall tumor burden has increased sufficiently to 
merit discontinuation of therapy (see examples in Appendix 2 and further details below). A 
modest ‘increase’ in the size of one or more non-target lesions is usually not sufficient to qualify 
for unequivocal progression status. The designation of overall progression solely on the basis of 
change in non-target disease in the face of SD or PR of target disease will therefore be extremely 
rare.
3.2.1.2 When the patient has only non-measurable disease
This circumstance arises in some trials when it is not a criterion of study entry to have 
measurable disease. The same general concepts apply here as noted above, however, in this 
instance there is no measurable disease assessment to factor into the interpretation of an increase 
in non-measurable disease burden. Because worsening in non-target disease cannot be easily 
quantified (by definition: if all lesions are truly non-measurable) a useful test that can be applied 
when assessing patients for unequivocal progression is to consider if the increase in overall 
disease burden based on the change in non-measurable disease is comparable in magnitude to the 
increase that would be required to declare PD for measurable disease: ie, an increase in tumor 
burden representing an additional 73% increase in ‘volume’ (which is equivalent to a 20% 
increase diameter in a measurable lesion). Examples include an increase in a pleural effusion 
from ‘trace’ to ‘large’, an increase in lymphangitic disease from localized to widespread, or may 
be described in protocols as ‘sufficient to require a change in therapy’. If ‘unequivocal 
progression’ is seen, the patient should be considered to have had overall PD at that point. While 





it would be ideal to have objective criteria to apply to non-measurable disease, the very nature of 
that disease makes it impossible to do so; therefore the increase must be substantial.
3.2.2 New Lesions
The appearance of new malignant lesions denotes disease progression; therefore, some 
comments on detection of new lesions are important. There are no specific criteria for the 
identification of new radiographic lesions; however, the finding of a new lesion should be 
unequivocal: ie, not attributable to differences in scanning technique, change in imaging 
modality or findings thought to represent something other than tumor (for example, some ‘new’ 
bone lesions may be simply healing or flare of pre-existing lesions). This is particularly 
important when the patient’s baseline lesions show partial or complete response. For example, 
necrosis of a liver lesion may be reported on a CT scan report as a ‘new’ cystic lesion, which it is 
not.
A lesion identified on a follow-up study in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progression. An example of this is 
the patient who has visceral disease at baseline and while on study has a CT or MRI brain 
ordered which reveals metastases. The patient’s brain metastases are considered to be evidence 
of PD even if he/she did not have brain imaging at baseline.
If a new lesion is equivocal, for example because of its small size, continued therapy and 
follow-up evaluation will clarify if it represents truly new disease. If repeat scans confirm there 
is definitely a new lesion, then progression should be declared using the date of the initial scan. 
While FDG-PET response assessments need additional study, it is sometimes reasonable to 
incorporate the use of FDG-PET scanning to complement CT scanning in assessment of 
progression (particularly possible ‘new’ disease). New lesions on the basis of FDG-PET imaging 
can be identified according to the following algorithm:
1. Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of PD based 
on a new lesion.
2. No FDG-PET at baseline and a positive FDG-PET at follow-up: If the positive FDG-PET at 
follow-up corresponds to a new site of disease confirmed by CT, this is PD. If the positive 
FDG-PET at follow-up is not confirmed as a new site of disease on CT, additional follow-up 
CT scans are needed to determine if there is truly progression occurring at that site (if so, the 
date of PD will be the date of the initial abnormal FDG-PET scan). If the positive FDG-PET 
at follow-up corresponds to a pre-existing site of disease on CT that is not progressing on the 
basis of the anatomic images, this is not PD.
3.3 Response Assessment
3.3.1 Evaluation of Best Overall Response
The best overall response is the best response recorded from the start of the study treatment until 
the end of treatment taking into account any requirement for confirmation. The patient’s best 
overall response assignment will depend on the findings of both target and non-target disease and 





will also take into consideration the appearance of new lesions. Furthermore, depending on the 
nature of the study and the protocol requirements, it may also require confirmatory measurement.
3.3.2 Time Point Response
It is assumed that at each protocol specified time point, a response assessment occurs. Table 
3.3.2-1 provides a summary of the overall response status calculation at each time point for 
patients who have measurable disease at baseline. When patients have non-measurable (therefore 
non-target) disease only, Table 3.3.2-2 is to be used. 
Table 3.3.2-1: Time Point Response: Patients With Target (+/- Non-Target) 
Disease
Target Lesions Non-Target Lesions New Lesions Overall Response
CR CR No CR
CR Non-CR/non-PD No PR
CR Not evaluated No PR
PR




Non-PD or not all 
evaluated
No SD
Not all evaluated Non-PD No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease and NE = inevaluable
Table 3.3.2-2: Time Point Response: Patients with Non-target Disease Only
Non-Target Lesions New Lesions Overall Response
CR No CR
Non-CR/non-PD No Non-CR/non-PDa
Not all evaluated No NE
Unequivocal PD Yes or No PD
Any Yes PD
CR = complete response, PD = progressive disease and NE = inevaluable
a Non-CR/non-PD is preferred over SD for non-target disease since SD is increasingly used as endpoint for 
assessment of efficacy in some trials so to assign this category when no lesions can be measured is not advised.





3.3.3 Best Overall Response 
Best response determination of complete or partial response requires confirmation: Complete or 
partial responses may be claimed only if the criteria for each are met at a subsequent time point 
of  4 weeks later. In this circumstance, the best overall response can be interpreted as in Table 
3.3.3-1.
Special note on response assessment: When nodal disease is included in the sum of target 
lesions and the nodes decrease to ‘normal’ size (< 10 mm), they may still have a measurement 
reported on scans. This measurement should be recorded even though the nodes are normal in 
order not to overstate progression should it be based on increase in size of the nodes. As noted 
earlier, this means that patients with CR may not have a total sum of ‘zero’ on the case report 
form (CRF).







CR PR SD, PD OR PRa
CR SD SD provided minimum criteria for SD duration
b met, 
otherwise, PD
CR PD SD provided minimum criteria for SD duration
b met, 
otherwise, PD






PR PD SD provided minimum criteria for SD duration
b met, 
otherwise, PD





CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, and 
NE = inevaluable
a If a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease meeting PR 
criteria relative to baseline, makes the disease PD at that point (since disease must have reappeared after CR). 
Best response would depend on whether minimum duration for SD was met. However, sometimes ‘CR’ may be 
claimed when subsequent scans suggest small lesions were likely still present and in fact the patient had PR, not 
CR at the first time point. Under these circumstances, the original CR should be changed to PR and the best 
response is PR.
b Minimum criteria for SD duration is 6 weeks.






Verification of Response: To be assigned a status of CR or PR, changes in tumor measurements 
must be confirmed by consecutive repeat assessments that should be performed no less than 
28 days after the criteria for response are first met. For this study, the next scheduled tumor 
assessment can meet this requirement.
Verification of Progression: Progression of disease should be verified in cases where progression 
is equivocal. If repeat scans confirm PD, then progression should be declared using the date of 
the initial scan. If repeat scans do not confirm PD, then the subject is considered to not have 
progressive disease.





APPENDIX 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile. Permanent sterilization methods include hysterectomy, bilateral 
salpingectomy, and bilateral oophorectomy.
Women in the following categories are not considered WOCBP
 Premenarchal
 Premenopausal female with 1 of the following:
 Documented hysterectomy
 Documented bilateral salpingectomy
 Documented bilateral oophorectomy
Note:   Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.
 Postmenopausal female
 A postmenopausal state is defined as 12 months of amenorrhea in a woman over age 
45 years in the absence of other biological or physiological causes. In addition, females 
under the age of 55 years must have a serum follicle stimulating hormone, (FSH) level 
> 40 mIU/mL to confirm menopause.
CONTRACEPTION GUIDANCE FOR FEMALE PARTICIPANTS OF CHILD BEARING 
POTENTIAL
One of the highly effective methods of contraception listed below is required during study 
duration and until the end of relevant systemic exposure, defined as 5 months after the end of 
study treatment. 
Local laws and regulations may require use of alternative and/or additional contraception 
methods.
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of <1% per year when used consistently and correctly.a










 Progestogen-only hormonal contraception associated with inhibition of ovulationb
 oral 
 injectable 
Highly Effective Methods That Are User Independent 
 Implantable progestogen-only hormonal contraception associated with inhibition of 
ovulationb
 Hormonal methods of contraception including oral contraceptive pills containing a 
combination of estrogen and progesterone, vaginal ring, injectables, implants and 
intrauterine hormone-releasing system (IUS)c
 Intrauterine device (IUD)c
 Bilateral tubal occlusion
 Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the 
partner is the sole male sexual partner of the WOCBP and the absence of sperm has been 
confirmed. If not, an additional highly effective method of contraception should be used. 
 Sexual abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the 
study and the preferred and usual lifestyle of the participant.
 It is not necessary to use any other method of contraception when complete abstinence 
is elected. 
 WOCBP participants who choose complete abstinence must continue to have 
pregnancy tests, as specified in Section 2. 
 Acceptable alternate methods of highly effective contraception must be discussed in 
the event that the WOCBP participants chooses to forego complete abstinence 
NOTES: 
a Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants participating in clinical studies. 
b Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of 
the contraceptive method. Hormonal contraception is permissible only when there is sufficient evidence that the 
IMP and other study medications will not alter hormonal exposures such that contraception would be ineffective 
or result in increased exposures that could be potentially hazardous. In this case, alternative methods of 
contraception should be utilized.
c Intrauterine devices and intrauterine hormone releasing systems are acceptable methods of contraception in the 
absence of definitive drug interaction studies when hormone exposures from intrauterine devices do not alter 
contraception effectiveness





Unacceptable Methods of Contraception
 Male or female condom with or without spermicide. Male and female condoms cannot be 
used simultaneously
 Diaphragm with spermicide
 Cervical cap with spermicide
 Vaginal Sponge with spermicide
 Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the 
primary mechanism of action
 Periodic abstinence (calendar, symptothermal, post-ovulation methods)
 Withdrawal (coitus interruptus).
 Spermicide only
 Lactation amenorrhea method (LAM)
CONTRACEPTION GUIDANCE FOR MALE PARTICIPANTS WITH PARTNER(S) OF 
CHILD BEARING POTENTIAL.
Male participants with female partners of childbearing potential are eligible to participate if they 
agree to the following during the treatment and until the end of relevant systemic exposure.
 Inform any and all partner(s) of their participation in a clinical drug study and the need to 
comply with contraception instructions as directed by the investigator.
 Male participants are required to use a condom for study duration and until end of relevant 
systemic exposure defined as 7 months after the end of study treatment.
 Female partners of males participating in the study to consider use of effective methods of 
contraception until the end of relevant systemic exposure, defined as 7 months after the end 
of treatment in the male participant.
 Male participants with a pregnant or breastfeeding partner must agree to remain abstinent 
from penile vaginal intercourse or use a male condom during each episode of penile 
penetration during the treatment and until 7 months after the end of study treatment. 
 Refrain from donating sperm for the duration of the study treatment and until 7 months after 
the end of study treatment.
COLLECTION OF PREGNANCY INFORMATION
Guidance for collection of Pregnancy Information and outcome of pregnancy on the Pregnancy 
Surveillance Form is provided in Section 6.1.1 and Section 6.4.
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